Biaryl compounds preparation methods and medicinal uses thereof
Patent Information
- Application Number
- PCT/CN2024/093338
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-01-26
- Filing Date
- 2024-05-15
- Publication Date
- 2024-11-21
Smart Images

Figure CN2024093338_21112024_PF_FP_ABST
Abstract
Description
BIARYL COMPOUNDS PREPARATION METHODS AND MEDICINAL USES THEREOFFIELD OF THE INVENTION
[0001] The present invention belongs to the field of medicine, and relates to biaryl compounds, preparation methods thereof, pharmaceutical compositions comprising the compounds, and medical uses thereof.BACKGROUND OF THE INVENTION
[0002] The Hippo signaling is an evolutionarily conserved pathway that controls organ size by regulating cell proliferation and apoptosis. Core to the Hippo pathway is a kinase cascade consists of protein kinases Mst1 / 2, LATS1 / 2 and transcription co-activators YAP / TAZ. When Hippo pathway is activated (Hippo-On) , Mst1 / 2 phosphorylate and activate LATS1 / 2. LATS1 / 2 in turn phosphorylate YAP / TAZ and limit YAP / TAZ function by means of cytoplasmic retention and proteasomal degradation. On the other hand, inactive Hippo pathway (Hippo-Off) allows YAP / TAZ to enter the nucleus where YAP / TAZ associate primarily with TEAD family transcription factors to activate expression of pro-proliferation and anti-apoptosis genes.
[0003] Hippo signaling pathway dysregulation, characterized by hyperactivity of YAP / TAZ, have been implicated in different types of cancers. The most prominent cancer related to Hippo pathway dysregulation is malignant pleural mesothelioma (MPM) . In MPM, loss of NF2 and / or LATS1 / 2 function results in Hippo-Off and YAP / TAZ hyperactivation. Moreover, elevated levels of YAP / TAZ have been observed and connected to poor prognosis in breast cancer, lung cancer, ovarian cancer, colorectal cancer, pancreas cancer, prostate cancer, gastric cancer, liver cancer, etc.
[0004] In addition to controlling cell growth and apoptosis, the Hippo pathway is also implicated in drug resistance and immunosurveillance escape of cancer cells. As reported in several genetic and pharmacological studies, YAP / TAZ activation confers resistance to both chemotherapeutic drugs and small molecule drugs targeting KRAS, BRAF, MEK, EGFR, etc. Accumulating evidence has demonstrated the immunomodulatory effects of YAP / TAZ in malignant neoplasms. YAP / TAZ can promote not only the PD-L1 expression in cancer cells, but also the expression of CXCL5 which recruits myeloid derived suppressor cells (MDSCs) to suppress T cells in tumor microenvironment.
[0005] Association with TEAD family transcription factors is necessary for YAP / TAZ’s function due to the lack of DNA-binding domain in themselves. Therefore, modalities disrupting YAP / TAZ-TEAD interaction have emerged as attractive strategies for YAP / TAZ inhibition in cancer. In this invention, we designed and optimized compounds as TEADs binders that selectively disrupt the YAP / TAZ-TEAD interaction and benefit the treatment of diseases mentioned above.SUMMARY OF THE INVENTION
[0006] The present invention, in one aspect, provides a compound of formula (I-a) , or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof,
[0007] wherein,
[0008] X is CH2 or N;
[0009] Q is selected from the group consisting of C6-10 aryl, C3-10 cycloalkyl, C6-10 hereroaryl containing one or more heteroatoms selected from N, O or S, and C6-10 heterocyclyl containing one or more heteroatoms selected from N, O or S, optionally substituted with one or more substituents selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkylamino, NH3-C1-6 alkyl, and -S (O) 2Re;
[0010] W is - (CRaRb) n-NRcRd, or W is a C3-6 mono-cycloalkyl, C3-6 mono-, C7-10 fused-or C6-10 bridged heterocyclyl containing 1, 2 or 3 heteroatoms selected from N, O, or S, optionally substituted with one or more substituents selected from hydrogen, deuterium, halogen, amino, C1-3 alkylamino, cyano, hydroxyl, C1-3 alkyl, with the proviso that the carbon atom adjacent to the N atom is the attachment point to the parent moiety;
[0011] ;
[0012] Ra and Rb are each independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, and C3-10 cycloalkyl;
[0013] Rc and Rd are each independently selected from (i) hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, and C1-6 hydroxyalkyl, (ii) C3-10 cycloalkyl, C3-10 heterocyclyl containing one or more heteroatoms selected from N, O or S, C6-10 aryl and C6-10 heteroaryl containing one or more heteroatoms selected from N, O or S, optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-6 aminoalkyl, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, and C1-6 hydroxyalkyl;
[0014] or, Rc and Rd together with the N atom to which they are attached form a 3-10 membered heterocyclyl optionally containing another 1, 2 or 3 heteroatoms selected from N, O or S and a 5-10 membered heteroaryl optionally containing another 1, 2 or 3 heteroatoms selected from N, O or S, wherein the heterocyclyl and the heteroaryl are optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-6 aminoalkyl, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, and C1-6 hydroxyalkyl;
[0015] or, Ra and Rd together with the C and N atoms to which they are attached form a 3-10 membered heterocyclyl optionally containing another 1, 2 or 3 heteroatoms selected from N, O or S and a 5-10 membered heteroaryl optionally containing another 1, 2 or 3 heteroatoms selected from N, O or S, wherein the heterocyclyl and the heteroaryl are optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-6 aminoalkyl, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, and C1-6 hydroxyalkyl; R1, R2, R3 and R4 are selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-6 aminoalkyl, cyano, -CONH-, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, and 3-6 membered cycloalkyl, optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, and C1-6 alkyl;
[0016] R5 is selected from the group consisting of hydrogen, deuterium, halogen, amino, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 aminoalkyl, C1-6 hydroxyalkoxy, -O- (CH2) m5- (CRa8Rb8) m7- (CH2) m6-OH, - (CRaRb) n-C (O) Re, -OS (O) 2Re, -S (O) 2Re, and C3-6 cycloalkyl, optionally substituted with one or more substituents selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, and C1-6 hydroxyalkyl;
[0017] R6 is selected from (i) hydrogen, deuterium, halogen, amino, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 aminoalkyl, C1-6 hydroxyalkoxy, C2-6 aminoalkenyl, C2-6 aminoalkynyl, C2-6 hydroxyalkynyl, - (CRaRb) n-C (O) Re, -OS (O) 2Re, - (CRaRb) n-C (O) NHRe, -S (O) 2Re, -NReC (O) Rf; (ii) C3-10 cycloalkyl, C2-10 spiro heterocyclyl-C1-6 alkylene-, C3-10 heterocyclyl-C1-6 alkylene-, C3-10 heterocyclyl, C6-10 aryl and C5-10 heteroaryl, wherein the spiro heterocyclyl, heterocyclyl, and heteroaryl comprise 1, 2 or 3 heteroatoms selected from N, O or S, wherein the cycloalkyl, heterocyclyl, spiro heterocyclyl, aryl and heteroaryl are each optionally substituted with one or more substituents selected from hydrogen, halogen, amino, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, oxo, C3-10 heterocyclyl, C1-6 acyl, C3-10 heterocyclyl-NH-, and C3-10 haloheterocyclyl; (iii) (C1-6 alkyl) 2P (O) -, -C1-6 alkyleneNHCH2CHmF3-m, -C1-6 alkylene-NH-Rg;
[0018] Re is selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-6 alkyl, deuterated C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, C5-10 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O or S;
[0019] Rf is selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl;
[0020] Rg is C3-10 cycloalkyl, C3-10 heterocyclyl, C2-10 spiro heterocyclyl, wherein the cycloalkyl, heterocyclyl and spiro heterocyclyl are each optionally substituted with one or more substituents selected from hydrogen, halogen, amino, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, oxo, and CF3;
[0021] Ra8 and Rb8 are each independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl;
[0022] optionally, one Ra8 and one Rb8 together with different C atoms they are attached to form a C3-6 cycloalkyl, C6-10 aryl, C5-10 heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O or S, 5-10 membered heterocyclyl containing 1, 2 or 3 heteroatoms selected from N, O or S, optionally substituted with one or more substituents seleted from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl;
[0023] each n is independently selected from 0, 1, 2 or 3; and
[0024] each m is independently selected from 0, 1, 2;
[0025] m5 and m6 are independently selected from 0, 1, 2 or 3,
[0026] and m7 is 2, 3 or 4.
[0027] In some embodiments, Q is selected from the group consisting of phenyl, pyridyl, pyrrolyl, thiazolyl, cyclopropyl, cyclobutyl, cyclopentyl, optionally substituted with 1 or 2 substituents selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyano, C1-3 alkyl, -NHCH3, -NHCH2CH3, -S (O) 2F, and -S (O) 2Cl.
[0028] In some embodiments, Ra and Rb are each independently selected from the group consisting of hydrogen;
[0029] Rc and Rd are each independently hydrogen, deuterium, halogen, amino, cyano, C1-3 alkyl;
[0030] each n is independently selected from 0, 1, 2 or 3.
[0031] In some embodiments,
[0032] Ra and Rb are hydrogen;
[0033] Rc is selected from hydrogen, deuterium, halogen, amino, cyano, C1-3 alkyl;
[0034] Rd is C3-6 cycloalkyl optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-6 aminoalkyl, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl;
[0035] each n is independently selected from 0, 1, 2, 3.
[0036] In some embodiments, Ra is hydrogen;
[0037] Rb is C3-6 cycloalkyl optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-6 aminoalkyl, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl;
[0038] Rc and Rd are each independently hydrogen, deuterium, halogen, amino, cyano, and C1-3 alkyl;
[0039] n is 0, 1, 2, 3.
[0040] In some embodiments, W is a C3-6 mono-cycloalkyl, C3-6 mono-, C7-10 fused-or C6-10 bridged heterocyclyl containing 1, 2 or 3 heteroatoms selected from N, O, or S, optionally substituted with one or more substituents selected from hydrogen, deuterium, halogen, amino, C1-3 alkylamino, cyano, hydroxyl, C1-3 alkyl, with the proviso that the carbon atom adjacent to the N atom is the attachment point to the parent moiety.
[0041] In some embodiments, W is selected from the group consisting of optionally substituted with one or more substituents selected from hydrogen, deuterium, halogen, amino, -NHCH3, cyano, hydroxyl, and C1-3 alkyl.
[0042] In some embodiments, R1, R2, R3 and R4 are each independently selected from the group consisting of (i) hydrogen, deuterium, F, Cl, Br, amino, C1-3 aminoalkyl, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl, (ii) cyclopropyl, cylcobutyl, optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, C1-3 alkyl.
[0043] In some embodiments, R5 is selected from the group consisting of (i) hydrogen, deuterium, halogen, amino, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl, C1-3 aminoalkyl, C1-3 hydroxyalkoxy, -COH, -CH2COH, -CH2COOH, -COOH, -OS (O) 2F, -S (O) 2F, -CONH2, and -CH2CONH2; (ii) cyclobutyl, cyclopropyl or cyclopentyl optionally substituted with one or more substituents selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, and C1-3 hydroxyalkyl. In some embodiments, R6 is selected from the group consisting of hydrogen, deuterium, halogen, amino, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl, C1-3 aminoalkyl, -, C2-3 aminoalkynyl, C2-3 hydroxyalkynyl, C1-3 hydroxyalkoxy, -C (O) H, -CH2C (O) H, -CH2COOH, -COOH, -OS (O) 2F, -S (O) 2F, -CONH2, -CH2CONH2, -NHC (O) CH3, -NCH3C (O) CH3, and -S (O) 2NH2.
[0044] In some embodiments, R6 is selected from the group consisting of
[0045] In some embodiments, the compound of formula (I-a) , or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, is the compound of formula (I-b)
[0046] wherein,
[0047] X is CH2 or N;
[0048] ring B is a 5-10 membered hereroaryl comprising 1, 2 or 3 heteroatoms selected from N, O or S and a 3-8 membered cycloalkyl, optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, aminoalkyl, cyano, hydroxyl, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, hydroxyalkyl, oxo and nitro;
[0049] Q, W, R1, R2, R3, R4, R5 and R6 are as defined above.
[0050] In some embodiments, ring B is selected from the group consisting of optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, aminoalkyl, cyano, hydroxyl, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, hydroxyalkyl, oxo and nitro.
[0051] In some embodiments, the compound of formula (I-a) , or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, is the compound of formula (I-c) :
[0052] wherein,
[0053] X1, X2, X3, X4 and X5 are each independently selected from CH2, NH, O, S or bond; X6 is CH or N;
[0054] R7 is hydrogen;
[0055] or, two of R7 together with two adjacent atoms to which they are attached form a 3-6 membered cycloalkyl group;
[0056] or, two of R7 together with two non-adjacent atoms to which they are attached form a 3-6 membered cycloalkyl group;
[0057] or, two of R7 together with the same atom to which they are attached form a 3-6 membered cycloalkyl group;
[0058] m is 0, 1, 2 or 3;
[0059] X, Q, R1, R2, R3, R4, R5 and R6 are as defined above;
[0060] provided that, when is R5 is –O (CH2) 2OH, then R1 is not selected from H or methoxy;
[0061] provided that, when is R5 is methoxy, then R1 is not selected from methoxy, hydroxyl;
[0062] provided that, when is R2, R3, R4 and R5 are not hydrogen;
[0063] provided that, when is R2, R3, R4 and R5 are not hydrogen;
[0064] rovided that, when is R5 is not methoxy;
[0065] provided that, when R5 is -OCHF2, then is not
[0066] provided that, when R5 is –O (CH2) 2OH, then is not
[0067] In some embodiments, is selected from the group consisting of
[0068] In some embodiments, the compound of formula (I-a) , or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, is the compound of formula (I-d) :
[0069] wherein,
[0070] Y is CH2, NH, O or S;
[0071] z1, z2, z3 and z4 are each independently selected from CH2, NH, O, S or bond; R8 is selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-6 aminoalkyl, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, and C1-6 hydroxyalkyl;
[0072] k is 1, 2 or 3;
[0073] X, Q, R1, R2, R3, R4, R5 and R6 are as defined above.
[0074] In some embodiments, is selected from the group consisting of
[0075] In some embodiments, the compound of formula (I-a) , or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, is the compound of formula (I-e) :
[0076] wherein,
[0077] Y is CH2, NH, O or S;
[0078] Ring C is a 5-, 6-, 7-membered hereroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S;
[0079] R9 is selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-6 aminoalkyl, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl;
[0080] j is 1, 2 or 3;
[0081] X, Q, W, R1, R2, R3, R4, R5 and R6 are as defined above.
[0082] In some embodiments, is
[0083] In some embodiments, the compound of formula (I-a) , or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, is the compound of formula (I-f) :
[0084] wherein,
[0085] Y is CH2, NH, O or S;
[0086] y1, y2, y3 y4 and y5 are each independently selected from CH, N, S, with the proviso that (i) at least two of y1, y2, y3 y4 and y5 are N atom, or (ii) at least one of y1, y2, y3 y4 and y5 is S atom;
[0087] Q, W, R1, R2, R3, R4, R5 and R6 are as defined above.
[0088] In some embodiments, is selected from
[0089] In some embodiments, the compound of formula (I-a) , or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, is the compound of formula (I-g) :
[0090] wherein,
[0091] Y is CH2, NH, O or S;
[0092] Ring D is a 5-, 6-, 7-membered hereroaryl comprising 1, 2 or 3 heteroatoms selected from N, O, S and B,
[0093] Q, W, R1, R2, R3, R4, R5 and R6 are as defined above.
[0094] In some embodiments, is selected from In some embodiments, the compound of formula (I-a) , or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, is the compound of formula (I-h) :
[0095] wherein,
[0096] Y is CH2, NH, O or S;
[0097] M1 is CH, N;
[0098] M2 is CH, CH2, N, NH, O or S;
[0099] M3 is CH, CH2, N, NH, O or S;
[0100] M4 is CH, CH2, N, NH, O, S or bond;
[0101] M5 is CH, CH2, N, NH, O or S;
[0102] M6 is CH, N, O, S;
[0103] L1 is NH, CH2, CHRh, O or S;
[0104] L2 is CH2, O or S;
[0105] L3 is NH, CH2, O or S;
[0106] Rh is hydrogen, deuterium, halogen, amino, aminoalkyl, cyano, hydroxyl, C1-3 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl, oxo and nitro; p is 0, 1, 2 or 3;
[0107] Q, W, R1, R2, R3, R4, R5 and R6 are as defined above.
[0108] In some embodiments, is selected from phenyl, thienyl, In some embodiments, the compound of formula (I-a) , or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, is the compound of formula (I-i) :
[0109] wherein,
[0110] Y is CH2, NH, O or S;
[0111] ring E is a 5-, 6-, 7-membered hereroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S;
[0112] preferably, ring E is
[0113] X, Q, W, R1, R2, R3, R4, R5 and R6 are as defined above.
[0114] In some embodiments, the compound of formula (I-a) , or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, is the compound of formula (I-j) :
[0115] wherein,
[0116] Y is CH2, NH, O or S;
[0117] R10 is selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-6 aminoalkyl, cyano, hydroxy, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl;
[0118] z is 1, 2 or 3;
[0119] X, Q, R1, R2, R3, R4, R5 and R6 are as defined in any one ofabove;
[0120] provided that R6 is not -CONH2 or -CONH-CH3.
[0121] In some embodiments, the compound of formula (I-a) , or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, is the compound of formula (I-k) :
[0122] wherein,
[0123] k1 is 0 , 1, 2 or 3;
[0124] X, Q, W, R1, R2, R3, R4, R5 and R6 are as defined in any one ofabove.
[0125] In some embodiments, the compound of formula (I-a) , or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, is the compound of formula (I-l) :
[0126] wherein,
[0127] Y is CH2, NH, O or S;
[0128] E is selected from the group selected from fused C4-12 heterocyclic containing one or more heteroatoms from N, O or S, fused C4-12 cycloalkyl;
[0129] In a preferred embodiment, E is selected from the group selected from fused C6-10 heterocyclic containing one or more heteroatoms from N, fused C6-10 cycloalkyl;
[0130] In a preferred embodiment, E is selected from the group selected from
[0131] L4 is selected from bond, alkyl-NH-;
[0132] preferably, L4 is selected from bond, C1-4 alkyl-NH-;
[0133] Re is selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-6 aminoalkyl, cyano, hydroxy, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl;
[0134] X, Q, R1, R2, R3, R4, R5 and R6 are as defined in any one ofabove;
[0135] k1 is 0 , 1, 2 or 3;
[0136] k2 is 1, 2 or 3.
[0137] In some embodiments, the compound of formula (I-a) , or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, is the compound of formula (I-m) :
[0138] wherein,
[0139] Y is CH2, NH, O or S;
[0140] x11, x12, x13, x14, x15 and x16 are each independently selected from CH, CH2, N, NH, O, S or bond;
[0141] preferably, is selected from the group consisted of phenyl, pyridyl, pyrazolyl, pyrrolyl, thiazolyl, cyclopropyl, cyclobutyl and cyclopentyl;
[0142] preferably, is selected from phenyl and pyrazol-4-yl;
[0143] R11 and R12 are each independently selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-6 aminoalkyl, cyano, hydroxy, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl;
[0144] X, Q, R1, R2, R3, R4, R5 and R6 are as defined above.
[0145] k1 is 0 , 1, 2 or 3;
[0146] g is 0 , 1, 2 or 3; and
[0147] g1 is 0 , 1, 2 or 3.
[0148] In some embodiments, the compound of formula (I-a) , or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, is the compound of formula (I-n) , (I-n1) or (I-n2) ,
[0149] wherein,
[0150] R1 is selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, and C1-6 alkyl;
[0151] R2 is selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, C1-3 alkyl, amino, C1-3 aminoalkyl, and cyano;
[0152] R3 is selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-3 aminoalkyl, cyano, -CONH-, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl;
[0153] R4 is selected from the group consisting of deuterium, halogen, amino, C1-3 aminoalkyl, cyano, -CONH-, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl, C1-3 hydroxyalkenyl;
[0154] R5 is selected from the group consisting of deuterium, halogen, amino, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl, C1-3 aminoalkyl, C1-3 hydroxyalkoxy, - (CRaRb) n-C (O) Re, -OS (O) 2Re, -S (O) 2Re, -O- (CH2) m5--CRa5Rb5- (CH2) m6-OH, C3-6 cycloalkyl, optionally substituted with one or more substituents selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, and C1-3 hydroxyalkyl; R6 is selected from -C (O) OCH3, -CONH2, -NHC (O) OC1-6 alkyl, -NHCH2C (O) NH2, -NHC(O) NHC1-6 alkyl, -C≡CCH2Re1, -C≡CRe1, -CH3, -NHC (O) Re1, -C≡CCH2NH2, S (O) 2Re, -CONC1-6 alkyl, -C1-6 alkylene-NHC1-6 alkyl, -C1-6 alkyleneNH2, -C1-6 alkylene-N (C1-6 alkyl) 2, -CH (OH) C1-6 alkyl, -CH2 (OCH2) C1-6 alkyl, -CH2OMe, -C (O) H, C1-6 hydroxyalkyl, -NHC1-6 alkyl, - (CH2) n1NH (CH2) m1Rf, - (CH2) n1O (CH2) m1Rf, -CH (Rg) NH (CH2) m1Rf, -C1-6 alkyleneNHC (O) C1-6 alkyl, R6A, -C1-6 alkylene-R6A, -C1-6 alkylene-R6B, -C1-6 alkylene-NHCH2CHm2F3-m2, -C1-6 alkylene-NHC1-6 alkylene-OH, -C1-6 alkylene-NHC1-6 alkylene-OC1-6 alkyl, -C1-6 alkylene-NHm3 (C1-6 alkyl) 1-m3C (O) NHm4 (C1-6 alkyl) 2-m4, -C1-6 alkylene-NHC (O) OR6C, (C1-6 alkyl) 2P (O) -, (C1-6 alkyl) 2N- (C1-6 alkyl) P (O) -, MeNH-C3-10 cycloalkylene-, OH-C3-10 cycloalkylene-, NHm4 (C1-6 alkyl) 2-m4 (COOH) CH-, -C (O) NH-R6B, and -C (O) -R6B;
[0155] R6A is C5-10 heteroaryl which is optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-3 aminoalkyl, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C2-3 haloalkyl, C1-3hydroxyalkyl, -CH2OC1-6 alkyl;
[0156] R6B is C5-10 heterocyclyl, C5-10 heterocyclyl, C5-10 spiro heterocyclyl, wherein the heterocyclyl and spiro heterocyclyl are optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-3 aminoalkyl, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C2-3 haloalkyl, C1-3hydroxyalkyl, -CH2OC1-6 alkyl, oxo, C5-10 heterocyclyl, C1-6 acyl, C5-10 heterocyclyl, C5-10 heterocyclyl-NH-, and halo-C5-10 heterocyclyl;
[0157] R6C is C1-6 alkyl, C3-10 cycloalkyl, wherein said cycloalkyl is optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-3 aminoalkyl, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C2-3 haloalkyl, C1-3hydroxyalkyl, -CH2OC1-6 alkyl, oxo;
[0158] Re1 is selected from the group consisting of deuterium, halogen, amino, cyano, hydroxyl, -C (O) NH2, deuterated C1-3 alkyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl, C5-10 heteroaryl comprising 1 2 or 3 heteroatoms selected from N, O or S;
[0159] Rf is selected from the group consisting of C3-10 cycloalkyl, 5-10 membered hereroaryl, C5-10 spiro heterocyclyl, C5-10 heterocyclyl, wherein the hereroaryl, spiro heterocyclyl, and heterocyclyl comprise 1, 2 or 3 heteroatoms selected from N, O and S, wherein the the cycloalkyl, hereroaryl, spiro heterocyclyl and heterocyclyl are each optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-3 aminoalkyl, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C2-3 haloalkyl, C1-3 hydroxyalkyl, oxo, nitro and CF3; Rg is selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl;
[0160] Ra and Rb are each independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, and C3-10 cycloalkyl;
[0161] Re is selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, C5-10 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O or S;
[0162] n, n1 and m1 are each indepently 0, 1, 2 or 3;
[0163] m3 is 0, 1;
[0164] m2 and m4 are each indepently 0, 1, 2; and,
[0165] m5 and m6 are 0, 1, 2 or 3;
[0166] provided that, the compound is not
[0167] In a preferred embodiment, Rf is seleced from
[0168] In some embodiments, R1 is selected from the group consisting of hydrogen, deuterium, F, Cl, Br, hydroxyl, C1-3 alkyl.
[0169] In some embodiments, R2 is selected from the group consisting of hydrogen, deuterium, F, Cl, Br, hydroxyl, C1-3 alkyl, amino, C1-3 aminoalkyl, cyano.
[0170] In some embodiments, R3 is selected from the group consisting of hydrogen, deuterium, F, Cl, Br, amino, C1-3 aminoalkyl, cyano, -CONH-, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl.
[0171] In some embodiments, R4 is selected from the group consisting of deuterium, F, Cl, Br, amino, C1-3 aminoalkyl, cyano, -CONH-, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl, C1-3 hydroxyalkenyl.
[0172] In some embodiments, R5 is selected from the group consisting of deuterium, halogen, amino, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, -OMe, -OEt, -OC3H7, C1-3 haloalkyl, C1-3 hydroxyalkyl, C1-3 aminoalkyl, C1-3 hydroxyalkoxy, - (CRaRb) n-C (O) Re, -OS (O) 2Re, -S (O) 2Re, C3-6 cycloalkyl, optionally substituted with one or more substituents selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl. In some embodiments, R6 is selected from the group consisting of -C (O) OCH3, -CONH2, -NHC (O) OC1-3 alkyl, -NHCH2C (O) NH2, -NHC (O) NHC1-3 alkyl, -C≡CCH2Re1, -C≡CRe1, -CH3, -NHC (O) Re1, -C≡CCH2NH2, S (O) 2Re, -CONC1-3 alkyl, -C1-3 alkylene-NHC1-3 alkyl, -C1-3 alkylene NH2, -C1-3 alkylene N (C1-3 alkyl) 2, -CH (OH) C1-3 alkyl, -CH2 (OCH2) C1-3 alkyl, -CH2OMe, -C (O) H, C1-3 hydroxyalkyl, -NHC1-3 alkyl, - (CH2) n1NH (CH2) m1Rf, - (CH2) n1O (CH2) m1Rf, -CH (Rg) NH (CH2) m1Rf, , -C1-3 alkyleneNHC (O) C1-3 alkyl, R6A, -C1-3 alkylene-R6A, -C1-3 alkylene-R6B, -C1-3 alkylene-NHCH2CHm2F3-m2, -C1-3 alkylene –NH-C1-3 alkylene-OH, -C1-3 alkylene-NH-C1-3 alkylene-OC1-3 alkyl, -C1-3 alkylene-NH m3 (C1-3 alkyl) 1-m3C (O) NHm4 (C1-3 alkyl) 2-m4, -C1-3 alkylene-NHC (O) OR6C, (C1-3 alkyl) 2P (O) -, (C1-3 alkyl) 2N- (C1-3 alkyl) P (O) -. In some embodiments, R6 is selected from the group consisting of -CH2NHMe, -CH2NHEt, -CH2NHC3H7, - (CH2) 2NHMe, - (CH2) 2NHEt, - (CH2) 2NH C3H7, - (CH2) 3NHMe, - (CH2) 3NHEt, (CH2) 3NHC3H7, -CH2N (Me) 2, -CH2N (Et) 2, -CH2N (C3H7) 2, - (CH2) 2N (Me) 2, - (CH2) 2N (Et) 2, - (CH2) 2N (C3H7) 2, - (CH2) 3N (Me) 2, - (CH2) 3N (Et) 2, - (CH2) 3N (C3H7) 2, -CH2OH, - (CH2) 2OH, - (CH2) 3OH; -CH2OMe, -CH2(OCH2) Me, -CH2 (OCH2) Et, -CH2 (OCH2) C3H7, -CH2NHCH2CF3, - (CH2) 2NHCH2CF3, - (CH2) 3NHCH2CF3, -CH2NHCH2CHF2, - (CH2) 2NHCH2CHF2, - (CH2) 3NHCH2CHF2, -CH2NHC (O) OMe, -CH2NHC (O) OEt, -CH2NHC (O) OC3H7, - (CH2) 2NHC (O) OMe, - (CH2) 2NHC (O) OEt, - (CH2) 2NHC (O) OC3H7, - (CH2) 3NHC (O) OMe, - (CH2) 3NHC (O) OEt, and - (CH2) 3NHC (O) OC3H7.
[0173] In some embodiments, the compound of formula (I-a) , or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, is the compound of formula (I-o) :
[0174] wherein,
[0175] ring B is a 5-10 membered hereroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S, optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, aminoalkyl, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, oxo and nitro.
[0176] In a preferred embodiment, ring B is selected from the group consisting of optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, aminoalkyl, cyano, hydroxyl, C1-3 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl, oxo and nitro.
[0177] In some embodiments, the compound of formula (I-a) , or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, is the compound of formula (I-p) or (I-p1) ,
[0178] wherein,
[0179] X is CH2 or N;
[0180] Rp is selected from the group consisting of (i) hydrogen, deuterium, halogen, amino, cyano, hydroxy, C1-6 aminoalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, (ii) 3-6 membered cycloalkyl, optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, aminoalkyl, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, oxo and nitro;
[0181] preferably, 3-6 membered cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl and cyclohexane, optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, aminoalkyl, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, oxo and nitro;
[0182] k1 is 0, 1, 2 or 3.
[0183] In some embodiments, the compound of formula (I-a) , or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, is the compound of formula (I-q) , (I-q1) , (I-q2) , (I-q3) , (I-q4) , (I-q5) , (I-q6) , (I-q7) or (I-q8) :
[0184] wherein,
[0185] R1 is selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, C1-6 alkyl;
[0186] R2 is selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, C1-3 alkyl, amino, C1-3 aminoalkyl, cyano;
[0187] R3 is selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-3 aminoalkyl, cyano, -CONH-, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl;
[0188] R4 is selected from the group consisting of deuterium, halogen, amino, C1-3 aminoalkyl, cyano, -CONH-, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl, C1-3 hydroxyalkenyl;
[0189] R5 is selected from the group consisting of deuterium, halogen, amino, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl, C1-3 aminoalkyl, C1-3 hydroxyalkoxy, - (CRaRb) n-C (O) Re, -OS (O) 2Re, -S (O) 2Re, -O- (CH2) m5 -CRa5Rb5- (CH2) m6-OH, -O- (CH2) m5- (CRa8Rb8) m7- (CH2) m6-OH , C3-6 cycloalkyl, -O-C3-6 cycloalkyl, -NRa6Rb6, wherein, the C3-6 cycloalkyl is optionally substituted with one or more substituents selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl;
[0190] R6 is selected from -C (O) OCH3, -CONH2, -NHC (O) OC1-6 alkyl, -NHCH2C (O) NH2, -NHC (O) NHC1-6 alkyl, -CONHC1-6 deuterated alkyl, -C≡CCH2Re1, -C≡CRe1, -CH3, -NHC (O) Re1, -C≡CCH2NH2, S (O) 2Re, -CONHC1-6 alkyl, -CONHC1-6 deuterated alkyl, -C1-6 alkylene NHC1-6 alkyl, -C1-6 alkyleneNH2, -C1-6 alkylene-N (C1-6 alkyl) 2, -CH (OH) C1-6 alkyl, -CH2 (OCH2) C1-6 alkyl, -CH2OMe, -C (O) H, C1-6 hydroxyalkyl, -NHC1-6 alkyl, - (CH2) n1NH (CH2) m1Rf, - (CH2) n1O (CH2) m1Rf, -CH (Rg) NH (CH2) m1Rf, -C1-6 alkylene NHC (O) C1-6 alkyl, R6A, -C1-6 alkylene-R6A, -C1-6 alkylene-R6B, -C1-6 alkylene-NHCH2CHm2F3-m2, -C1-6 alkylene-NHC1-6 alkylene-OH, -C1-6 alkylene-NH-C1-6 alkylene-OC1-6 alkyl, -C1-6 alkylene-NHm3 (C1-6 alkyl) 1-m3C (O) NHm4 (C1-6 alkyl) 2-m4, -C1-6 alkylene-NHC (O) OR6C, (C1-6 alkyl) 2P (O) -, (C1-6 alkyl) 2N- (C1-6 alkyl) P (O) -, MeNH-C3-10 cycloalkylene-, OH-C3-10 cycloalkylene-, NHm4 (C1-6 alkyl) 2-m4 (COOH) CH-, -C (O) NH-R6B, -C (O) -R6B;
[0191] R6A is -C2-10 heteroaryl which is optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-3 aminoalkyl, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C2-3 haloalkyl, C1-3hydroxyalkyl, -CH2OC1-6 alkyl;
[0192] R6B is C5-10 cylcoalkyl, C5-10 spiro cylcoalkyl, C5-10 fused cylcoalkyl, C5-10 bridged cylcoalkyl, C5-10 heterocyclyl, C5-10 spiro heterocyclyl, C5-10 fused heterocyclyl and C5-10 bridged heterocyclyl, wherein said heterocyclyl, spiro heterocyclyl, fused heterocyclyl and bridged heterocyclyl contain one or more heteroatoms slected from N, O or S, optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-3 aminoalkyl, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C2-3 haloalkyl, C1-3hydroxyalkyl, -CH2OC1-6 alkyl, oxo, C5-10 heterocyclyl, C1-6 acyl, C5-10 heterocyclyl -NH-, halo C5-10 heterocyclyl;
[0193] preferably, R6B is selected from the group of optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, fluoro, chloro, amino, C1-3 aminoalkyl, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C2-3 haloalkyl, C1-3hydroxyalkyl; R6C is C1-6 alkyl, C3-10 cycloalkyl, the cycloalkyl is optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-3 aminoalkyl, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C2-3 haloalkyl, C1-3hydroxyalkyl, -CH2OC1-6 alkyl, oxo;
[0194] Re1 is selected from the group consisting of deuterium, halogen, amino, cyano, hydroxyl, C (O) NH2, deuterated C1-3 alkyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl, C5-10 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O or S;
[0195] Rf is selected from the group consisting of C3-10 cycloalkyl, 5-10 membered hereroaryl, C2-10 spiro heterocyclyl, C5-10 heterocyclyl, wherein the hereroaryl, spiro heterocyclyl, heterocyclyl comprising 1, 2 or 3 heteroatoms selected from N, O and S, the cycloalkyl, hereroaryl, spiro heterocyclyl and heterocyclyl are each optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-3 aminoalkyl, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C2-3 haloalkyl, C1-3hydroxyalkyl, oxo, nitro, and CF3; preferably, Rf is seleced from
[0196] Rg is selected from the group consisting of deuterium, halogen, amino, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl; Ra and Rb are each independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, C3-10 cycloalkyl;
[0197] Ra5, Rb5, Ra8 and Rb8 are each independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl;
[0198] or, Ra5 and Rb5 together with atom which they are attached to form a C3-6 cycloalkyl, C6-10 aryl, C5-10 heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O or S, 5-10 membered heterocyclyl containing 1, 2 or 3 heteroatoms selected from N, O or S, optionally substituted with one or more substituents seleted from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl;
[0199] optionally, one Ra8 and one Rb8 together with different C atoms they are attached to form a C3-6 cycloalkyl, C6-10 aryl, C5-10 heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O or S, 5-10 membered heterocyclyl containing 1, 2 or 3 heteroatoms selected from N, O or S, optionally substituted with one or more substituents seleted from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl;
[0200] Ra6 and Rb7 are each independently selected from the group consisting of deuterium, halogen, amino, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl;
[0201] Re is selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, C5-10 heteroaryl comprising 1 2 or 3 heteroatoms selected from N, O or S;
[0202] Rq21 is selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, C3-10 cycloalkyl;
[0203] preferably, Rq21 is selected from the hydrogen;
[0204] Rq22 is selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, C3-10 cycloalkyl;
[0205] preferably, Rq22 is selected from the group consisting of C1-6 haloalkyl, C3-6 cycloalkyl; or, Rq21 and Rq21 together with the carbon atom to which they are attached form a C3-6 cycloalkyl;
[0206] preferably, Rq21 and Rq21 are together with the carbon atom to which they are attached form cyclobutyl, cyclopropyl;
[0207] Rq23 and Rq24 are selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, C3-10 cycloalkyl;
[0208] or, Rq23 and Rq24 together with the carbon atom to which they are attached form a C3-6 cycloalkyl;
[0209] ring E is selected from the group C3-10 cycloalkyl, C6-10 aryl, 5-10 membered hereroaryl, 5-10 membered heterocyclyl, wherein containing 1, 2 or 3 heteroatoms selected from N, O or S;
[0210] n, n1 and m1 are each indepently 0, 1, 2 or 3;
[0211] m3 is 0, 1;
[0212] m2 and m4 are each indepently 0, 1 or 2;
[0213] m5 and m6 are each indepently 0, 1, 2 or 3,
[0214] and m7 is 2, 3 or 4.
[0215] In some embodiments, R5 is selected from the group consisting of optionally substituted with one or more substituents seleted from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, and C1-3 hydroxyalkyl.
[0216] In some embodiments, R6B is selected from the group consisting of optionally substituted with one or more substituents seleted from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, and C1-3 hydroxyalkyl.
[0217] In some embodiments, one Ra8 and one Rb8 together with different C atoms they are attached to form
[0218] The present invention also provides a pharmaceutical composition, comprising a therapeutically effective amount of a compound of formula desiered above, or a tautomer, cis-or trans isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, together with one or more pharmaceutically acceptable carriers, diluents or excipients. In some embodiments, in above stated pharmaceutical composition, the amount of the compound, tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salts thereof is about 0.1-95%by weight of free base; preferably, is about 5-70%, e.g. 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%.
[0219] In some embodiment, above stated pharmaceutical composition is formulated as a tablet, capsule, liquid form or injection form.
[0220] In some embodiment, in above stated pharmaceutical composition, the amount of the compound, tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salts thereof is about 1-1000mg; preferably, is about 1-500mg, more preferably, is about 1mg, 2mg, 3mg, 5mg, 10mg, 20mg, 40mg, 50mg, 60mg, 80mg, 100mg, 200mg, 300mg, 400m or 500mg. In some embodiment, the compound, tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salts thereof is can be administered by any suitable route of administration, e.g. oral, parenteral, buccal, sublingual, nasal, rectal, intrathecal or transdermal administration, and the pharmaceutical compositions adapted accordingly.
[0221] In some embodiment, the compound, tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salts is formulated as a soild or liquid form, e.g. syrups, suspension, emulsion, tablets, capsules, powders, granules or lozenges.
[0222] In other aspect, the present invention provides a method of treating a disease or condition mediated by YAP overexpression and / or YAP amplification and / or YAP / TAZ-TEAD interaction comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formulas desired herein, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition the same.. In other aspect, the present invention provides a method of treating a cancer or tumor that harbors one or more YAP / TAZ fusions, or one or more functional YAP / TAZ fusions, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula desired herein, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition the same.
[0223] In another aspect, the present invention relates to a method for treating a disease, condition, cancer or tumor comprising administering to a subject in need thereof an effective amount of the compound of the formula desired herein or a pharmaceutical composition comprising the same.
[0224] In some embodiments, the disease, condition, cancer or tumor is selected from mesothelioma (including pleural mesothelioma, malignant pleural mesothelioma, peritoneal mesothelioma, pericardial mesothelioma and mesothelioma of the tunica vaginalis) , carcinoma (including cervical squamous cell carcinoma, endometrial carcinoma, esophageal squamous cell carcinoma, esophageal adenocarcinoma, urothelial carcinoma of the bladder and squamous cell carcinoma of the skin) , poroma (benign poroma) , porocarcinoma (including malignant porocarcinoma) , supratentorial ependymoma (including childhood supratentorial ependymoma) , epithelioid hemangioendothelioma (EHE) , ependymal tumor, a solid tumor, breast cancer (including triple negative breast cancer) , lung cancer (including non-small cell lung cancer) , ovarian cancer, colorectal cancer (including colorectal carcinoma) , melanoma, pancreatic cancer (including pancreatic adenocarcinoma) , prostate cancer, gastric cancer, esophageal cancer, liver cancer (including hepatocellular carcinoma, cholangiocarcinoma and hepatoblastoma) , neuroblastoma, Schwannoma, kidney cancer, sarcoma (including rhabdomyosarcoma, embryonic rhabdomyosarcoma (ERMS) , osteosarcoma, undifferentiated pleomorphic sarcomas (UPS) , Kaposi’s sarcoma, soft-tissue sarcoma and rare soft-tissue sarcoma) , bone cancer, brain cancer, medulloblastoma, glioma, meningioma, and head and neck cancer (including head and neck squamous cell carcinoma) .DETAILED DESCRIPTION OF THE INVENTION
[0225] Various publications, articles and patents are cited or described throught the specification; each of these references is herein incorporated by references in its entirety. Discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is for the purpose of providing context for the disclosure. Such discussion is not an admission that any or all of these matters form part of the prior art with respect to the disclosure.
[0226] Given below are definitions of terms used in this invention. Any term not defined herein takes the normal meaning as the skilled person would understand the term.
[0227] Where it is stated that groups or substituents are “independently selected from” (and variants thereof) a list of choices, it is meant that the choice for any one of such groups or substituents does not determine the choice for any other one of such groups or substituents. By way of an illustration, but not as a limitation, the term “A and B are independently selected from a and b” or “each of A and B is independently selected from a and b” is meant to encompass selections where A is a and B is a, A is b and B is b, A is a and B is b, and A is b and B is a.
[0228] It must be noted that as used herein and in the appended claims, the singular forms “a, ” “an, ” and “the” include plural reference unless the context clearly dictates otherwise. Unless otherwise indicated, the term “at least” preceding a series of elements is to be understood to refer to every element in the series. For example, the phrase “at least A, B, and C” means that each of A, B, and C is present. The term “at least one of” preceding a series of elements is to be understood to refer to a single element in the series or any combination of two or more elements in the series. For example, the phrase “at least one of A, B, and C” means that only A is present, only B is present, only C is present, both A and B are present, both A and C are present, both B and C are present, or each of A, B, and C is present. Depending on the context, “at least one of” preceding a series of elements can also encompass situations in which any one or more of 3 the elements is present in greater than one instance, e.g., “at least one of A, B, and C” can also encompass situations in which A is present in duplicate alone or further in combination with any one or more of elements B and C.
[0229] As used herein, the conjunctive term “and / or” between multiple recited elements is understood as encompassing both individual and combined options. For instance, where two elements are conjoined by “and / or, ” a first option refers to the applicability of the first element without the second. A second option refers to the applicability of the second element without the first. A third option refers to the applicability of the first and second elements together. Any one of these options is understood to fall within the meaning, and therefore satisfy the requirement of the term “and / or” as used herein. Concurrent applicability of more than one of the options is also understood to fall within the meaning, and therefore satisfy the requirement of the term “and / or. ”
[0230] “Alkyl” refers to a saturated aliphatic hydrocarbon group including C1-C20 straight chain and branched chain groups. Preferably an alkyl group is an alkyl having 1 to 12, sometimes preferably 1 to 6, sometimes more preferably 1 to 4, carbon atoms. Representative examples include, but are not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1, 1-dimethyl propyl, 1, 2-dimethyl propyl, 2, 2-dimethyl propyl, 1-ethyl propyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1, 1, 2-trimethylpropyl, 1, 1-dimethylbutyl, 1, 2-dimethylbutyl, 2, 2-dimethylbutyl, 1, 3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2, 3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2, 3-dimethylpentyl, 2, 4-dimethylpentyl, 2, 2-dimethylpentyl, 3, 3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2, 3-dimethylhexyl, 2, 4-dimethylhexyl, 2, 5-dimethylhexyl, 2, 2-dimethylhexyl, 3, 3-dimethylhexyl, 4, 4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl- 2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2, 2-diethylpentyl, n-decyl, 3, 3-diethylhexyl, 2, 2-diethylhexyl, and the isomers of branched chain thereof. More preferably an alkyl group is a lower alkyl having 1 to 6 carbon atoms. Representative examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1, 1-dimethylpropyl, 1, 2-dimethylpropyl, 2, 2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1, 1, 2-trimethylpropyl, 1, 1-dimethylbutyl, 1, 2-dimethylbutyl, 2, 2-dimethylbutyl, 1, 3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2, 3-dimethylbutyl, etc. The alkyl group can be substituted or unsubstituted. When substituted, the substituent group (s) can be substituted at any available connection point, preferably the substituent group (s) is one or more substituents independently selected from the group consisting of alkyl, halogen, alkoxy, alkenyl, alkynyl, alkylsulfo, alkylamino, thiol, hydroxy, nitro, cyano, amino, cycloalkyl, heterocyclic alkyl, aryl, heteroaryl, cycloalkoxyl, heterocylic, cycloalkylthio, heterocylic alkylthio and oxo group.
[0231] “Alkenyl” refers to an alkyl defined as above that has at least two carbon atoms and at least one carbon-carbon double bond, for example, vinyl, 1-propenyl, 2-propenyl, 1-, 2-, or 3-butenyl, etc., preferably C2-20 alkenyl, more preferably C2-12 alkenyl, and most preferably C2-6 alkenyl. The alkenyl group can be substituted or unsubstituted. When substituted, the substituent group (s) is preferably one or more, sometimes preferably one to five, sometimes more preferably one to three, group (s) independently selected from the group consisting of alkyl, halogen, alkoxy, alkenyl, alkynyl, alkylsulfo, alkylamino, thiol, hydroxy, nitro, cyano, amino, cycloalkyl, heterocyclic alkyl, aryl, heteroaryl, cycloalkoxyl, heterocylic, cycloalkylthio, heterocylic alkylthio and oxo group.
[0232] “Alkynyl” refers to an alkyl defined as above that has at least two carbon atoms and at least one carbon-carbon triple bond, for example, ethynyl, 1-propynyl, 2-propynyl, 1-, 2-, or 3-butynyl etc., preferably C2-20 alkynyl, more preferably C2-12 alkynyl, and most preferably C2-6 alkynyl. The alkynyl group can be substituted or unsubstituted. When substituted, the substituent group (s) is preferably one or more, sometimes preferably one to five, sometimes more preferably one to three, group (s) independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylsulfo, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocyclic alkyl, aryl, heteroaryl, cycloalkoxyl, heterocylic alkoxyl, cycloalkylthio and heterocylic alkylthio.
[0233] “Alkylene” refers to a saturated linear or branched aliphatic hydrocarbon group, wherein having 2 residues derived by removing two hydrogen atoms from the same carbon atom of the parent alkane or two different carbon atoms. The straight or branched chain group containing 1 to 20 carbon atoms, preferably has 1 to 12 carbon atoms, more preferably 1 to 6 carbon atoms. Non-limiting examples of alkylene groups include, but are not limited to, methylene (-CH2-) , 1, 1-ethylene (-CH (CH3) -) , 1, 2-ethylene (-CH2CH2) -, 1, 1-propylene (-CH (CH2CH3) -) , 1, 2-propylene (-CH2CH (CH3) -) , 1, 3-propylene (-CH2CH2CH2-) , 1, 4-butylidene (-CH2CH2CH2CH2-) etc. The alkylene group can be substituted or unsubstituted. When substituted, the substituent group (s) is preferably one or more, sometimes preferably one to five, sometimes more preferably one to three, group (s) independently selected from the group consisting of selected from alkyl, alkenyl, alkynyl, alkoxy, alkylsulfo, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocyclic alkyl, aryl, heteroaryl, cycloalkoxyl, heterocylic alkoxyl, cycloalkylthio and heterocylic alkylthio.
[0234] “Alkenylene” refers to an alkylene defined as above that has at least two carbon atoms and at least one carbon-carbon double bond, preferably C2-20 alkenylene, more preferably C2-12 alkenylene, and most preferably C2-6 alkenylene. Non-limiting examples of alkenylene groups include, but are not limited to, -CH=CH-, -CH=CHCH2-, -CH=CHCH2CH2-, -CH2CH=CHCH2-etc. The alkenylene group can be substituted or unsubstituted. When substituted, the substituent group (s) is preferably one or more, sometimes preferably one to five, sometimes more preferably one to three, group (s) independently selected from the group consisting of selected from alkyl, alkenyl, alkynyl, alkoxy, alkylsulfo, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocyclic alkyl, aryl, heteroaryl, cycloalkoxyl, heterocylic alkoxyl, cycloalkylthio and heterocylic alkylthio.
[0235] “Alkynylene” refers to an alkynyl defined as above that has at least two carbon atoms and at least one carbon-carbon triple bond, preferably C2-20 alkynylene, more preferably C2-12 alkynylene, and most preferably C2-6 alkynylene. Non-limiting examples of alkenylene groups include, but are not limited to, -CH≡CH-, -CH≡CHCH2-, -CH≡CHCH2CH2-, -CH2CH≡CHCH2-etc. The alkynylene group can be substituted or unsubstituted. When substituted, the substituent group (s) is preferably one or more, sometimes preferably one to five, sometimes more preferably one to three, group (s) independently selected from the group consisting of selected from alkyl, alkenyl, alkynyl, alkoxy, alkylsulfo, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocyclic alkyl, aryl, heteroaryl, cycloalkoxyl, heterocylic alkoxyl, cycloalkylthio and heterocylic alkylthio.
[0236] “Cycloalkyl” refers to a saturated and / or partially unsaturated monocyclic or polycyclic hydrocarbon group having 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, more preferably 3 to 10 carbon atoms, and most preferably 3 to 8 carbon atoms or 3 to 6 carbon atoms. Representative examples of monocyclic cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, etc. Polycyclic cycloalkyl includes a cycloalkyl having a spiro ring, fused ring or bridged ring.
[0237] “Spiro Cycloalkyl” refers to a 5 to 20 membered polycyclic group with rings connected through one common carbon atom (called a spiro atom) , wherein one or more rings can contain one or more double bonds, but none of the rings has a completely conjugated pi-electron system. Preferably a spiro cycloalkyl is 6 to 14 membered, and more preferably 7 to 10 membered. According to the number of common spiro atoms, a spiro cycloalkyl is divided into mono-spiro cycloalkyl, di-spiro cycloalkyl, or poly-spiro cycloalkyl, and preferably refers to a mono-spiro cycloalkyl or di-spiro cycloalkyl, more preferably 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered, or 5-membered / 6-membered mono-spiro cycloalkyl. Representative examples of spiro cycloalkyl include, but are not limited to the following substituents:
[0238] “Fused Cycloalkyl” refers to a 5 to 20 membered polycyclic hydrocarbon group, wherein each ring in the system shares an adjacent pair of carbon atoms with another ring, wherein one or more rings can contain one or more double bonds, but none of the rings has a completely conjugated pi-electron system. Preferably, a fused cycloalkyl group is 6 to 14 membered, more preferably 7 to 10 membered. According to the number of membered rings, fused cycloalkyl is divided into bicyclic, tricyclic, tetracyclic or polycyclic fused cycloalkyl, and preferably refers to a bicyclic or tricyclic fused cycloalkyl, more preferably 5-membered / 5-membered, or 5-membered / 6-membered bicyclic fused cycloalkyl. Representative examples of fused cycloalkyls include, but are not limited to, the following substituents:
[0239] “Bridged Cycloalkyl” refers to a 5 to 20 membered polycyclic hydrocarbon group, wherein every two rings in the system share two disconnected carbon atoms. The rings can have one or more double bonds, but have no completely conjugated pi-electron system. Preferably, a bridged cycloalkyl is 6 to 14 membered, and more preferably 7 to 10 membered. According to the number of membered rings, bridged cycloalkyl is divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl, and preferably refers to a bicyclic, tricyclic or tetracyclic bridged cycloalkyl, more preferably a bicyclic or tricyclic bridged cycloalkyl. Representative examples of bridged cycloalkyls include, but are not limited to, the following substituents:
[0240] The cycloalkyl can be fused to the ring of an aryl, heteroaryl or heterocyclic alkyl, wherein the ring bound to the parent structure is cycloalkyl. Representative examples include, but are not limited to indanylacetic, tetrahydronaphthalene, benzocycloheptyl and so on:
[0241] The cycloalkyl is optionally substituted or unsubstituted. When substituted, the substituent group (s) is preferably one or more, sometimes preferably one to five, sometimes more preferably one to three, substituents independently selected from the group consisting of alkyl, halogen, alkoxy, alkenyl, alkynyl, alkylsulfo, alkylamino, thiol, hydroxy, nitro, cyano, amino, cycloalkyl, heterocyclic alkyl, aryl, heteroaryl, cycloalkoxyl, heterocylic, cycloalkylthio, heterocylic alkylthio and oxo group. “Heterocyclyl” refers to a 3 to 20 membered saturated and / or partially unsaturated monocyclic or polycyclic hydrocarbon group having one or more, sometimes preferably one to five, sometimes more preferably one to three, heteroatoms selected from the group consisting of N, O, and S (O) m (wherein m is 0, 1, or 2) as ring atoms, but excluding -O-O-, -O-S-or -S-S-in the ring, the remaining ring atoms being C. Preferably, heterocyclyl is a 3 to 12 membered having 1 to 4 heteroatoms; more preferably a 3 to 10 membered having 1 to 3 heteroatoms; most preferably a 5 to 6 membered having 1 to 2 heteroatoms. Representative examples of monocyclic heterocyclyls include, but are not limited to, pyrrolidyl, piperidyl, piperazinyl, morpholinyl, sulfo-morpholinyl, homopiperazinyl, and so on. Polycyclic heterocyclyl includes the heterocyclyl having a spiro ring, fused ring or bridged ring.
[0242] “Spiro heterocyclyl” refers to a 5 to 20 membered polycyclic heterocyclyl with rings connected through one common carbon atom (called a spiro atom) , wherein said rings have one or more, sometimes preferably one to five, sometimes more preferably one to three, heteroatoms selected from the group consisting of N, O, and S (O) m (wherein m is 0, 1 or 2) as ring atoms, the remaining ring atoms being C, wherein one or more rings can contain one or more double bonds, but none of the rings has a completely conjugated pi-electron system. Preferably a spiro heterocyclyl is 6 to 14 membered, and more preferably 7 to 10 membered. According to the number of common spiro atoms, spiro heterocyclyl is divided into mono-spiro heterocyclyl, di-spiro heterocyclyl, or poly-spiro heterocyclyl, and preferably refers to mono-spiro heterocyclyl or di-spiro heterocyclyl, more preferably 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered, or 5-membered / 6-membered mono-spiro heterocyclyl. Representative examples of spiro heterocyclyl include, but are not limited to the following substituents:
[0243] “Fused Heterocyclyl” refers to a 5 to 20 membered polycyclic heterocyclyl group, wherein each ring in the system shares an adjacent pair of carbon atoms with the other ring, wherein one or more rings can contain one or more double bonds, but none of the rings has a completely conjugated pi-electron system, and wherein said rings have one or more, sometimes preferably one to five, sometimes more preferably one to three, heteroatoms selected from the group consisting of N, O, and S (O) p (wherein p is 0, 1, or 2) as ring atoms, the remaining ring atoms being C. Preferably a fused heterocyclyl is 6 to 14 membered, and more preferably 7 to 10 membered. According to the number of membered rings, fused heterocyclyl is divided into bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclyl, preferably refers to bicyclic or tricyclic fused heterocyclyl, more preferably 5-membered / 5-membered, or 5-membered / 6-membered bicyclic fused heterocyclyl. Representative examples of fused heterocyclyl include, but are not limited to, the following substituents:
[0244] “Bridged Heterocyclyl” refers to a 5 to 14 membered polycyclic heterocyclic alkyl group, wherein every two rings in the system share two disconnected atoms, the rings can have one or more double bonds, but have no completely conjugated pi-electron system, and the rings have one or more heteroatoms selected from the group consisting of N, O, and S (O) m (wherein m is 0, 1, or 2) as ring atoms, the remaining ring atoms being C. Preferably a bridged heterocyclyl is 6 to 14 membered, and more preferably 7 to 10 membered. According to the number of membered rings, bridged heterocyclyl is divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocyclyl, and preferably refers to bicyclic, tricyclic or tetracyclic bridged heterocyclyl, more preferably bicyclic or tricyclic bridged heterocyclyl. Representative examples of bridged heterocyclyl include, but are not limited to, the following substituents:
[0245] The ring of said heterocyclyl can be fused to the ring of an aryl, heteroaryl or cycloalkyl, wherein the ring bound to the parent structure is heterocyclyl. Representative examples include, but are not limited to the following substituents:
[0246] etc.
[0247] The heterocyclyl is optionally substituted or unsubstituted. When substituted, the substituent group (s) is preferably one or more, sometimes preferably one to five, sometimes more preferably one to three, group (s) independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylsulfo, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocyclic alkyl, aryl, heteroaryl, cycloalkoxyl, heterocylic alkoxyl, cycloalkylthio, heterocylic alkylthio and -NR9R10. “Aryl” refers to a 6 to 14 membered all-carbon monocyclic ring or a polycyclic fused ring (a "fused" ring system means that each ring in the system shares an adjacent pair of carbon atoms with another ring in the system) group, and has a completely conjugated pi-electron system. Preferably aryl is 6 to 10 membered, such as phenyl and naphthyl, most preferably phenyl. The aryl can be fused to the ring of heteroaryl, heterocyclyl or cycloalkyl, wherein the ring bound to parent structure is aryl. Representative examples include, but are not limited to, the following substituents:
[0248] The aryl group can be substituted or unsubstituted. When substituted, the substituent group (s) is preferably one or more, sometimes preferably one to five, sometimes more preferably one to three, substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylsulfo, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocyclic alkyl, aryl, heteroaryl, cycloalkoxyl, heterocylic alkoxyl, cycloalkylthio, heterocylic alkylthio.
[0249] “Heteroaryl” refers to an aryl system having 1 to 4 heteroatoms selected from the group consisting of O, S and N as ring atoms and having 5 to 14 annular atoms. Preferably a heteroaryl is 5-to 10-membered, more preferably 5-or 6-membered, for example, thiadiazolyl, pyrazolyl, oxazolyl, oxadiazolyl, imidazolyl, triazolyl, thiazolyl, furyl, thienyl, pyridyl, pyrrolyl, N-alkyl pyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl, and the like. The heteroaryl can be fused with the ring of an aryl, heterocyclyl or cycloalkyl, wherein the ring bound to parent structure is heteroaryl. Representative examples include, but are not limited to, the following substituents:
[0250] The heteroaryl group can be substituted or unsubstituted. When substituted, the substituent group (s) is preferably one or more, sometimes preferably one to five, sometimes more preferably one to three, substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylsulfo, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocyclic alkyl, aryl, heteroaryl, cycloalkoxyl, heterocylic alkoxyl, cycloalkylthio, heterocylic alkylthio.
[0251] “Alkoxy” refers to both an -O- (alkyl) and an -O- (unsubstituted cycloalkyl) group, wherein the alkyl is defined as above. Representative examples include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like. The alkoxyl can be substituted or unsubstituted. When substituted, the substituent is preferably one or more, sometimes preferably one to five, sometimes more preferably one to three, substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylsulfo, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocyclic alkyl, aryl, heteroaryl, cycloalkoxyl, heterocylic alkoxyl, cycloalkylthio and heterocylic alkylthio.
[0252] “Bond” refers to a covalent bond using a sign of “-” .
[0253] "Hydroxyalkyl" refers to an alkyl group substituted by a hydroxy group, wherein alkyl is as defined above.
[0254] “Hydroxyl” or “hydroxy” refers to an -OH group.
[0255] “Halogen” or “halo” refers to fluoro, chloro, bromo or iodo.
[0256] “Amino” refers to a -NH2 group.
[0257] “Cyano” refers to a -CN group.
[0258] “Nitro” refers to a -NO2 group.
[0259] “Oxo group” refers to a =O group.
[0260] “Carboxyl” refers to a -C (O) OH group.
[0261] “Alkoxycarbonyl” refers to a -C (O) O (alkyl) or (cycloalkyl) group, wherein the alkyl and cycloalkyl are defined as above.
[0262] The term “isotopic substitution” as used herein refers to the substitution of an atom with its isotope. The term “isotope” as used herein refers to an atom having the same atomic number as that of atoms dominant in nature but having a mass number (neutron number) different from the mass number of the atoms dominant in nature. It is understood that a compound with an isotopic substitution refers to a compound in which at least one atom contained therein is substituted with its isotope. Atoms that can be substituted with its isotope include, but are not limited to, hydrogen, carbon, and oxygen. Examples of the isotope of a hydrogen atom include2H (also represented as D) and3H. Examples of the isotope of a carbon atom include13C and14C. Examples of the isotope of an oxygen atom include18O. Unless otherwise stated, all isotopic substitution of the compounds described herein are within the scope of the disclosure.
[0263] “Optional” or “optionally” means that the event or circumstance described subsequently can, but need not, occur, and the description includes the instances in which the event or circumstance may or may not occur. For example, “the heterocyclic group optionally substituted by an alkyl” means that an alkyl group can be, but need not be, present, and the description includes the case of the heterocyclic group being substituted with an alkyl and the heterocyclic group being not substituted with an alkyl. “Substituted” refers to one or more hydrogen members in a group independently substituted with a corresponding number of substituents. In some embodiments, the number of such hydrogen members is up to 5. In other embodiemtns it si between 1 and 3. It goes without saying that the substituents exist in their only possible chemical position. The person skilled in the art is able to determine if the substitution is possible or impossible without paying excessive efforts by experiment or theory. For example, the combination of amino or hydroxyl group having free hydrogen and carbon atoms having unsaturated bonds (such as olefinic) may be unstable.
[0264] A “pharmaceutical composition” refers to a mixture of one or more of the compounds described in the present invention or physiologically / pharmaceutically acceptable salts or prodrugs thereof and other chemical components such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism, which is conducive to the absorption of the active ingredient and thus displaying biological activity.
[0265] “Pharmaceutically acceptable salts” refer to salts of the compounds described herein, such salts being safe and effective when used in a mammal and have corresponding biological activity.
[0266] One skilled in the art will recognize that in certain embodiments compounds described herein can have one or more asymmetric carbon atoms in their structure. As used herein, any chemical formulas with bonds shown only as solid lines and not as solid wedged or hashed wedged bonds contemplates each possible stereoisomer, or mixture of two or more stereoisomers. Stereoisomers includes enantiomers and diastereomers. Enantiomers are stereoisomers that are non-super-imposable mirror images of each other. A 1: 1 mixture of a pair of enantiomers is a racemate or racemic mixture. Diastereomers (or diastereoisomers) are stereoisomers that are not enantiomers, i.e., they are not related as mirror images, and occur when two or more stereoisomers of a compound have different configurations at one or more of the equivalent stereocenters and are not mirror images of each other. Substituent groups (e.g., alkyl, heterocyclyl, etc. ) can contain stereocenters in either the R or S configuration.
[0267] Thus, included within the scope of the invention are the stereochemically pure isomeric forms of the compounds described herein (i.e., a single enantiomer or a single diastereomer) as well as mixtures thereof including their racemates. For example, when a compound is for instance specified as (R) , this means that the compound is substantially free of the (S) isomer. Compounds described herein can be used as racemic mixtures, enantiomerically or diastereomerically enriched mixtures, or as enantiomerically or diastereomerically pure individual stereoisomers.
[0268] Stereochemically pure isomeric forms can be obtained by techniques known in the art in view of the present disclosure. For example, diastereoisomers can be separated by physical separation methods such as fractional crystallization and chromatographic techniques, and enantiomers can be separated from each other by the selective crystallization of the diastereomeric salts with optically active acids or bases or by chiral chromatography. Pure stereoisomers can also be prepared synthetically from appropriate stereochemically pure starting materials, or by using stereoselective reactions.
[0269] Compounds described herein can also have mesomers. The term “mesomer” refers to a non-optically active stereoisomer. A mesomer contains two or more stereogenic centers but is not chiral.
[0270] Compounds described herein can also form tautomers. The term “tautomer” refers to compounds that are interchangeable forms of a particular compound structure and that vary in the displacement of hydrogen atoms and electrons. Tautomers are constitutional isomers of chemical compounds that readily interconvert, usually resulting in relocation of a proton (hydrogen) . Thus, two structures can be in equilibrium through the movement of pi electrons and an atom (usually hydrogen) . All tautomeric forms and mixtures of tautomers of the compounds described herein are included with the scope of the invention.
[0271] Compounds described herein can exist in solvated and unsolvated forms. The term “solvate” means a physical association, e.g., by hydrogen bonding, of a compound of the invention with one or more solvent molecules. The solvent molecules in the solvate can be present in a regular arrangement and / or a non-ordered arrangement. The solvate can comprise either a stoichiometric or nonstoichiometric amount of the solvent molecules. “Solvate” encompasses both solution-phase and isolable solvates. Compounds of the invention can form solvates with water (i.e., hydrates) or common organic solvents. Exemplary solvates include, but are not limited to, hydrates, ethanolates, methanolates, and isopropanolates.
[0272] As used herein, the name of a compound is intended to encompass all possible existing isomeric forms, including stereoisomers (e.g., enantiomers, diastereomers, racemate or racemic mixture, and any mixture thereof) of the compound.
[0273] EXAMPLES
[0274] The following examples serve to illustrate the invention, but the examples should not be considered as limiting the scope of the invention. If specific conditions for an experimental method are not specified in the examples of the present invention, they are generally in accordance with conventional conditions or recommended conditions of the raw materials and the product manufacturer. The reagents without a specific source indicated are commercially available, conventional reagents.
[0275] Synthetic Procedure
[0276] Synthesis of Key Intermediate A-0’
[0277] To 2- (tert-butoxycarbonyl) -2-azabicyclo [4.1.0] heptane-3-carboxylic acid (5.3 g, 22.1 mmol) in toluene (50 mL) at -78℃ was added 1.5 M DIBAL in toluene (33.8 mL, 50.7 mmol) drop-wise over 40 minutes. Methanol (120 mL) was then added drop-wise at -78 ℃ over 10 minutes. The reaction mixture was moved to an ice-bath where 10%wt citric acid (500 mL) was added and then mixture was stirred for an additional 1 hour. After the resulting mixture was extracted with ethyl acetate (2 times) , the organic layer washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to provide tert-butyl 3-formyl-2-azabicyclo [4.1.0] heptane-2-carboxylate (4.7 g, 95%) . m / z = 226.3 (M+1, ESI+)
[0278] Synthesis of Key Intermediate A
[0279] Step 1: Tert-butyl (S) -2-vinylpyrrolidine-1-carboxylate (Int A-1)
[0280] At room temperature, under a nitrogen atmosphere, a suspension of Ph3PCH3Br (161.4 g, 451.7 mmol) and KOtBu (50.7 g, 451 . 7 mmol) in THF (500 mL) was stirred for 4 h, then cooled to -70 ℃. A solution of (S) -tert-butyl 2-formylpyrrolidine-1-carboxylate (CAS: 69610-41-9 75.0 g, 376 mmol) in THF (150 mL) was added dropwise over 30 min while maintaining the internal temperature below -20 ℃. The reaction mixture was then stirred for 16 h at room temperature. Upon completion of the reaction, 20 wt%NH4Cl (200 mL) was added, and the organic layer was separated. The water layer was extracted with EtOAc (100 mL) . The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to give a pale-yellow oil. Heptane (400 mL) was added, and the resulting suspension was stirred vigorously at 0~5 ℃ for 1 h and filtered. The filtrate was dried under vacuum to give the title product (76 g) as a yellow oil which was directly used in the next step without further purification.
[0281] Step 2: Tert-butyl (2S) -2- (oxiran-2-yl) pyrrolidine-1-carboxylate (Int A-2)
[0282] At 0 ℃, under a nitrogen atmosphere, mCPBA (155.4 g, 693.5 mmol, 77%w / w) was added portion-wise to tert-butyl (S) -2-vinylpyrrolidine-1-carboxylate (Int A-1) (76 g, 424 mmol) dissolved in DCM (700 mL) , while maintaining the internal temperature below 10 ℃. The reaction mixture was then stirred for 2 h at room temperature. Upon completion of the reaction, a solution of Na2S2O3 (48.6 g, 385 mmol) in water (300 mL) was added slowly to quench the excess of mCPBA. Saturated aq. Na2CO3 (200 mL) was added to adjust the pH to 7-8. The organic layer was separated and the water layer extracted with DCM (100 mL) . The combined organic layers were washed with 5%NaHCO3 (100 mL) , then with brine (100 mL) , dried over Na2SO4, filtered, and concentrated to a volume of ca. 100 mL. Heptane (600 mL) was added and the resulting suspension filtered. The filtrate was concentrated, and the obtained residue was purified by flash chromatography on silica gel with n-heptane / EtOAc to give the title product (62 g) as a yellow oil.
[0283] Step 3: Tert-butyl (2S) -2- (2- (2-bromo-4, 6-difluorophenyl) -1 hydroxyethyl) pyrrolidine-1-carboxylate (Int A-3)
[0284] At -70 ℃, under a nitrogen atmosphere, iPrMgCl (190 mL, 2.0 M in THF, 102.8 mmol) was added dropwise over 30 min to a solution of 1-bromo-3, 5-difluoro-2-iodobenzene (120.5 g, 377.9 mmol) in THF (800 mL) while maintaining an internal temperature at -40 ℃ to -35 ℃. The reaction mixture was stirred at this temperature for 1 h. Upon completion of the reaction, CuI (11.1 g, 58.1 mmol) was added quickly in one portion. A solution of tert-butyl (2S) -2- (oxiran-2-yl) pyrrolidine-1-carboxylate (Int A-2) (62 g, 290.7 mmol) in THF (100 mL) was added dropwise over 10 min while maintaining the internal temperature at -40 ℃ to -30 ℃. The reaction mixture was then gradually warmed to room temperature and stirred overnight. 20 wt%aq. NH4Cl (700 mL) was added carefully to quench the reaction followed by MTBE (400 mL) . The organic layer was separated, and the water layer was extracted with MTBE (200 mL) . The combined organic layers were washed with 20 wt%brine (300 mL) , dried over anhydrous Na2SO4, filtered and concentrated to give the title product (118 g) as a pale-yellow oil which was used directly in the next step. 1H NMR (400 MHz, CDCl3) δ 7.13 (dt, J= 8.1, 2.2 Hz, 1H) , 6.80 (td, J= 9.1, 2.6 Hz, 1H) , 4.63 (s, 1H) , 4.04 -3.94 (m, 1H) , 3.86 -3.72 (m, 1H) , 3.58 -3.44 (m, 1H) , 3.41 -3.28 (m, 1H) , 3.01 -2.78 (m, 2H) , 2.14 -1.81 (m, 4H) , 1.47 (s, 9H) . HRMS m / z calcd for C12H15BrF2NO [M-Boc] + 306.0, found 306.03.
[0285] Step 4: Tert-butyl (S) -2- (2- (2-bromo-4, 6-difluorophenyl) acetyl) pyrrolidine-1-carboxylate (Int A-4)
[0286] At room temperature, under a nitrogen atmosphere, a solution of tert-butyl (2S) -2- (2- (2-bromo-4, 6-difluorophenyl) -1-hydroxyethyl) pyrrolidine-1-carboxylate (Int A-3) (118 g, 290 mmol) in DCM (700 mL) was added dropwise over 30 min at room temperature to a solution of Dess-Martin periodinane (135.5 g, 319.5 mmol) in DCM (700 mL) . The reaction mixture was stirred at room temperature for 45 min. Upon completion of the reaction a solution of Na2SO3 (58.6 g) in water (300 mL) was added carefully to quench the reaction while maintaining the internal temperature at 0 -5 ℃. 15 wt%NaOH (350 mL) was added to adjust the pH to 7-8 while maintaining the internal temperature below 10 ℃. The organic layer was separated and the water layer extracted with DCM (500 mL) . The combined organic layers were washed with 5 wt%NaHCO3 (300 mL) then with 20 wt%brine (300 mL) , dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash chromatography (silica; heptane / MTBE; gradient: 3%to 20%MTBE) to give the title product (75 g) . 1H NMR (400 MHz, CDCl3) δ 7.21 -7.12 (m, 1H) , 6.88 -6.78 (m, 1H) , 4.49 (dd, J =8.5, 4.5 Hz, 0.3H) , 4.37 (dd, J= 8.8, 5.2 Hz, 0.7H) , 4.08 -3.86 (m, 2H) , 3.67 -3.39 (m, 2H) , 2.35 -2.05 (m, 2H) , 2.02 -1.86 (m, 2H) , 1.48 (s, 2.7H) , 1.47 (s, 6.3H) . HRMS m / z calcd for C12H13BrF2NO [M-Boc] + 304.0143, found 303.9271.
[0287] Step 5: Tert-butyl (S) -2- ( (S) -2- (2-bromo-4, 6-difluorophenyl) -1-hydroxy-1-phenylethyl) pyrrolidine-1-carboxylate (Int A-5)
[0288] At 0 ℃, under a nitrogen atmosphere PhMgBr (40 mL, 128.6 mmol, 2.5 M in Et2O) was added dropwise over 30 min to tert-butyl (S) -2- (2- (2-bromo-4, 6-difluorophenyl) acetyl) pyrrolidine-1-carboxylate (Int A-4) (26.0 g, 64.3 mmol) in a mixture of DCM (260 mL) and heptane (260 mL) , while maintaining the internal temperature at -5–0 ℃. The reaction mixture was stirred at 0 ℃ for 10 min before it was quenched by adding sat. aq. NH4Cl (150 mL) . MTBE (200 mL) was added and the organic layer was separated. The water layer was extracted with MTBE (200 mL) . The combined organic layers were washed with 20 wt%brine (300 mL) , dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash chromatography (silica; heptane / MTBE; gradient: 2%to 3%MTBE) to afford the title product (14 g) , as a light yellow solid. 1H NMR (400 MHz, DMSO-D6) δ 7.48 (s, 2H) , 7.31 (dt, J= 8.4, 2.1 Hz, 1 H) , 7.26 -7.16 (m, 3H) , 7.08 -7.00 (m, 1 H) , 4.42 -4.19 (m, 1 H) , 3.62 -3.45 (m, 2H) , 3.45 -3.34 (m, 2H) , 1.93 -1.82 (m, 1 H) , 1.75 -1.60 (m, 1 H) , 1.43 (s, 9H) , 1.41 -1.21 (m, 2H) . HRMS m / z calcd for C23H27BrF2NO3 [M+H] + 482.1137, found 481.9654.
[0289] The compounds in the table below were synthesized using the route described above for
[0290] Step 6: Tert-butyl (S) -2- ( (S) -4-bromo-6-fluoro-2-phenyl-2, 3-dihydrobenzofuran-2-yl) pyrrolidine-1-carboxylate (Int A-6)
[0291] At 0 ℃, under a nitrogen atmosphere, KOtBu (37.3 mL, 37.3 mmol, 1 M in THF) was added dropwise over 15 min to a solution of tert-butyl (S) -2- ( (S) -2- (2-bromo-4, 6- difluorophenyl) -1-hydroxy-1-phenylethyl) pyrrolidine-1-carboxylate (Int A-5) (15 g, 31 . 1 mmol) in THF (150 mL) , while maintaining the internal temperature at -5 -0 ℃. The reaction mixture was stirred at -5 -0 ℃ for 30 min. Upon completion, the mixture was diluted with MTBE (200 mL) and was quenched by adding 5 wt%aq. NaHCO3 (150 mL) while maintaining the internal temperature at -5 -0 ℃. The mixture was stirred for 15 min at -5 -0 ℃. The organic layer was separated and the aqueous layer extracted with MTBE (200 mL) . The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to afford the title product (14.3 g) which was used directly in the next step. 1H NMR (400 MHz, DMSO-D6) δ 7.45 -7.28 (m, 5H) , 6.98 (dd, J = 9.1 , 2.2 Hz, 1 H) , 6.90 (dd, J =9.5, 2.2 Hz, 1 H) , 4.41 (dd, J = 6.9, 3.5 Hz, 1 H) , 4.19 -3.78 (m, 1 H) , 3.44 -3.19 (m, 2H) , 2.91 -2.72 (m, 1 H) , 1.90 -1.83 (m, 2H) , 1.57 -1.47 (m, 1 H) , 1.35 (s, 2H) , 1 . 34 (s, 7H) , 1 . 28 -1 . 21 (m, 1 H) . HRMS m / z calcd for C18H18BrFNO [M-Boc] +362.0550, found 361.9654.
[0292] Step 7: Tert-butyl (S) -2- ( (S) -4-bromo-5-chloro-6-fluoro-2-phenyl-2, 3-dihydrobenzofuran-2-yl) pyrrolidine-1-carboxylate (Int A-7)
[0293] At 0 ℃, under a nitrogen atmosphere, p-TsOH (6.9 g, 36.3 mmol) and N-chlorosuccinimide (4.85 g, 36.3 mmol) were added to a solution of tert-butyl (S) -2- ( (S) -4-bromo-6-fluoro-2-phenyl-2, 3-dihydrobenzofuran-2-yl) pyrrolidine-1-carboxylate (Int A-6) (14 g, 30.3 mmol) in acetonitrile (280 mL) and THF (140 mL) , while maintaining the internal temperature at -8 -0 ℃. The reaction mixture was stirred at -8-0 ℃ for 3 h. The mixture was diluted with MTBE (200 mL) and quenched by adding 6 wt%aq. Na2CO3 (150 mL) . The organic layer was separated and the aqueous layer extracted with MTBE (200 mL) . The combined organic phases were washed with 6 wt%aq. Na2CO3, brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash chromatography (silica; heptane / MTBE; 5%MTBE) to afford the title product (14 g) , as a light-yellow foam. Step 8: Tert-butyl (S) -2- ( (S) -5-chloro-6-fluoro-2-phenyl-4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -2, 3-dihydrobenzofuran-2-yl) pyrrolidine-1-carboxylate (Int A) . A 250 mL, three-neck round bottomed flask was charged with tert-butyl (S) -2- ( (S) -4-bromo-5-chloro-6-fluoro-2-phenyl-2, 3-dihydrobenzofuran-2-yl) pyrrolidine-1-carboxylate (Int A-6) (20.0 g, 40.26 mmol) , bis (pinacolato) diboron (13.3 g, 52.34 mmol) , KOAc (11.9 g, 120.77 mmol) and toluene (140 mL) . The mixture was degassed with nitrogen for 20 min. PdCl2 (dppf) (2.4 g, 3.22 mmol) was added under a nitrogen atmosphere in one portion. The mixture was heated to 100 ℃ and stirred for 16 h. The mixture was then cooled to room temperature, filtered through Celite and concentrated to dryness. The residue was purified by flash chromatography (silica, heptane / MTBE 5: 1) to give the title compound (14.5 g) as a foam. 1H NMR (400 MHz, CDCl3) δ 7.46 -7.41 (m, 2H) , 7.34 -7.27 (m, 3H) , 6.70 (d, J = 9.3 Hz, 1 H) , 4.54 -4.38 (m, 1 H) , 4.34 -3.98 (m, 1 H) , 3.45 (d, J = 16.7 Hz, 2H) , 3.06 -2.83 (m, 1 H) , 2.09 -1 . 78 (m, 2H) , 1.58 -1.46 (m, 2H) , 1.42 (s, 9H) , 1.36 (s, 12H) . HRMS m / z calcd for C29H37BClFNO5 [M+H] + 544.2432, found 544.2897.
[0294] The compounds in the table below were synthesized using the route described above for
[0295] Synthesis of Key Intermediate A-5 ii
[0296] tert-butyl (2S) -2- (2- (2-bromo-4, 6-difluorophenyl) -1-hydroxy-1-phenylethyl) pyrrolidine-1-carboxylate (96 mg, 0.20 mmol) was dissolved in concentrated hydrochloric acid (1.5 mL) ; thiourea (22.8 mg, 0.30 mmol) was then added and the reaction mixture refluxed for 18 h under nitrogen atmosphere. After cooling to room temperature, 6M sodium hydroxide solution was added up to pH 10 and the reaction mixture heated to a gentle reflux for 3 h under nitrogen atmosphere. After the resulting suspension was acidified with concentrated hydrochloric acid, the crude reaction mixture extracted with diethyl ether and then dried over anhydrous sodium sulfate and concentrated to give the title compound as a yellow solid (76.6 mg) HRMS m / z calcd for C23H26BrF2NO2S [M+H] + 498.1, found 498.2.
[0297] Synthesis of Key Intermediate B
[0298] Step 1: 2-bromo-3-fluoro-4- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) benzonitrile At 0 ℃, NaH (0.477 g, 11 . 9 mmol, 60%in mineral oil) was added portion-wise to a stirred solution of 2- (tetrahydro-2H-pyran-2-yloxy) ethanol (CAS: 2162-31-4, 1.34 g, 9.17 mmol) in DMF (40 mL) under Ar. After 5 min, 2-bromo-3, 4-difluorobenzonitrile (CAS: 1517611-20-9, 2 g, 9.17 mmol) was added and the reaction mixture was stirred at 0 ℃ for 1.5 h. The reaction mixture was quenched with a saturated solution of NH4Cl, then extracted with EtOAc. The organic layers were combined and washed with a sat solution of NH4Cl, dried over Na2SO4 and concentrated. The residue was purified by flash chromatography (silica, hexane / EtOAc 2: 1) to afford the title compound (1.93 g) . 1H NMR (400 MHz, DMSO-D6) δ (ppm) : 7.87 -7.74 (m, 1 H) , 7.53 -7.29 (m, 1 H) , 4.73 -4.57 (m, 1 H) , 4.47 -4.28 (m, 2H) , 4.04 -3.90 (m, 1 H) , 3.87 -3.63 (m, 2H) , 3.55 -3.35 (m, 1 H) , 1.88 -1 . 24 (m, 6H) .
[0299] Step 2: 2-bromo-3-fluoro-4- (2-hydroxyethoxy) benzonitrile
[0300] A solution of 2-bromo-3-fluoro-4- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) benzonitrile (Int B-1) (2.47 g, 7.2 mmol) and p-TsOH (0.55 g, 2.9 mmol) in EtOH (35 ml. ) was stirred at room temperature for 24 h. A saturated solution of NaHCO3 was added and the mixture was extracted with EtOAc. The combined organic extracts were dried over anhydrous Na2SO4 and concentrated to afford the title compound (1 . 48 g) as a colorless powder. m / z 304.0 [M+formate] -. The compounds in the table below were synthesized using the route described above for
[0301] Synthesis of Key Intermediate C-1’
[0302] To a 100 mL round-bottomed flask was added 4-bromo-2, 3-difluorobenzonitrile (194 mg 0.900 mmol) , (l-fluorovinyl) (methyl) diphenylsilane (0.358 g, 1.48 mmol) , and l, 3-dimethylimidazolidin-2-one (4 mL) . Tetrakis (triphenylphosphine) palladium (0) (45.9 mg, 0.0400 mmol) , copper (I) iodide (0.00760 g, 0.0400 mmol) , and cesium fluoride (362 mg, 2.39 mmol) were added and the reaction was stirred at room temperature for 24 hours under a nitrogen atmosphere. Water was added to the mixture and the mixture was diluted with 3: 1 hexanes / diethyl ether. The layer was separated, and the organic layer was dried over sodium sulfate, concentrated, and the residue was purified by flash column chromatography provided the title compound as a colorless oil (158 mg, 0.864 mmol) . m / z 184 ( [M+H] +) .
[0303] Synthesis of Key Intermediate C
[0304] Step 1: 2, 3-difluoro-4- (3-methoxycyclobutyl) benzonitrile, Int C-1
[0305] A 20 mL screw-cap vial was charged with Ir [dF (CF3) ppy] 2 (dtbbpy) PF6 (0.01 g, 0.009 mmol) , 4-bromo-2, 3-difluorobenzonitrile (194 mg 0.900 mmol) , 1-bromo-3-methoxycyclobutane (220 mg, 1.3 mmol) , Na2CO3 (0.19 g, 1.8 mmol) and tris (trimethylsilyl) silane (0.28 mL, 0.9 mmol) . The vial was sealed, evacuated and backfilled with N2. Degassed DME (7 mL) was added to the mixture. Vial B: A separate 5 mL screw-cap vial was charged with NiCl2-gIyme (0.0028 g, 0.012 mmol) and 4, 4-di-tert-butyl-2, 2-bipyridine (0.0034 g, 0.012 mmol) . The vial was sealed, evacuated and backfilled with N2. Degassed DME (1 mL) was added and the mixture was stirred for exactly 5 min to obtain a stock solution of Ni pre-catalyst. 0.36 mL of this solution was transferred via cannula into vial A. The suspension in vial A is again degassed by bubbling N2 through the mixture for 10 min. The vial is carefully sealed and irradiated with a 24W blue LED strip until full consumption of the starting material. The mixture was filtered and the filtrate concentrated under reduced pressure. The residue is purified by column chromatography to give 3-difluoro-4- (3-methoxycyclobutyl) benzonitrile, Int C-1 (123 mg, 0.55 mmol) as a yellow solid. m / z 224.3 [M+H] +.
[0306] Step 2: 3-fluoro-2-hydroxy-4- (3-methoxycyclobutyl) benzonitrile, Int C-2
[0307] To a solution of 3-difluoro-4- (3-methoxycyclobutyl) benzonitrile, Int C-1 (123 mg, 0.55 mmol) and 2- (methylsulfonyl) ethanol (68.2 mg, 0.55 mmol) in DMF (1.5 mL) was added sodium hydride (48 mg, 50%in mineral oil, 1 mmol) in small portions at room temperature. After stirring at room temperature for 30 minutes, the reaction was poured onto ice water (10 mL) . The aqueous solution was extracted with ethyl ether (5 mL) twice. The aqueous layer was acidified with conc. HCl to pH 2, then extracted with ether (2 x 50 mL) . The organic layer was dried over sodium sulfate, filtered and evaporated to dryness to give the title compound as a pale yellow oil (122 mg, 0.550 mmol) . m / Z = 222 (M+H) +.
[0308] Step 3: 6-cyano-2-fluoro-3- (3-methoxycyclobutyl) phenyl trifluoromethanesulfonate, Int C
[0309] To a solution of 3-fluoro-2-hydroxy-4- (3-methoxycyclobutyl) benzonitrile, Int C-2 (122 mg, 0.55 mmol) in DCM (3 mL) was added triethylamine (0.093 mL, 0.66 mmol) followed by trifluoromethanesulfonic anhydride (0.11 mL, 0.66 mmol) at 0 ℃. The reaction mixture was stirred at room temperature for 30 min. Saturated NaHCO3 was added, and the aqueous layer was extracted with DCM. The combined organic extracts were dried over MgSO4, filtered, and concentrated. The crude product was purified by chromatography (eluting with DCM) to give the product (188.3 mg, 0.53 mmol) as a yellow oil. m / Z = 354.3 (M+H) +.
[0310] The compounds in the table below were synthesized using the route described above for
[0311] Synthesis of Example 1
[0312] Step 1: tert-butyl ( (1S) -1- (5-chloro-4- (6-cyano-2-fluoro-3- (2-hydroxyethoxy) phenyl) -6-fluoro-2-phenyl-2, 3-dihydrobenzofuran-2-yl) pentyl) carbamate, compound 1 At room temperature, a mixture of tert-butyl ( (1S) -1- (5-chloro-6-fluoro-2-phenyl-4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -2, 3-dihydrobenzofuran-2-yl) pentyl) carbamate, Int A-i (232 mg, 0.415 mmol) , 2-bromo-3-fluoro-4- (2-hydroxyethoxy) benzonitrile, Int B (164 mg, 0.623 mmol) and potassium triphosphate (264 mg, 1 . 25 mmol) suspended in toluene (4 mL) and water (0.8 mL) was degassed with Ar. N-Xantphos (22.9 mg, 0.042 mmol) and Pd2 (dba) 3 (19 mg, 0.021 mmol) were added. The reaction mixture was heated at 100 ℃ for 12 h. After cooling to room temperature, the reaction mixture was partitioned between water and EtOAc. The organic phase was separated and the aqueous phase extracted again with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by flash chromatography (silica, cyclohexane / EtOAc, gradient: 0%to 30%EtOAc) to afford a mixture of the title compounds (165 mg) . m / z 613.3 [M+H] +.
[0313] Step 2: 2- (2- ( (S) -1-aminopentyl) -5-chloro-6-fluoro-2-phenyl-2, 3-dihydrobenzofuran-4-yl) -3-fluoro-4- (2-hydroxyethoxy) benzonitrile, compound 2
[0314] At room temperature, a mixture of tert-butyl ( (1S) -1- (5-chloro-4- (6-cyano-2-fluoro-3- (2-hydroxyethoxy) phenyl) -6-fluoro-2-phenyl-2, 3-dihydrobenzofuran-2-yl) pentyl) carbamate, compound 1 (165 mg, 0.270 mmol) was treated with HCl (0.68 mL, 2.7 mmol, 4M in dioxane) for 16 h. The reaction mixture was quenched with a sat solution of NaHCO3. The combined organic layers were washed with sat. NaHCO3 and brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by flash chromatography (silica, DCM / MeOH, gradient: 0%to 10%MeOH) to give a mixture of the title compounds (48 mg) , as a colorless solid. m / z 513.3 [M+H] +.
[0315] Step 3: 2- (2- ( (S) -1-aminopentyl) -5-chloro-6-fluoro-2-phenyl-2, 3-dihydrobenzofuran-4-yl) -3-fluoro-4- (2-hydroxyethoxy) benzamide, Example 1
[0316] At room temperature hydrido (dimethylphosphinous acid-kP) [hydrogen bis (dimethylphosphinito-kP) ] platinum (II) (CAS 173416-05-2) (6.9 mg, 0.016 mmol) was added to a solution of a mixture of 2- (2- ( (S) -1-aminopentyl) -5-chloro-6-fluoro-2-phenyl-2, 3-dihydrobenzofuran-4-yl) -3-fluoro-4- (2-hydroxyethoxy) benzonitrile, 2 (48 mg, 0.095 mmol) in EtOH (50 mL. ) and water (0.10 mL) . Then, the reaction mixture was stirred at 80 ℃ for 1 h. The reaction mixture was quenched by the addition of a saturated solution of NaHCO3 and extracted with EtOAc. The organic layers were combined and washed with a sat solution of NaHCO3, dried over anhydrous Na2SO4 and concentrated. The residue was purified by flash chromatography (silica, hexane / EtOAc, gradient 0%to 100%EtOAc) to afford a mixture of the title compounds (4.0 mg) . m / z 531 [M+H] +.
[0317] Synthesis of Example 8
[0318] A mixture of 2- (2- (1-aminopentyl) -5-chloro-6-fluoro-2-phenyl-2, 3-dihydrobenzofuran-4-yl) -3-fluoro-4- (2-hydroxyethoxy) benzamide, Example 1 (4.0 mg, 0.0075 mmol) , tetrakis- (triphenylphosphine) palladium (0.2 mg, 0.00015 mmol) , and copper (I) iodide (0.44 mg 0.0023 mmol) in freshly distilled triethylamine (0.05 mL) was stirred for 10 min under N2. Trimethylsilylacetylene (1.1 mg 0.011 mmol) was added and the suspension heated at 80 ℃ for 4 h. After removal of the solvent and purification by column chromatography (SiO2) using petroleum ether 100%, a yellow solid was produced. The silyl alkyne was directly treated with K2CO3 (10.5 mg, 0.075 mmol) in MeOH (1 mL) for 2 h at room temperature to provide 2- (2- (1-aminopentyl) -5-ethynyl-6-fluoro-2-phenyl-2, 3-dihydrobenzofuran-4-yl) -3-fluoro-4- (2-hydroxyethoxy) benzamide (3.8 mg) Example 8 as a yellow solid. m / z 521 [M+H] +.
[0319] Synthesis of Example 16
[0320] Step 1: 2- (5-chloro-6-fluoro-2-phenyl-2- (pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -3-fluoro-4- (2-hydroxyethoxy) benzoic acid
[0321] A mixture of 2- (5-chloro-6-fluoro-2-phenyl-2- (pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -3-fluoro-4- (2-hydroxyethoxy) benzoate (122 mg, 0.425 mmol) was dissolved in THF (5 mL) and water (1 mL) . LiOH-H2O (94 mg, 2.25 mmol) was added and the reaction mixture stirred at 55 ℃ for 4 h. After cooling to room temperature, the reaction mixture was partitioned between EtOAc and a saturated solution of NaHSO4. The organic phase was separated, dried over anhydrous Na2SO4 and concentrated to yield a mixture of the title compounds (124 mg, 0.425 mmol) . m / z 530.2 [M+H] +
[0322] Step 2: methyl (2- (5-chloro-6-fluoro-2-phenyl-2- (pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -3-fluoro-4- (2-hydroxyethoxy) phenyl) carbamate, Example 16
[0323] A solution of 2- (5-chloro-6-fluoro-2-phenyl-2- (pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -3-fluoro-4- (2-hydroxyethoxy) benzoic acid (122 mg, 0.425 mmol) and Et3N (0.067 mL, 0.48 mmol) in toluene (2 mL) was stirred at room temp. for 15 min, then treated with a solution of DPPA (0.131 mg, 0.48 mmol) in toluene (0.5 mL) via pipette. The resulting mixture was heated at 80 ℃. for 2 h. After cooling the mixture to room temp, methanol (0.05 mL, 0.5 mmol) was added via syringe. The mixture was then warmed to 80 ℃ and stirred overnight. The resulting mixture was cooled to room temp., quenched with a 10%citric acid solution, and extracted with EtOAc (2×5 mL) . The combined organic layers were washed with a saturated NaCl solution, dried (MgSO4) and concentrated under reduced pressure. The residue was purified by column chromatography, (14%EtOAc / 86%hexane) to give the title compound as a pale-yellow oil (231 mg, 0.425 mmol) . m / z 545.2 [M+H] +
[0324] Synthesis of Example 17
[0325] Step 1: 2- (5-chloro-6-fluoro-2-phenyl-2- (pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -3-fluoro-4- (2-hydroxyethoxy) benzohydrazide
[0326] To a solution 2- (5-chloro-6-fluoro-2-phenyl-2- (pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -3-fluoro-4- (2-hydroxyethoxy) benzoate (122 mg, 0.425 mmol) in MeOH (2 mL) was added NH2NH2·H2O (4 mL) at room temperature, then the mixture was stirred at 100 ℃ for 1 h. The LCMS of aliquot showed that product was formed. The solution was concentrated to obtain crude product (60 mg) which was used for next step without further purification. MS: m / z = 530.3 (M+1, ESI+) .
[0327] Step 2: benzyl (S) -2, 2-difluoro-6- (4- (5-oxo-4, 5-dihydro-1, 3, 4-oxadiazol-2-yl) phenyl) -7-azaspiro [3.5] nonane-7-carboxylate, Example 17
[0328] Crude 2- (5-chloro-6-fluoro-2-phenyl-2- (pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -3-fluoro-4- (2-hydroxyethoxy) benzohydrazide (60 mg) , triphosgene (309 mg, 1.05 mmol) and DIPEA (406 mg, 3.15 mmol) were dissolved in DCM (10 mL) and the mixture stirred at room temperature for 2 h. The mixture was diluted with H2O and extracted with ethyl acetate (20 mL x 3) . The combined organic phases were dried on Na2SO4, filtered and evaporated in vacuo and the residue was purified by silica gel to afford the title product, 5- (2- (5-chloro-6-fluoro-2-phenyl-2- (pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -3-fluoro-4- (2-hydroxyethoxy) phenyl) -1, 3, 4-oxadiazol-2 (3H) -one Example 17 (141 mg, 0.255 mmol) . m / z = 556.3 (M+1, ESI+) .
[0329] Synthesis of Example 19
[0330] 2- (5-chloro-6-fluoro-2-phenyl-2- (pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -3-fluoro-4- (2-hydroxyethoxy) benzohydrazide (CAS: 2714586-13-5 122 mg, 0.425 mmol) and triethyl orthoformate (0.24 mL) were placed in a 5 mL two-neck round bottom flask, and the mixture was vigorously stirred at 160 ℃. After 4 h, the formed ethanol and residual triethyl orthoformate were distilled off under reduced pressure. The resulting oil was purified by distillation under higher vacuum to afford 2- (3- (5-chloro-6-fluoro-2-phenyl-2- (pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -2-fluoro-4- (1, 3, 4-oxadiazol-2-yl) phenoxy) ethan-1-ol, Example 19 (229 mg, 0.425 mmol) . m / z =540.3 (M+1, ESI+) .
[0331] Synthesis of Example 20
[0332] Step 1: 2- (5-chloro-6-fluoro-2-phenyl-2- (pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -3-fluoro-4- (2-hydroxyethoxy) benzamide
[0333] Toluene (2 mL) was added to a mixture of DMF-DMA (80 mg, 0.7 mmol) and 2- (5-chloro-6-fluoro-2-phenyl-2- (pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -3-fluoro-4- (2-hydroxyethoxy) benzamide (218 mg, 0.425 mmol) in a 5 mL round-bottom flask. The reaction was stirred at 90 ℃ for 4 h and concentrated down to dryness. The residue was purified by column chromatography (dichloromethane / methanol 100: 1) to provide the DMF-DMA adduct. (125 mg, 0.200 mmol) . m / z = 570.3 (M+1, ESI+) .
[0334] Step 2: 2- (3- (5-chloro-6-fluoro-2-phenyl-2- (pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -2-fluoro-4- (1, 2, 4-oxadiazol-5-yl) phenoxy) ethan-1-ol, Example 20 2- (5-chloro-6-fluoro-2-phenyl-2- (pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -3-fluoro-4- (2-hydroxyethoxy) benzamide (125 mg, 0.200 mmol) was added to a mixture of hydroxylamine hydrochloride (16.7 mg, 0.240 mmol) , 5N sodium hydroxide (0.05 mL, 0.237 mmol) and 70%acetic acid (0.5 mL) . The reaction mixture was stirred at room temperature for 30 min, and then diluted the reaction with water, and cooled on ice for 1 h. The precipitate was collected upon filtration and washed with cooled water. The precipitate was dissolved in a mixture of acetic acid (1 mL) and dioxane (1 mL) , and stirred for 3 h at 90 ℃. The reaction was then dried under vacuum, dissolved in ethyl acetate, washed with water, and dried over sodium sulfate. The filtrate was concentrated purified by column chromatography (dichloromethane / methanol 100: 1) to provide 2- (3- (5-chloro-6-fluoro-2-phenyl-2- (pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -2-fluoro-4- (1, 2, 4-oxadiazol-5-yl) phenoxy) ethan-1-ol,
[0335] Example 20. m / z = 540.3 (M+1, ESI+) .
[0336] The examples in the table below were synthesized using the route described above for The examples in the table below were synthesized using the route described above for
[0337] Synthesis of 2-bromo-3-fluoro-4- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) benzaldehyde Compound 6
[0338] To a solution of 2-tetrahydropyran-2-yloxyethanol (1.34 g, 9.17 mmol, 1.0 eq. ) in DMF (30 mL) was added NaH (477 mg, 11.93 mmol, 1.0 eq., 60%purity) portion-wise at 0℃ under N2, the mixture was stirred for 5 min. After that, 2-bromo-3, 4-difluoro- benzonitrile (2 g, 9.17 mmol, 1.0 eq. ) was added, the mixture was stirred at 0℃ for 1.5 h. The reaction was quenched with NH4Cl (50 mL) and extracted with ethyl acetate (50 mL×3) . The organic layers were combined and washed with brine (50 mL) , dried over Na2SO4, filtered and concentrated under reduced pressure to afford the residue. The residue was purified with silica gel column (petroleum ether : EA = 5: 1) to afford 2-bromo-3-fluoro-4- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) benzonitrile (3 g, 8.74 mmol) as yellow oil. LCMS-ESI (m / z) : [M+H] + calc’d for C14H16BrFNO3, 344.0; found, 344.1.
[0339] To a solution of 2-bromo-3-fluoro-4- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) benzonitrile (2 g, 5.81 mmol, 1.1 eq. ) in DCM (20 mL) was added diisobutylaluminium hydride (8.72 mL, 8.72 mmol, 1.5 eq., 1 M in THF) at -78℃ under N2 atmosphere, the mixture was stirred at -78℃ for 2 h. The reaction wafs quenched with NH4Cl (50 mL) and extracted with EtOAc (50 mL×3) . The organic layer was washed with brine (50 mL) , dried over Na2SO4, filtered and concentrated under reduced pressure to afford the crude 2-bromo-3-fluoro-4- (2-hydroxyethoxy) benzaldehyde (2 g) as yellow oil. LCMS-ESI (m / z) : [M+H] + calc’d for C9H9BrFO3, 263.0; found, 263.1.
[0340] To a solution of 2-bromo-3-fluoro-4- (2-hydroxyethoxy) benzaldehyde (2 g, crude) in THF (20 mL) was added p-TsOH (392 mg, 2.28 mmol, 0.3 eq. ) and 3, 4-dihydro-2H-pyran (1.28 g, 15.21 mmol, 2.0 eq. ) , the mixture was stirred at room temperature for 4 h. The mixture was diluted with H2O (50 mL) and extracted with EtOAc (50 mL×3) . The organic layer was washed with brine (50 mL) , dried over Na2SO4 and concentrated under reduced pressure to afford the residue. The residue was purified with silica gel column (petroleum ether : EA=5: 1) to afford 2-bromo-3-fluoro-4- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) benzaldehyde (1.6 g, 4.61 mmol) as yellow oil. LCMS-ESI (m / z) : [M+H] + calc’d for C14H17BrFO4, 347.0; found, 347.2.
[0341] Synthesis of 2- (3- ( (2S, 4R) -5-chloro-6-fluoro-2-phenyl-2- ( (S) -pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -2-fluoro-4- (1H-1, 2, 3-triazol-4-yl) phenoxy) ethan-1-ol
[0342] Example 34 isomer 1
[0343] Step 1: Synthesis of tert-butyl (2S) -2- ( (2S) -5-chloro-6-fluoro-4- (2-fluoro-6-formyl-3- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) phenyl) -2-phenyl-2, 3-dihydrobenzofuran-2-yl) pyrrolidine-1-carboxylate, Int 34A
[0344] To a solution of tert-butyl (2S) -2- [ (2S) -5-chloro-6-fluoro-2-phenyl-4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -3H-benzofuran-2-yl] pyrrolidine-1-carboxylate 7 (2.07 g, 3.80 mmol, 1.1 equiv) , 2-bromo-3-fluoro-4- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) benzaldehyde (1.2 g, 3.46 mmol, 1.0 equiv) , K3PO4 (2.20 g, 10.37 mmol, 3.0 equiv) and N-XantPhos (190 mg, 345.65 μmol, 0.1 equiv) in toluene (20 mL) and H2O (4 mL) was added Pd2 (dba) 3 (158 mg, 172.82 μmol, 0.05 equiv) under N2, the mixture was stirred at 100 ℃ for 12 h. The mixture was diluted with H2O (50 mL) and extracted with EtOAc (50 mL × 3) , The organic layer was washed with brine (50 mL) , dried over Na2SO4, filtered, and concentrated under reduced pressure to afford the residue. The mixture was purified with silica gel column (petroleum ether: EA=3: 1) to afford the Int 34A (1.5 g, 2.19 mmol, 63%) as yellow oil. LCMS-ESI (m / z) : [M+H] + calc’d for C37H41ClF2NO7, 684.2; found, 684.1.
[0345] Step 2: Synthesis of tert-butyl (2S) -2- ( (2S) -5-chloro-4- (6-ethynyl-2-fluoro-3- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) phenyl) -6-fluoro-2-phenyl-2, 3-dihydrobenzofuran-2-yl) pyrrolidine-1-carboxylate, Int 34B
[0346] To a solution of Int 34A (200 mg, 0.29 mmol, 1.0 equiv) in MeOH (5 mL) was added dimethyl (1-diazo-2-oxopropyl) phosphonate (84 mg, 0.44 mmol, 1.5 equiv) and potassium carbonate (61 mg, 0.44 mmol, 1.5 equiv) , the mixture was stirred at room temperature for 12 h. The mixture was concentrated and purified with silica gel column (petroleum ether : EA=5: 1) to afford the two atropisomers Int 34Ba (60 mg, 0.088 mmol, 30%) as colorless oil and the Int 34Bb (100 mg, 0.15 mmol, 50%) as colorless oil. LCMS-ESI (m / z) : [M+H] + calc’d for C38H40ClF2NO6, 680.26; found, 496.01.
[0347] Step 3: Synthesis of tert-butyl (2S) -2- ( (2S) -5-chloro-6-fluoro-4- (2-fluoro-3- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) -6- (1H-1, 2, 3-triazol-4-yl) phenyl) -2-phenyl-2, 3-dihydrobenzofuran-2-yl) pyrrolidine-1-carboxylate, Int 34Ca
[0348] To a solution of the first eluting isomer Int 34Ba (60 mg, 0.09 mmol, 1.0 equiv) in DMF (0.9 mL) and H2O (0.1 mL) was added copper sulfate pentahydrate (2 mg, 0.009 mmol, 0.1 equiv) , then azidotrimethylsilane (20 mg, 0.18 mmol, 2.0 equiv) and sodium ascorbate (4 mg, 0.018 μmol, 0.2 equiv) was added under N2, the mixture was stirred at 90 ℃ for 12 h. The mixture was diluted with H2O (20 mL) and extracted with EtOAc (20 mL×3) . The organic layer was washed with brine (30 mL) , dried over Na2SO4, filtered and concentrated under reduced pressure to afford the residue. The residue was purified with silica gel column (petroleum ether : EA =1: 1) to afford the Int 34Ca (50 mg, 0.069 mmol, 78%) as colorless oil. LCMS-ESI (m / z) : [M+H] + calc’d for C38H41ClF2N4O6, 723.28; found, 539.07.
[0349] The other isomer Int 34Cb was synthesized using the step above (40 mg, 0.055 mmol, 37%) as colorless oil. LCMS-ESI (m / z) : [M+H] + calc’d for C38H41ClF2N4O6, 723.28; found, 539.01.
[0350] Step 3: Synthesis of 2- (3- ( (2S, 4R) -5-chloro-6-fluoro-2-phenyl-2- ( (S) -pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -2-fluoro-4- (1H-1, 2, 3-triazol-4-yl) phenoxy) ethan-1-ol
[0351] Example 34 isomer 1, and isomer 2
[0352] To a solution of Int 34Ca (50 mg, 68.94 μmol, 1.0 equiv) in dichloromethane (1 mL) was added HCl / dioxane (1 mL) , the mixture was stirred at room temperature for 2 h. The pH of the mixture was adjusted to 8~9 with NaHCO3 (aq. ) . The mixture was extracted with EtOAc (20 mL × 3) and the organic layer was washed with brine (20 mL) , dried over Na2SO4, filtered and concentrated under reduced pressure to afford the residue. The residue was purified with pre-HPLC to afford the compound Example 34 Iso 1 (4.3 mg, 0.0079 mmol, 11%) as white solid. LCMS-ESI (m / z) : [M+H] + calc’d for C28H25ClF2N4O3, 539.17; found, 539.03.
[0353] 1H NMR (DMSO-d6) : δ 8.19 (s, 0.45H) , 7.66 (d, J = 8.4 Hz, 1H) , 7.40 (t, J = 9.0 Hz, 1H) , 7.31 -7.19 (m, 5H) , 7.09 (d, J = 8.4 Hz, 1H) , 6.74 (s, 1H) , 4.99 (s, 1H) , 4.19 (t, J = 4.8 Hz, 2H) , 3.81 (t, J = 4.8 Hz, 2H) , 3.59 -3.57 (m, 1H) , 2.79 -2.74 (m, 1H) , 2.72 (d, J = 15.6 Hz, 1H) , 2.65-2.64 (m, 1H) , 2.49 -2.43 (m, 1H) , 1.55 -1.44 (m, 2H) , 1.40 -1.38 (m, 1H) , 1.36 -1.29 (m, 1H) .
[0354] The other isomer Example 34 Iso 2 was synthesized using the step above (7.9 mg, 0.015 mmol, 26%) as white solid. LCMS-ESI (m / z) : [M+H] + calc’d for C28H25ClF2N4O3, 539.17; found, 539.06.
[0355] 1H NMR (DMSO-d6) : 8.18 (s, 0.46H) , 7.71 (d, J = 8.4 Hz, 1H) , 7.49 -7.43 (m, 2H) , 7.40 (t, J = 8.4 Hz, 1H) , 7.36 -7.33 (m, 2H) , 7.30-7.27 (m, 2H) , 7.09 (d, J = 9.6 Hz, 1H) , 4.96 (s, 1H) , 4.16 (t, J = 4.8 Hz, 2H) , 3.77 (t, J = 4.8 Hz, 2H) , 3.47 -3.44 (m, 1H) , 3.11 (d, J = 16.2 Hz, 1H) , 2.97 (d, J = 15.6 Hz, 1H) , 2.75 -2.68 (m, 1H) , 2.56 -2.53 (m, 1H) , 1.44-1.41 (m, 1H) , 1.36 -1.33 (m, 1H) , 1.32 -1.23 (m, 2H) .
[0356] The compounds below are synthesized using a route like the one described above.
[0357] Synthesis of example 40
[0358] Step 1: Synthesis of (2S) -2- ( (S) -2- ( (S) -1- (tert-butoxycarbonyl) pyrrolidin-2-yl) -5-chloro-6-fluoro-2-phenyl-2, 3-dihydrobenzofuran-4-yl) -3-fluoro-4- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) benzoic acid (Int 40A)
[0359] To a solution of Int 34A (2.8 g, 4.09 mmol) in acetone (40 mL) was added a solution of KMnO4 (970 mg, 6.14 mmol) in water (40 mL) . The resulting mixture was stirred at room temperature for 1 h. The reaction mixture was quenched with 5%Na2SO3 (200 mL) and the pH of the mixture was adjusted to 6 by aqueous HCl (1 M) . The resulting mixture was extracted with ethyl acetate (50 mL×2) . The organic layer was washed with brine (100mL) , dried over Na2SO4, filtered and concentrated. The crude reside was purified by column chromatography (SiO2, eluent: DCM / MeOH = 0~2%) to afford Int 40A (1.67 g, 2.39 mmol, 58%) as white soild.
[0360] LCMS: m / z 600.01 [M+H-Boc] +.
[0361] Step 2: Synthesis of tert-butyl (2S) -2- ( (2S, 4S) -5-chloro-6-fluoro-4- (2-fluoro-3- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) -6- ( ( (R) -tetrahydrofuran-3-yl) carbamoyl) phenyl) -2-phenyl-2, 3-dihydrobenzofuran-2-yl) pyrrolidine-1-carboxylate (Int 40B)
[0362] To a solution of Int 40A (100 mg, 143 μmol) , HATU (97 mg, 257 μmol) and DIEA (28 mg, 214 μmol) in DMF (1 mL) was added (R) -tetrahydrofuran-3-amine (15 mg, 172 μmol) , the resulting mixture was stirred at room temperature for 1 h. The reaction mixture was diluted with EtOAc (20 mL) and washed by brine (10 mL×2) , dried over Na2SO4, filtered and concentrated. The crude reside was purified by column chromatography (SiO2, eluent: DCM / MeOH = 0~2%) to afford Int 40B (100 mg, 130 μmol, 91%) as colorless oil.
[0363] LCMS: m / z 768.99 [M+H] +.
[0364] Step 3: Synthesis of 2- ( (2S, 4S) -5-chloro-6-fluoro-2-phenyl-2- ( (S) -pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -3-fluoro-4- (2-hydroxyethoxy) -N- ( (R) -tetrahydrofuran-3-yl) benzamide (Example 40)
[0365] To a solution of compound Int 40B (100 mg, 130 μmol) in 1, 4-dioxane (0.5 mL) was added the solution of HCl (4 M) in 1, 4-dioxane (2 mL, 8 mmol) . The resulting mixture was stirred at room temperature for 2 h and concentrated. The residue was purified by prep-HPLC to afford compound Example 40 (contained 1.5 TFA, 36 mg, 47.62 μmol, 36%) . LCMS: m / z 585.17 [M+H] +. 1H NMR (400 MHz, CD3OD) δ 7.59 -7.56 (m, 2H) , 7.51 -7.40 (m, 4H) , 7.30 -7.26 (m, 1H) , 7.03 (d, J = 9.2 Hz, 1H) , 4.40 -4.35 (m, 1H) , 4.27 -4.19 (m, 3H) , 3.97 -3.90 (m, 3H) , 3.84 -3.77 (m, 2H) , 3.57 (d, J = 17.6 Hz, 1H) , 3.51 (dd, J = 8.8, 3.6 Hz, 1H) , 3.39 -3.45 (m, 1H) , 3.26 -3.19 (m, 2H) , 2.29 -2.20 (m, 2H) , 2.15 -1.91 (m, 4H) .
[0366] Synthesis of Example 41
[0367] Step 1: Synthesis of tert-butyl (2S) -2- ( (2S) -4- ( (1S) -6- ( (5- ( (tert-butoxycarbonyl) amino) pyridin-2-yl) carbamoyl) -2-fluoro-3- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) phenyl) -5-chloro-6-fluoro-2-phenyl-2, 3-dihydrobenzofuran-2-yl) pyrrolidine-1-carboxylate (Int 41A)
[0368] To a solution of Int 40A (40 mg, 0.057 mmol) in DMF (1 mL) was added HATU (32 mg, 0.086 mmol) , DIEA (30 mg, 0.23 mmol) and tert-butyl (6-aminopyridin-3-yl) carbamate (18 mg, 0.086 mmol) , the mixture was stirred at room temperature overnight. The reaction was quenched with water (5 mL) and extracted with EtOAc (10 mL×3) . The organic phase was dried over Na2SO4, filtrated and concentrated to give the compound Int 41A (70 mg, crude) as a yellow oil.
[0369] LCMS: m / z 891.00 [M+H] +.
[0370] Step 2: Synthesis of (S) -N- (5-aminopyridin-2-yl) -2- ( (S) -5-chloro-6-fluoro-2-phenyl-2- ( (S) -pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -3-fluoro-4- (2-hydroxyethoxy) benzamide (Example 41)
[0371] Int 41A (51 mg, 0.057 mmol, 1.0 eq. ) was added to HCl (4 M) in 1, 4-dioxane (1 mL) . The reaction mixture was stirred at room temperature for 3 h. The mixture was concentrated and purified with prep-HPLC to give Example 41 (contained 2 TFA, 18 mg, 0.021 mmol, 37%) as white solid.
[0372] LCMS: m / z 607.00 [M+H] +.
[0373] 1H NMR (400 MHz, CD3OD) δ 7.77 (d, J = 2.8 Hz, 1H) , 7.71 (d, J = 8.4 Hz, 1H) , 7.58-7.35 (m, 8H) , 7.03 (d, J = 9.2 Hz, 1H) , 4.27-4.23 (m, 3H) , 4.01 -3.86 (m, 2H) , 3.58 (d, J = 16.4 Hz, 1H) , 3.37 -3.27 (m, 1H) , 3.21 -3.15 (m, 2H) , 2.24 -2.11 (m, 1H) , 2.01 -1.86 (m, 3H) .
[0374] Synthesis of Example 42
[0375] Step 1: Synthesis of methyl 4-chloro-5, 6-difluoro-pyridine-3-carboxylate (Int 42A)
[0376] To a solution of 4-chloro-5, 6-difluoro-pyridine-3-carboxylic acid (2.5 g, 12.92 mmol) and potassium carbonate (4.5 g, 32.29 mmol) in DMF (25 mL) was added iodomethane (2.2 g, 15.50 mmol) at 0℃, the mixture was stirred at room temperature for 12 h. The mixture was diluted with water (100 mL) and extracted with EtOAc (100 mL×3) . The organic layer was washed with brine (200 mL) , dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc=10: 1) to afford the compound Int 42A (2.2 g, 10.60 mmol, 82 %) as colorless liquid.
[0377] Step 2: Synthesis of methyl 4-chloro-5-fluoro-6- (2-tetrahydropyran-2-yloxyethoxy) pyridine-3-carboxylate (Int 42B)
[0378] To a solution of 2-tetrahydropyran-2-yloxyethanol (1.4 g, 9.64 mmol) in THF (30 mL) was added NaH (60%, 385 mg, 9.64 mmol) at 0℃ under N2 atmosphere. After stirring at 0℃ for 5 min, compound Int 42A (2.0 g, 9.64 mmol, 1.0 equiv) was added to the reaction and the mixture was stirred at 0℃ for another 1.5 h. The mixture was quenched with saturated NH4Cl aqueous solution (50 mL) and extracted with EtOAc (50 mL×3) . The combined organic layer was washed with brine (50 mL) , dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, eluent: PE / EA=5: 1) to afford the compound Int 42B (1.4 g, 4.19 mmol, 43%) as colorless oil.
[0379] Step 3: Synthesis of methyl 4- [ (2S) -2- [ (2S) -1-tert-butoxycarbonylpyrrolidin-2-yl] -5-chloro-6-fluoro-2-phenyl-3H-benzofuran-4-yl] -5-fluoro-6- (2-tetrahydropyran-2-yloxyethoxy) pyridine-3-carboxylate (Int 42C)
[0380] To a solution of compound Int A (1.8 g, 3.31 mmol) , compound Int 42B (662 mg, 1.99 mmol) , K3PO4 (2.1 g, 9.93 mmol) and N-XantPhos (182 mg, 0.33 mmol) in toluene (20 mL) and H2O (5 mL) was added Pd2 (dba) 3 (151 mg, 165.48 μmol, 0.05 equiv) under N2 atmosphere. The mixture was stirred at 100 ℃ for 12 h. The mixture was diluted with water (50 mL) and extracted with EtOAc (50 mL×3) . The organic layer was washed with brine (50 mL) , dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, eluent: PE / EA=5: 1) to afford the compound Int 42C (1.2 g, 1.75 mmol, 52%) as yellow oil.
[0381] LCMS: m / z 574.89 [M+H-THP-56] +.
[0382] Step 4: Synthesis of 4- ( (2S, 4S) -2- ( (S) -1- (tert-butoxycarbonyl) pyrrolidin-2-yl) -5-chloro-6-fluoro-2-phenyl-2, 3-dihydrobenzofuran-4-yl) -5-fluoro-6- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) nicotinic acid (Int 42D)
[0383] To a solution of compound Int 42C (1.0 g, 1.47 mmol) in MeOH (10 mL) and THF (5 mL) was added a solution of NaOH (587 mg, 14.68 mmol) in water (5 mL) . The mixture was stirred at 50 ℃ for 2 h. The mixture was adjusted to pH 6-7 with saturated NaH2PO4 aqueous solution and extracted with EtOAc (50 mL×3) . The organic layer was washed with brine (50 mL) , dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, eluent: PE / EA / HOAc=5: 1: 0.01) to afford the compound Int 42D (400 mg, 0.57 mmol, 38%) as colorless oil.
[0384] LCMS: m / z 600.89 [M+H -Boc] +.
[0385] Step 5: Synthesis of tert-butyl (2S) -2- ( (2S, 4S) -5-chloro-6-fluoro-4- (3-fluoro-2- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) -5- ( ( (R) -tetrahydrofuran-3-yl) carbamoyl) pyridin-4-yl) -2-phenyl-2, 3-dihydrobenzofuran-2-yl) pyrrolidine-1-carboxylate (Int 42E)
[0386] To a solution of compound Int 42D (50 mg, 71.31 μmol) in DMF (1.0 mL) was added (3R) -tetrahydrofuran-3-amine (24 mg, 285.24 μmol) , HATU (80 mg, 213.93 μmol) and DIEA (73 mg, 570.49 μmol) . The mixture was stirred at room temperature for 12 h. The mixture was diluted with water (20 mL) and extracted with EtOAc (20 mL×3) . The organic layer was washed with brine (30 mL) , dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, eluent: DCM / MeOH=20: 1) to afford the compound Int 42E (50 mg, 64.91 μmol, 91%) as colorless oil.
[0387] LCMS: m / z 670.11 [M+H -Boc] +.
[0388] Step 6: Synthesis of 4- ( (2S, 4S) -5-chloro-6-fluoro-2-phenyl-2- ( (S) -pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -5-fluoro-6- (2-hydroxyethoxy) -N- ( (R) -tetrahydrofuran-3-yl) nicotinamide (Example 42)
[0389] To a solution of compound Int 42E (50 mg, 64.91 μmol) in DCM (1.0 mL) was added a solution of HCl in 1, 4-dioxane (4 M, 1.5 mL, 6000 μmol) . The mixture was stirred at room temperature for 2 h. The mixture was concentrated under reduced pressure to afford the residue. The residue was purified by prep-HPLC to afford the compound Example 42 (contianed 1 TFA, 20 mg, 28.57 μmol, 44%) as white solid. LCMS: m / z 585.94 [M+H] +.
[0390] 1H NMR (400 MHz, CD3OD) : δ 8.28 (s, 1H) , 7.62 -7.56 (m, 2H) , 7.53 -7.49 (m, 2H) , 7.46 -7.42 (m, 1H) , 7.09 (d, J = 9.2 Hz, 1H) , 4.62 -4.50 (m, 2H) , 4.43 -4.38 (m, 1H) , 4.28 -4.24 (m, 1H) , 3.99 -3.92 (m, 3H) , 3.86 -3.79 (m, 2H) , 3.64 -3.53 (m, 2H) , 3.39 -3.32 (m, 1H) , 3.28 -3.18 (m, 2H) , 2.34 -2.21 (m, 2H) , 2.14 -1.92 (m, 4H) .
[0391] The example (s) in the table below are synthesized using a route like the one described above.
[0392] Synthesis of rel-4- ( (S) -5-chloro-6-fluoro-2-phenyl-2- ( (S) -pyrrolidin-2-yl) -2, 3 dihydrobenzofuran-4-yl) -5-fluoro-6- ( ( (1S, 2R) -2-hydroxycyclopentyl) oxy) -N- ( (R) -tetrahydrofuran-3-yl) nicotinamide (Example 826)
[0393] Step 1: Synthesis of rel-methyl 4-chloro-5-fluoro-6- ( ( (1S, 2R) -2-hydroxycyclopentyl) oxy) nicotinate (826A)
[0394] To a solution of methyl 4-chloro-5, 6-difluoronicotinate (21.0 g, 101.2 mmol) and cis-1, 2-cyclopentanediol (10.3 g, 100.9 mmol) in DMF (80 mL) was added Cs2CO3 (36.4 g, 111.7 mmol) . The resulting mixture was stirred at room temperature for 2 h. The reaction was treated with water (600 mL) and ethyl acetate (500 mL) . The organic layer was washed with brine (300 ml) , dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, eluent: PE / EA=5: 1) to afford compound 826A (12.0 g, 41.4 mmol, 41%) as colorless oil. LCMS: m / z 290.13 [M+H] +. Step 2: Synthesis of rel-methyl 4- ( (S) -2- ( (S) -1- (tert-butoxycarbonyl) pyrrolidin-2-yl) -5-chloro-6-fluoro-2-phenyl-2, 3-dihydrobenzofuran-4-yl) -5-fluoro-6- ( ( (1S, 2R) -2-hydroxycyclopentyl) oxy) nicotinate (826B)
[0395] To a solution of compound 826A (5.0 g, 17.3 mmol) , INTA (10.3 g, 18.9 mmol) , K3PO4 (11.0 g, 51.8 mmol) and N-XantPhos (1.9 g, 3.4 mmol) in toluene (100 mL) and H2O (20 mL) was added Pd2 (dba) 3 (1.6 g, 1.7 mmol) under N2 atmosphere. The resulting mixture was stirred at 100 ℃ overnight and concentrated to dryness under vacuum. The residue was purified by column chromatography (SiO2, eluent: PE / EA=10: 1 to 1: 1) to afford 826B (6.3 g, 9.4 mmol, 54%) as yellow oil. LCMS: m / z 614.91 [M+H-tBu] +.
[0396] Step 3: Synthesis of rel-4- ( (S) -2- ( (S) -1- (tert-butoxycarbonyl) pyrrolidin-2-yl) -5-chloro-6-fluoro-2-phenyl-2, 3-dihydrobenzofuran-4-yl) -5-fluoro-6- ( ( (1S, 2R) -2-hydroxycyclopentyl) oxy) nicotinic acid (826C)
[0397] To a solution of compound 826B (2.1 g, 3.1 mmol) in THF (100 mL) and H2O (50 mL) was added sodium hydroxide (1.0 g, 25.0 mmol) . The resulting mixture was stirred at 80 ℃ overnight. After cooling to room temperature, the reaction was treated with saturated aqueous NaH2PO4 (40 ml) and ethyl acetate (200 mL) . The organic layer was washed with brine (300 ml) and dried over Na2SO4. After filtration, the filtrate was concentrated to afford compound 826C (2.1 g, 3.2 mmol, 100%) as yellow oil. LCMS: m / z 600.93 [M+H-tBu] +.
[0398] Step 4: Synthesis of rel-tert-butyl (2S) -2- ( (2S) -5-chloro-6-fluoro-4- (3-fluoro-2- ( ( (1S, 2R) -2-hydroxycyclopentyl) oxy) -5- ( ( (R) -tetrahydrofuran-3-yl) carbamoyl) pyridin-4-yl) -2-phenyl-2, 3-dihydrobenzofuran-2-yl) pyrrolidine-1-carboxylate (826D)
[0399] To a solution compound 826C (2.1 g, 3.2 mmol) , (R) -tetrahydrofuran-3-amine (477 mg, 5.5 mmol) and N, N-diisopropylethylamine (1.1 g, 8.5 mmol) in DMF (10 mL) was added HATU (2.1 g, 5.6 mmol) . The resulting mixture was stirred at room temperature overnight. The reaction solution was treated with water (100 mL) and filtered. The wet cake was washed with water (50 mL) and dried at 50℃ under vacuum to afford compound 826D (1.7 g, 2.3 mmol, 87 %yield) as yellow solid. LCMS: m / z 725.72 [M+H] +.
[0400] Step 5: Synthesis of rel-4- ( (S) -5-chloro-6-fluoro-2-phenyl-2- ( (S) -pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -5-fluoro-6- ( ( (1S, 2R) -2-hydroxycyclopentyl) oxy) -N- ( (R) -tetrahydrofuran-3-yl) nicotinamide (Example 826)
[0401] To a solution of compound 826D (1.7 g, 2.3 mmol) in dioxane (5 mL) was added 4 N HCl in dioxane (5 mL, 20 mmol) . The mixture was stirred at room temperature for 2 h. The reaction was concentrated to dryness under vacuum. The residue was purified by prep-HPLC to afford four isomers of Example 826.
[0402] Purification condition for isomers of Example 826
[0403] Column: Morphling Triart-C18 30*250 mm, 10 μm
[0404] Mobile phase: A: 0.05%TFA in water; B: acetonitrile
[0405] Gradient: 0 -25 min, 10%B to 50%B
[0406] Flow rate: 30 mL / min
[0407] Column temperature: 25 ℃
[0408] Isomer 1: retention time = 22.5 min
[0409] Isomer 2: retention time = 23.5 min
[0410] Isomer 3: retention time = 24.5 min
[0411] Isomer 4: retention time = 26 min.
[0412] Isomer 1: 300 mg, 20%Yield, white solid. 1H NMR (400 MHz, CD3OD) δ 8.22 (s, 1H) , 7.58 -7.56 (m, 2H) , 7.52 -7.48 (m, 2H) , 7.46 -7.40 (m, 1H) , 7.09 (d, J = 9.1 Hz, 1H) , 5.47 -5.43 (m, 1H) , 4.42 -4.37 (m, 1H) , 4.30 -4.25 (m, 1H) , 4.17 -4.10 (m, 1H) , 3.82 -3.65 (m, 3H) , 3.62 -3.57 (m, 1H) , 3.41 -3.38 (m, 1H) , 3.37 -3.35 (m, 1H) , 3.31 -3.28 (m, 1H) , 3.25 -3.17 (m, 1H) , 2.33 -1.85 (m, 12H) . LCMS: m / z 625.98 [M+H] +.
[0413] Isomer 2: 200 mg, 13%Yield, white solid. 1H NMR (400 MHz, CD3OD) δ 8.26 (s, 1H) , 7.60 -7.56 (m, 2H) , 7.53 -7.49 (m, 2H) , 7.47 -7.41 (m, 1H) , 7.08 (d, J = 9.1 Hz, 1H) , 5.45 -5.39 (m, 1H) , 4.43 -4.38 (m, 1H) , 4.36 -4.32 (m, 1H) , 4.29 -4.21 (m, 1H) , 4.00 -3.93 (m, 1H) , 3.87 -3.78 (m, 2H) , 3.59 -3.54 (m, 2H) , 3.40 -3.36 (m, 1H) , 3.29 -3.19 (m, 2H) , 2.33 -1.90 (m, 12H) . LCMS: m / z 625.96 [M+H] +.
[0414] Isomer 3: 200 mg, 13%Yield, white solid. 1H NMR (400 MHz, CD3OD) δ 8.21 (s, 1H) , 7.58 -7.54 (m, 2H) , 7.47 -7.45 (m, 2H) , 7.45 -7.40 (m, 1H) , 7.09 (d, J = 9.1 Hz, 1H) , 5.49 -5.45 (m, 1H) , 4.44 -4.39 (m, 1H) , 4.29 -4.25 (m, 1H) , 4.17 -4.11 (m, 1H) , 3.82 -3.65 (m, 3H) , 3.62 -3.56 (m, 1H) , 3.43 -3.38 (m, 1H) , 3.36 -3.35 (m, 1H) , 3.30 -3.27 (m, 1H) , 3.26 -3.20 (m, 1H) , 2.34 -1.67 (m, 12H) . LCMS: m / z 625.99 [M+H] +.
[0415] Isomer 4: 200 mg, 13%Yield, white solid. 1H NMR (400 MHz, CD3OD) δ 8.26 (s, 1H) , 7.59 -7.57 (m, 2H) , 7.53 -7.49 (m, 2H) , 7.45 -7.42 (m, 1H) , 7.08 (d, J = 9.1 Hz, 1H) , 5.46 -5.42 (m, 1H) , 4.43 -4.34 (m, 2H) , 4.29 -4.25 (m, 1H) , 4.00 -3.94 (m, 1H) , 3.86 -3.79 (m, 2H) , 3.60 -3.54 (m, 2H) , 3.39 -3.36 (m, 1H) , 3.31 -3.19 (m, 2H) , 2.29 -1.75 (m, 12H) . LCMS: m / z 626.01 [M+H] +.
[0416] The example (s) in the table below are synthesized using a route like the one described above.
[0417] Synthesis of rel- (1S, 2R) -2- ( (tert-butyldiphenylsilyl) oxy) cyclobutan-1-ol, Int D
[0418] Step 1: To a solution of trimethyl- (2-trimethylsilyloxycyclobuten-1-yl) oxy-silane (cas: 17082-61-0, 5 g, 21.74 mmol) in H2O (1.2 mL) and acetone (24 mL) was added ferric chloride in silica (25 mg, 0.5%w / w) . The reaction mixture was stirred at room temperature for 1.5 h and then concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, eluent: DCM / MeOH=100: 1 to 100: 3) to afford INT D-1 (1.5 g, 17.44 mmol, 80%) as colorless oil. 1HNMR (400 MHz, CD3Cl) δ 4.91 -4.86 (m, 1H) , 2.79 -2.57 (m, 2H) , 2.42 -2.33 (m, 1H) , 1.84 -1.74 (m, 1H) .
[0419] Step 2: To a solution of INT D-1 (2.3 g, 26.74 mmol) and triethylamine (5.41 g, 53.6 mmol) in DMF (20 mL) was added TBDPSCl (11.2 g, 40.7 mmol) . The reaction was stirred at room temperature for 12 h. The mixture was diluted with H2O (25 mL) and extracted with EA (25 mL×3) . The combined organics were washed with brine (25 mL) , dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, eluent: PE / EA=50: 1 to 10: 1) to afford INT D-2 (3 g, 9.25 mmol, 34%) as colorless oil.
[0420] Step 3: To a solution of INT D-2 (3 g, 9.25 mmol) in MeOH (25 mL) was added NaBH4 (700 mg, 18.52 mmol) in portions at 0 ℃. The reaction was stirred at 0 ℃ for 0.5 h. The mixture was treated with ice-water (50 mL) and evaporated to remove most MeOH. The resulting mixture was extracted with EA (50 mL) . The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, eluent: PE / EA=50: 1 to 10: 1) to afford rel cis- (±) -INT D (800 mg, 2.45 mmol, 26%) as colorless oil and rel trans- (±) -INT D (1.7 g, 5.21 mmol, 56%) as colorless oil, respectively.
[0421] Cis- (±) -C. 1HNMR (400 MHz, CD3Cl) δ 7.68 –7.64 (m, 4H) , 7.47 –7.37 (m, 6H) , 4.35 –4.30 (m, 1H) , 4.22 –4.16 (m, 1H) , 3.06 (d, J = 6.0 Hz, 1H) , 2.10 –2.04 (m, 1H) , 1.97 –1.88 (m, 3H) , 1.09 (s, 9H) .
[0422] Trans- (±) -C. 1HNMR (400 MHz, CD3Cl) δ 7.77 –7.74 (m, 2H) , 7.71 –7.68 (m, 2H) , 7.46 –7.38 (m, 6H) , 4.05 –3.99 (m, 1H) , 3.97 –3.92 (m, 1H) , 2.00 –1.93 (m, 1H) , 1.87 –1.80 (m, 1H) , 1.44 –1.39 (m, 1H) , 1.17 –1.11 (m, 1H) , 1.07 (s, 9H) .
[0423] Synthesis of Synthesis of rel-4- ( (S) -5-chloro-6-fluoro-2-phenyl-2- ( (S) -pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -5-fluoro-6- ( (1S, 2R) -2-hydroxycyclobutoxy) -N- ( (R) -tetrahydrofuran-3-yl) nicotinamide (Example 827)
[0424] Step 1: Synthesis of rel-methyl 6- ( (1S, 2R) -2- ( (tert-butyldiphenylsilyl) oxy) cyclobutoxy) -4-chloro-5-fluoronicotinate (827a)
[0425] To a solution of methyl 4-chloro-5, 6-difluoronicotinate (803 mg, 3.9 mmol) and rel-(1S, 2R) -2- ( (tert-butyldiphenylsilyl) oxy) cyclobutan-1-ol, INT D (1.2 g, 3.7 mmol) in anhydrous THF (25 mL) was added 60%NaH (221 mg, 5.5 mmol) at room temperature. The resulting mixture was stirred at room temperature for 2 h. The reaction mixture was diluted with H2O (10 mL) and extracted with ethyl acetate (50 mL) . Then the organic layer was washed with brine (10 mL) , dried over Na2SO4, filtered and concentrated under reduced pressure to afford crude compound 827A (2.0 g, 100%) , which was used for next step directly without purification. LCMS: m / z 514.2 [M+H] +.
[0426] Step 2: Synthesis of rel-methyl 4-chloro-5-fluoro-6- ( (1S, 2R) -2-hydroxycyclobutoxy) nicotinate (827B)
[0427] To a solution of compound 827A (2.0 g, 3.89 mmol) in THF (20 mL) was added TBAF (1M in THF, 12 mL, 12 mmol) . The resulting mixture was stirred at room temperature for 0.5 h. The reaction was diluted with H2O (20 ml) and extracted with ethyl acetate (40 mL) . The organic layer was washed with brine (20 ml) , dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, eluent: PE / EA=5: 1 to 3: 1) to afford compound 827B (350 mg, 1.27 mmol, 32%) as colorless oil. LCMS: m / z 275.96 [M+H] +.
[0428] Step 3: Synthesis of rel-methyl 4- ( (S) -2- ( (S) -1- (tert-butoxycarbonyl) pyrrolidin-2-yl) -5-chloro-6-fluoro-2-phenyl-2, 3-dihydrobenzofuran-4-yl) -5-fluoro-6- ( (1S, 2R) -2-hydroxycyclobutoxy) nicotinate (827C)
[0429] To a mixture of compound 827B (200 mg, 0.7 mmol) , INTA (520 mg, 1.0 mmol) and K3PO4 (484 mg, 2.3 mmol) in toluene (2 mL) and H2O (0.4 mL) was added Sphos-Pd-G2 (56 mg, 0.1 mmol) under N2 atmosphere. The resulting mixture was stirred at 95 ℃ overnight. After cooling to room temperature, the reaction was concentrated to dryness under vacuum. The residue was purified by column chromatography (SiO2, eluent: PE / EA=10: 1 to 1: 1) to afford compound 827C (220 mg, 0.3 mmol, 46%) as colorless oil. LCMS: m / z 557.00 [M+H-Boc] +.
[0430] Step 4: Synthesis of rel-4- ( (S) -2- ( (S) -1- (tert-butoxycarbonyl) pyrrolidin-2-yl) -5-chloro-6-fluoro-2-phenyl-2, 3-dihydrobenzofuran-4-yl) -5-fluoro-6- ( (1S, 2R) -2-hydroxycyclobutoxy) nicotinic acid (827D)
[0431] To a solution of compound 827C (220 mg, 0.3 mmol) in MeOH (10 mL) and H2O (5 mL) was added NaOH (88 mg, 2.2 mmol) . The resulting mixture was stirred at 50 ℃ for 2 h. After cooling to room temperature, the mixture was diluted with saturated aqueous NaH2PO4 (10 mL) and extracted with dichloromethane (50 mL) . Then the organic layer was dried over Na2SO4, filtered and concentrated to afford crude compound 827D (215 mg, 100 %) as yellow oil. LCMS: m / z 542.94 [M+H-Boc] +.
[0432] Step 5: Synthesis of rel-tert-butyl (2S) -2- ( (2S) -5-chloro-6-fluoro-4- (3-fluoro-2- ( (1S, 2R) -2-hydroxycyclobutoxy) -5- ( ( (R) -tetrahydrofuran-3-yl) carbamoyl) pyridin-4-yl) -2-phenyl-2, 3-dihydrobenzofuran-2-yl) pyrrolidine-1-carboxylate (827E)
[0433] To a solution of compound 827D (215 mg, 0.33 mmol) , (R) -tetrahydrofuran-3-amine (64 mg, 0.74 mmol) and triethylamine (74 mg, 0.73 mmol) in DMF (4 mL) was added HATU (250 mg, 0.66 mmol) . The resulting mixture was stirred at room temperature for 2 h. The reaction was diluted with H2O (5 mL) and extracted with ethyl acetate (15 mL) . Then the organic layer was washed with brine (15 mL) , dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, eluent: PE / EA=5: 1 to 1: 1) to afford compound 827D (200 mg, 0.28 mmol, 84%) as yellow oil. LCMS: m / z 611.96 [M+H-Boc] +.
[0434] Step 6: Synthesis of rel-4- ( (S) -5-chloro-6-fluoro-2-phenyl-2- ( (S) -pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -5-fluoro-6- ( (1S, 2R) -2-hydroxycyclobutoxy) -N- ( (R) -tetrahydrofuran-3-yl) nicotinamide (Example 827)
[0435] To a solution of compound 827D (200 mg, 0.3 mmol) in dichloromethane (2 mL) was added 4 N HCl in dioxane (2 mL) . The mixture was stirred at room temperature for 2 h and concentrated to dryness under vacuum. The residue was purified by prep-HPLC to afford four isomers of Example 827.
[0436] Purification condition for isomers of Example 827
[0437] Column: Morphling Triart-C18 30*250 mm, 10 μm
[0438] Mobile phase: A: 0.05%TFA in water; B: acetonitrile
[0439] Gradient: 0 -25 min, 10%B to 50%B
[0440] Flow rate: 30 mL / min
[0441] Column temperature: 25 ℃
[0442] Isomer 1: retention time = 21.8 min
[0443] Isomer 2: retention time = 23.5 min
[0444] Isomer 3: retention time = 24.0 min
[0445] Isomer 4: retention time = 25.2 min
[0446] Isomer 1: 6.8 mg, 3.7%Yield, white solid. 1HNMR (400 MHz, CD3OD) δ 8.19 (s, 1H) , 7.60 -7.55 (m 2H) , 7.52 -7.48 (m, 2H) , 7.44 -7.40 (m, 1H) , 7.09 (d, J = 9.2 Hz, 1H) , 5.48 -5.41 (m, 1H) , 4.61 -4.57 (m, 1H) , 4.34 -4.26 (m, 1H) , 4.16 -4.09 (m, 1H) , 3.81 -3.55 (m, 5H) , 3.40 -3.37 (m, 1H) , 3.31 -3.29 (m, 1H) , 3.25 -3.18 (m, 1H) , 2.34 -2.24 (m, 4H) , 2.12 -2.04 (m, 4H) , 1.93 -1.84 (m, 1H) , 1.73 -1.66 (m, 1H) . LCMS: m / z 611.98 [M+H] +.
[0447] Isomer 2: 2.9 mg, 1.5%Yield, white solid. 1HNMR (400 MHz, CD3OD) δ 8.23 (s, 1H) , 7.60 -7.58 (m 2H) , 7.53 -7.49 (m, 2H) , 7.46 -7.42 (m, 1H) , 7.08 (d, J = 9.2 Hz, 1H) , 5.44 -5.40 (m, 1H) , 4.58 -4.52 (m, 1H) , 4.44 -4.37 (m, 1H) , 4.27 -4.23 (m, 1H) , 3.99 -3.94 (m, 1H) , 3.86 -3.78 (m, 2H) , 3.61 -3.56 (m, 2H) , 3.40 -3.34 (m, 1H) , 3.28 -3.20 (m, 2H) , 2.32 -2.21 (m, 5H) , 2.13 -2.04 (m, 3H) , 2.01 -1.94 (m, 2H) . LCMS: m / z 612.24 [M+H] +.
[0448] Isomer 3: 9 mg, 4.9%Yield, white solid. 1HNMR (400 MHz, CD3OD) δ 8.19 (s, 1H) , 7.57 -7.55 (m 2H) , 7.52 -7.48 (m, 2H) , 7.44 -7.40 (m, 1H) , 7.09 (d, J = 9.2 Hz, 1H) , 5.50 -5.43 (m, 1H) , 4.63 -4.58 (m, 1H) , 4.32 -4.25 (m, 1H) , 4.15 -4.10 (m, 1H) , 3.83 -3.57 (m, 4H) , 3.41 -3.38 (m, 2H) , 3.32 -3.29 (m, 1H) , 3.26 -3.19 (m, 1H) , 2.36 -2.26 (m, 4H) , 2.16 -2.03 (m, 4H) , 1.94 -1.86 (m, 1H) , 1.74 -1.67 (m, 1H) . LCMS: m / z 612.16 [M+H] +.
[0449] Isomer 4: 5 mg, 2.7%Yield, white solid. 1HNMR (400 MHz, CD3OD) δ 8.23 (s, 1H) , 7.60 -7.58 (m 2H) , 7.53 -7.50 (m, 2H) , 7.46 -7.42 (m, 1H) , 7.08 (d, J = 9.2 Hz, 1H) , 5.49 -5.43 (m, 1H) , 4.57 -4.54 (m, 1H) , 4.42 -4.37 (m, 1H) , 4.28 -4.24 (m, 1H) , 3.99 -3.93 (m, 1H) , 3.85 -3.79 (m, 2H) , 3.62 -3.52 (m, 2H) , 3.40 -3.34 (m, 1H) , 3.31 -3.20 (m, 2H) , 2.31 -2.21 (m, 5H) , 2.13 -2.04 (m, 3H) , 2.01 -1.92 (m, 2H) . LCMS: m / z 612.02 [M+H] +.
[0450] The example (s) in the table below are synthesized using a route like the one described above.
[0451] The examples in the table below are synthesized using a route like the one described above.
[0452] The examples in the table below are synthesized using a route like the one described above.
[0453] Synthesis of Example 844:
[0454] Step 1: Synthesis of 4-chloro-5-fluoro-6- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) nicotinaldehyde (Int 844A)
[0455] A solution of Diisopropylamine (465 mg, 4.59 mmol, 647 μL) in THF (5.00 mL) was cooled to -78 ℃ and n-Butyllithium (2.5 M in hexanes) (2.5 M, 1.53 mL) was added dropwise. The resulting solution was stirred at -78 ℃ for 15 min. A solution of 4-chloro-3-fluoro-2- (2-tetrahydropyran-2-yloxyethoxy) pyridine (1.06 g, 3.83 mmol) in THF (1.00 mL) was added dropwise and stirred at -78 ℃ for 3 h prior to the addition of N, N-dimethylformamide (336 mg, 4.59 mmol, 356 μL) . The dry ice / acetone bath was removed and the reaction allowed to equilibrate to room temperature and stirred at that temperature overnight. The reaction was quenched by the addition of sat'd aq. NH4Cl (50 mL) , extracted with EtOAc (1 x 50 mL, then 2 x 20 mL) , dried over anhydrous MgSO4, filtered, and concentrated to obtain 1.23 g (106%) of a crude clear brown oil. The crude oil was purified by flash column chromatography (Biotage Sfar HC Duo 5 g, 12 mL / min, 0-50%EtOAc in n-Heptane) to obtain 4-chloro-5-fluoro-6- (2-tetrahydropyran-2-yloxyethoxy) pyridine-3-carbaldehyde (707 mg, 2.33 mmol, 61%yield) .
[0456] LCMS (m / z) : [M+Na] + calc’d for C13H15ClF2NO4Na, 326.1; found, 326.1.
[0457] Step 2: Synthesis of tert-butyl (2S) -2- ( (2S) -5-chloro-6-fluoro-4- ( (4S) -3-fluoro-5-formyl-2- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) pyridin-4-yl) -2-phenyl-2, 3-dihydrobenzofuran-2-yl) pyrrolidine-1-carboxylate (Int 844C)
[0458] A suspension of tert-butyl (2S) -2- [ (2S) -5-chloro-6-fluoro-2-phenyl-4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -3H-benzofuran-2-yl] pyrrolidine-1-carboxylate (0.180 g, 330.97 μmol) , 4-chloro-5-fluoro-6- (2-tetrahydropyran-2-yloxyethoxy) pyridine-3-carbaldehyde (121 mg, 397 μmol) , Potassium phosphate tribasic (211 mg, 993 μmol) , and N-XantPhos (18 mg, 33 μmol) in PhMe (3.60 mL) , and Water (0.708 mL) was degassed by sparging with Ar (g) . To the mixture was added Tris (dibenzylideneacetone) dipalladium (0) (15 mg, 17 μmol) and the mixture again degassed with Ar (g) . The mixture was sealed and heated to 100 ℃, and stirred at that temperature for 16 h. The reaction mixture was cooled to rt and quenched by the addition of sat'd aq NaHCO3 (25 mL) . The mixture was extracted with EtOAc (3 x 25 mL) . The combined organic layers were washed with sat'd aq NaHCO3 (1 x 25 mL) , dried over anhydrous Na2SO4, filtered, and concentrated to obtain a clear dark brown oil (275.4 mg) . The crude material was purified by flash column chromatography (Biotage, Sfar HC Duo 10 g, 30 mL / min, 0-30%EtOAc in Heptanes) to obtain one fraction of pure single atropisomer desired product, Int 844C (45 mg, 20%) , one fraction of mixed atropisomers of desired product, Int 844B + Int 844C (10 mg) , and one fraction of pure single atropisomer desired product, Int 884B (27 mg) , a total of 82 mg, 119.97 μmol, 36%yield) .
[0459] Step 3: Synthesis of (S) -4- ( (S) -5-chloro-6-fluoro-2-phenyl-2- ( (S) -pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -5-fluoro-6- (2-hydroxyethoxy) nicotinaldehyde (Example 844)
[0460] To a solution of tert-butyl (2S) -2- [ (2S) -5-chloro-6-fluoro-4- [3-fluoro-5-formyl-2- (2-tetrahydropyran-2-yloxyethoxy) -4-pyridyl] -2-phenyl-3H-benzofuran-2-yl] pyrrolidine-1-carboxylate (0.038 g, 55 μmol) in CH2Cl2 (4 mL) at room temperature was added Trifluoroacetic acid (149 mg, 1.31 mmol, 0.100 mL) dropwise and the solution stirred at that temperature for 4 h. The reaction mixture was washed with conc. aq. NaHCO3 (3 x 5 mL) and the organic layer dried over anhydrous Na2SO4, filtered, and concentrated to obtain crude material (41 mg) as a clear, yellow film. The crude material was purified by flash column chromatography (Biotage Sfar C18 6g, 3-97%MeCN in H2O + 0.1%formic acid) to obtain 29 mg of pure material. LCMS-ESI (m / z) : [M+H] + calcd for C26H24ClF2N2O4, 501.1; found 501.1.
[0461] Synthesis of Example 849:
[0462] Step 1: Synthesis of rel-tert-butyl (2S) -2- ( (2S) -5-chloro-6-fluoro-4- ( (4S) -3-fluoro-5- ( ( (3S, 4R) -4-fluorotetrahydrofuran-3-yl) carbamoyl) -2- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) pyridin-4-yl) -2-phenyl-2, 3-dihydrobenzofuran-2-yl) pyrrolidine-1-carboxylate (compound INT 849B)
[0463] To a solution of INT 849A (110 mg, 157 μmol) and trans-4-fluorotetrahydrofuran-3-amine hydrochloride (cas: 1903830-44-3, 33 mg, 235 μmol) in DMF (2 mL) was added HATU (88 mg, 235 μmol) and DIEA (60 mg, 470 μmol) . The mixture was stirred at room temperature overnight. Then the reaction was treated with H2O (10 mL) and extracted with EA (10 mL × 2) . The combined organics were washed with brine (20 mL) , dried over Na2SO4, filtered and concentrated under reduced pressure to afford the residue. The residue was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 10: 1 to 2: 1) to afford the INT 849B (70 mg, 88 μmol, 56%) as colorless oil. LCMS: m / z 688.20 [M-Boc+H] +.
[0464] Step 2: Separation of tert-butyl (2S) -2- ( (2S) -5-chloro-6-fluoro-4- ( (4S) -3-fluoro-5- ( ( (3R, 4S) -4-fluorotetrahydrofuran-3-yl) carbamoyl) -2- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) pyridin-4-yl) -2-phenyl-2, 3-dihydrobenzofuran-2-yl) pyrrolidine-1-carboxylate (INT 849B-iso1) and tert-butyl (2S) -2- ( (2S) -5-chloro-6-fluoro-4- ( (4S) -3-fluoro-5- ( ( (3S, 4R) -4-fluorotetrahydrofuran-3-yl) carbamoyl) -2- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) pyridin-4-yl) -2-phenyl-2, 3-dihydrobenzofuran-2-yl) pyrrolidine-1-carboxylate (INT 849B-iso2)
[0465] INT 849B (70 mg, 88 μmol) was separated by preparative HPLC (Morphling AQ-C18, 10μm, 20*250mm, eluent A: 0.1%TFA in H2O, eluent B: MeCN, gradient: 10%to 98%B in 30 min, 25 ℃, flow rate: 20 mL / min) to afford the title compounds as pure diastereoisomers, respectively:
[0466] INT 849B-iso1 (20 mg, 25 μmol, 28%) : colorless oil, tR = 10 min.
[0467] INT 849B -iso2 (20 mg, 25 μmol, 28%) : colorless oil, tR = 11.5 min.
[0468] Step 3: Synthesis of (S) -4- ( (S) -5-chloro-6-fluoro-2-phenyl-2- ( (S) -pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -5-fluoro-N- ( (3R, 4S) -4-fluorotetrahydrofuran-3-yl) -6- (2-hydroxyethoxy) nicotinamide (Example 849-iso1a) .
[0469] To a solution of compound INT849B-iso1 (20 mg, 25 μmol) in DCM (1 mL) was added 4 N HCl in dioxane (1 mL) . The mixture was stirred at room temperature for 2 h. The mixture was concentrated under reduced pressure to afford the residue. The residue was purified by preparative HPLC (Morphling AQ-C18, 10μm, 30*250mm, eluent A: 0.1%TFA in H2O, eluent B: MeCN, gradient: 10%to 30%B in 30 min, 25 ℃, flow rate: 20 mL / min) to afford Example 849-iso1a (7 mg, 11.6 μmol, 46%) as white solid. LCMS: m / z 604.18 [M+H] +. 1H NMR (400 MHz, CD3OD) δ 8.28 (s, 1H) , 7.61 -7.56 (m, 2H) , 7.54 -7.48 (m, 2H) , 7.47 -7.41 (m, 1H) , 7.10 (d, J = 9.2 Hz, 1H) , 4.96 -4.84 (m, 1H) 4.62 -4.53 (m, 2H) , 4.42 -4.39 (m, 1H) , 4.29 -4.23 (m, 1H) , 4.17 -4.12 (m, 1H) , 4.01 (d, J = 2.4 Hz, 1H) , 3.95 -3.90 (m, 3H) , 3.84 -3.81 (m, 1H) , 3.64 -3.57 (m, 1H) , 3.41 -3.34 (m, 1H) , 3.30 -3.19 (m, 2H) , 2.33 -2.23 (m, 1H) , 2.16 -1.93 (m, 3H) .
[0470] Step 4: Synthesis of (S) -4- ( (S) -5-chloro-6-fluoro-2-phenyl-2- ( (S) -pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -5-fluoro-N- ( (3S, 4R) -4-fluorotetrahydrofuran-3-yl) -6- (2-hydroxyethoxy) nicotinamide (Example 849-iso2a) .
[0471] To a solution of INT 849B-iso2 (20 mg, 25 μmol) in DCM (1 mL) was added 4 N HCl in dioxane (1 mL) . The mixture was stirred at room temperature for 2 h. The mixture was concentrated under reduced pressure to afford the residue. The residue was purified by preparative HPLC (Morphling AQ-C18, 10μm, 30*250mm, eluent A: 0.1%TFA in H2O, eluent B: MeCN, gradient: 10%to 30%B in 30 min, 25 ℃, flow rate: 20 mL / min) to afford Example 849-iso2a (10 mg, 16 μmol, 64%) as white solid. LCMS: m / z 604.18 [M+H] +. 1H NMR (400 MHz, CD3OD) δ 8.30 (s, 1H) , 7.61 -7.56 (m, 2H) , 7.54 -7.48 (m, 2H) , 7.46 -7.41 (m, 1H) , 7.09 (d, J = 9.2 Hz, 1H) , 5.23 -5.10 (m, 1H) , 4.62 -4.52 (m, 2H) , 4.47 -4.39 (m, 1H) , 4.29 -4.23 (m, 1H) , 4.14 -3.99 (m, 3H) , 3.97 -3.94 (m, 2H) , 3.69 -3.66 (m, 1H) , 3.64 -3.59 (m, 1H) , 3.41 -3.35 (m, 1H) , 3.29 -3.19 (m, 2H) , 2.32 -2.23 (m, 1H) , 2.16 -1.94 (m, 3H) .
[0472] Synthesis of Intermediate 850E:
[0473] Step 1: Synthesis of rel- (3R, 4S) -Tetrahydro-4-methyl-3-furanol (INT 850B)
[0474] To a suspension of CuI (132.7 g, 696.9 mmol) in THF (800 mL) was added Methylmagnesium Bromide (232.3 mL, 3 M in 2-MeTHF, 696.9 mmol) at -60 ℃ under N2 atmosphere. The mixture was stirred at -60 ℃ for 1 h, then compound INT 850A (cas: 285-69-8, 40.0 g, 464.6 mmol) was added. The resulting mixture was stirred at the same temperature for 3 h. The reaction was quenched with saturated aqueous NH4Cl (100 mL) and extracted with EtOAc (400 mL) . The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to afford the residue. The residue was purified by column chromatography (SiO2, eluent: DCM / MeOH = 20: 1) to afford INT 850B (12.0 g, 117.5 mmol, 25%) as yellow oil. 1H NMR (400 MHz, CDCl3) δ 4.14 -4.11 (m, 1H) , 4.06 -4.03 (m, 1H) , 3.96 -3.92 (m, 1H) , 3.74 -3.71 (m, 1H) , 3.45 -3.42 (m, 1H) , 2.27 -2.17 (m, 1H) , 1.87 -1.86 (m, 1H) , 1.06 -1.04 (m, 3H) .
[0475] Step 2: Synthesis of rel-2- ( (3S, 4R) -4-methyltetrahydrofuran-3-yl) isoindoline-1, 3-dione (INT 850C)
[0476] To a solution of INT 850B (12.0 g, 117.5 mmol) , isoindoline-1, 3-dione (25.9 g, 176.2 mmol) and PPh3 (46.2 g, 176.2 mmol) in THF (120 mL) was added DEAD (24.5 g, 141.0 mmol) dropwise at 0℃ under N2 atmosphere. The mixture was stirred at room temperature for 12 h. The reaction was treated with H2O (200 mL) and extracted with EtOAc (200 mL×5) . The combined organic layer was washed with brine (300 mL) , dried over Na2SO4 and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, eluent: DCM / MeOH =50: 1) to afford INT 850C (16.0 g, 69.2 mmol, 58%) as yellow oil. LCMS: m / z 232.14 [M+H] +.
[0477] Step 3: Synthesis of 2- ( (3S, 4R) -4-methyltetrahydrofuran-3-yl) isoindoline-1, 3-dione (INT 850C-1) and 2- ( (3R, 4S) -4-methyltetrahydrofuran-3-yl) isoindoline-1, 3-dione (INT 850C-2)
[0478] Racemic mixture INT 850C (16.0 g) was separated by preparative SFC (ChiralCel OX, 300*50mm I. D., 10 μm, CO2 / MeOH 3: 1, 25 ℃, flow rate: 200 mL / min) to afford the title compounds as pure enantiomers, respectively:
[0479] INT 850C-1 (7.46 g, 46%, colorless oil) : analytical SFC (ChiralCel OX, 150*4.6mm I.D., 3 μm, CO2 / MeOH (0.05%DEA) 3: 2, 35 ℃, flow rate: 2.5 mL / min, detection UV: 220 nm) tR = 0.95 min. LCMS: m / z 232.1 [M+H] +.
[0480] INT 850C-2 (6.23 g, 38%, colorless oil) : analytical SFC (ChiralCel OX, 150*4.6mm I.D., 3 μm, CO2 / MeOH (0.05%DEA) 3: 2, 35 ℃, flow rate: 2.5 mL / min, detection UV: 220 nm) tR = 1.07 min. LCMS: m / z 232.1 [M+H] +.
[0481] Step 4: Synthesis of tert-butyl ( (3R, 4S) -4-methyltetrahydrofuran-3-yl) carbamate (INT 850D)
[0482] To a solution of compound INT 850C-2 (6.5 g, 28.1 mmol) in EtOH (150 mL) was added Hydrazine hydrate (3 g, 85%in H2O, 51.0 mmol) at 25 ℃. The resulting mixture was stirred at 70 ℃ for 3 h. The reaction was filtered. To the filtrate was added DIEA (7.3 g, 56.5 mmol) , (Boc) 2O (9.2 g, 42.1 mmol) and DCM (150 mL) . The resulting mixture was stirred at room temperature overnight, and then concentrated under vacuum. The residue was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 20: 1) to afford INT 850D (5.5 g, 27.3 mmol, 97%) as colorless oil. LCMS: m / z 102.17 [M+H-Boc] +.
[0483] Step 5: Synthesis of (3R, 4S) -4-methyltetrahydrofuran-3-amine (INT 850E)
[0484] To a solution of INT 850D (5.5 g, 27.3 mmol) in 1'4-Dioxane (10 mL) was added HCl (4 M in 1'4-Dioxane, 40 mL, 160 mmol) . The resulting mixture was stirred at room temperature overnight. The reaction was concentrated under vacuum to afford INT 850E (3.3 g, 24.0 mmol, 87%) . 1H NMR (400 MHz, CD3OD) δ 4.05 -4.00 (m, 2H) , 3.88 -3.82 (m, 2H) , 3.54 (t, J = 8.6 Hz, 1H) , 3.34 -3.32 (m, 1H) , 1.16 (d, J = 7.2 Hz, 3H) .
[0485] Synthesis of Example 851:
[0486] Step 1: Synthesis of methyl 1- ( (tert-butyldimethylsilyl) oxy) cyclopropane-1-carboxylate (INT 851B)
[0487] To a solution of compound INT 851A (cas: 33689-29-1, 1.00 g, 8.62 mmol) in DCM (10 mL) was added TBSCl (1.43 g, 9.48 mmol) and imidazole (879 mg, 12.93 mmol) . The resulting mixture was stirred at room temperature overnight. The reaction was quenched with H2O (10 mL) and extracted with DCM (20 mL×3) . The combined organics were dried over Na2SO4, filtrated and concentrated directly to give crude compound INT 851B (2 g) as colorless oil.
[0488] Step 2: Synthesis of (1- ( (tert-butyldimethylsilyl) oxy) cyclopropyl) methanol (INT 851B)
[0489] To a solution of INT 851B (2.00 g, 8.62 mmol) in THF (20 mL) was added LiAlH4 (4.1 mL, 2.5 M in THF, 10.34 mmol) at 0 ℃ under N2 atmosphere. The mixture was stirred at that temperature for 1 h. After the reaction was completed, the mxiture was quenched with saturated aqueous NH4Cl (20 mL) and extracted with EtOAc (50 mL×3) . The combined organics were dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, eluent: EtOAc / petroleum ether = 1: 10 to 1:4) to give INT 851 C (750 mg, 3.71 mmol, 43%for two steps) as colorless oil. 1H NMR (400 MHz, CDCl3) δ 3.57 (d, J = 5.3 Hz, 2H) , 1.81 (t, J = 5.8 Hz, 1H) , 0.89 (s, 9H) , 0.82 -0.79 (m, 2H) , 0.62 -0.59 (m, 2H) , 0.15 (s, 6H) .
[0490] Step 3: Synthesis of tert-butyldimethyl (1- ( ( (tetrahydro-2H-pyran-2-yl) oxy) methyl) cyclopropoxy) silane (INT 851D)
[0491] To a solution of INT 851C (0.75 g, 3.71 mmol) in DCM (10 mL) was added DHP (0.47 g, 5.57 mmol) and pyridine 4-methylbenzenesulfonate (93 mg, 0.37 mmol) . The resulting mixture was stirred at room temperature overnight. After the reaction was completed, the mixture was quenched with H2O (10 mL) and extracted with DCM (20 mL×3) . The organic phase was dried over Na2SO4, filtrated and concentrated. The residue was purified by column chromatography (SiO2, eluent: EtOAc / petroleum ether = 1: 10 to 1: 4) to give INT 851D (900 mg, 3.14 mmol, 84%) as colorless oil. 1H NMR (400 MHz, CDCl3) δ 4.67 (t, J = 3.5 Hz, 1H) , 3.89 -3.83 (m, 1H) , 3.57 (s, 2H) , 3.54 -3.50 (m, 1H) , 1.94 -1.83 (m, 1H) , 1.79 -1.66 (m, 2H) , 1.61 -1.51 (m, 3H) , 0.87 (s, 9H) , 0.81 -0.71 (m, 2H) , 0.69 -0.56 (m, 2H) , 0.15 (d, J = 12.4 Hz, 6H) .
[0492] Step 4: Synthesis of 1- ( ( (tetrahydro-2H-pyran-2-yl) oxy) methyl) cyclopropan-1-ol (INT 851E)
[0493] To a solution of INT 851D (0.85 g, 2.97 mmol) in THF (10 mL) was added TBAF (4.5 mL, 1.0 M in THF, 4.5 mmol) . The resulting mixture was stirred at room temperature for 1 h. After the reaction was completed, the mixture was quenched with H2O (10 mL) and extracted with EtOAc (20 mL×3) . The organic phase was dried over Na2SO4, filtrated and concentrated. The residue was purified by column chromatography (SiO2, eluent: EtOAc / petroleum ether=1: 10 to 1: 4) to give INT 851E (500 mg, 2.91 mmol, 98%) as colorless oil. 1H NMR (400 MHz, CDCl3) δ 4.69 -4.67 (m, 1H) , 4.03 -3.98 (m, 1H) , 3.89 -3.84 (m, 2H) , 3.61 -3.53 (m, 2H) , 1.92 -1.78 (m, 2H) , 1.67 -1.59 (m, 4H) , 0.88 -0.80 (m, 2H) , 0.67 -0.55 (m, 2H) .
[0494] Step 5: Synthesis of methyl 4-chloro-5-fluoro-6- (1- ( ( (tetrahydro-2H-pyran-2-yl) oxy) methyl) cyclopropoxy) nicotinate (INT 851G)
[0495] To a solution of INT 851E (370 mg, 2.16 mmol) in DMF (5 mL) was added INT 851F (300 mg, 1.44 mmol) and Cs2CO3 (700 mg, 2.16 mmol) . The resulting mixture was stirred at room temperature for 2 h. After the reaction was completed, the mixture was diluted with EtOAc (100 mL) and washed with brine (20 mL×2) . The organic phase was dried over Na2SO4, filtrated and concentrated. The residue was purified by column chromatography (SiO2, eluent: EtOAc / petroleum ether=1: 20 to 1: 4) to give INT 851G (400 mg, 1.11 mmol, 77%) as colorless oil. 1H NMR (400 MHz, CDCl3) δ 8.58 (s, 1H) , 4.71 (t, J = 3.5 Hz, 1H) , 4.11 (d, J = 11.8 Hz, 1H) , 3.97 -3.94 (m, 4H) , 3.84 -3.78 (m, 1H) , 3.46 -3.43 (m, 1H) , 1.87 -1.79 (m, 1H) , 1.75 -1.68 (m, 1H) , 1.66 -1.63 (m, 1H) , 1.58 -1.48 (m, 3H) , 1.13 -0.99 (m, 4H) .
[0496] Step 6: Synthesis of methyl 4- ( (S) -2- ( (S) -1- (tert-butoxycarbonyl) pyrrolidin-2-yl) -5-chloro-6-fluoro-2-phenyl-2, 3-dihydrobenzofuran-4-yl) -5-fluoro-6- (1- ( ( (tetrahydro-2H-pyran-2-yl) oxy) methyl) cyclopropoxy) nicotinate (INT 851I)
[0497] To a solution of INT 851G (280 mg, 0.78 mmol) in tolunen (4 mL) and water (0.8 mL) were added to INT 851H (509 mg, 0.94 mmol) , Pd2dba3 (72 mg, 0.078 mmol) , Cphos (68 mg, 0.16 mmol) and K3PO4 (496 mg, 2.34 mmol) under N2 atmosphere. The mixture was stirred at 90 ℃ overnight. After cooling to room temperature, the mixture was treated with H2O (10 mL) and extracted with EtOAc (50 mL×3) . The organic phase was dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, eluent: EtOAc / petroleum ether=1: 20 to 1: 4) to give INT 851I (240 mg, 0.32 mmol, 42%) as yellow oil. LCMS: m / z 641.27 [M-Boc+H] +.
[0498] Step 7: Synthesis of 4- ( (S) -2- ( (S) -1- (tert-butoxycarbonyl) pyrrolidin-2-yl) -5-chloro-6-fluoro-2-phenyl-2, 3-dihydrobenzofuran-4-yl) -5-fluoro-6- (1- ( ( (tetrahydro-2H-pyran-2-yl) oxy) methyl) cyclopropoxy) nicotinic acid (INT 851J)
[0499] To a solution of INT 851I (240 mg, 0.32 mmol) in MeOH (5 mL) and THF (2.5 mL) was added a solution of NaOH (130 mg, 3.24 mmol) in H2O (2.5 mL) dropwise. The resulting mixture was stirred at 50 ℃ for 1 h. After cooling to room temperature, the mixture was adjusted to pH 6 by adding saturated aqueous NaH2PO4 and extracted with EtOAc (50 mL×3) . The organic phase was dried over Na2SO4, filtrated and concentrated directly to afford INT 851J (230 mg, 0.32 mmol, 99%) as brown oil. LCMS: m / z 627.25 [M-Boc+H] +.
[0500] Step 8: Synthesis of tert-butyl (2S) -2- ( (2S) -5-chloro-6-fluoro-4- (3-fluoro-2- (1- ( ( (tetrahydro-2H-pyran-2-yl) oxy) methyl) cyclopropoxy) -5- ( ( (R) -tetrahydrofuran-3-yl) carbamoyl) pyridin-4-yl) -2-phenyl-2, 3-dihydrobenzofuran-2-yl) pyrrolidine-1-carboxylate (INT 851K)
[0501] To a solution of INT 851J (230 mg, 0.32 mmol) and (R) -tetrahydrofuran-3-amine (41 mg, 0.48 mmol) in DMF (3 mL) were added DIEA (83 mg, 0.64 mmol) and HATU (182 mg, 0.48 mmol) . The resulting mixture was stirred at room temperature for 1.5 h. After the reaction was completed, the mixture was diluted with H2O (5 mL) , and a lot of solid was generated. After filtration, the wet cake was washed with H2O (5 mL) and dried under vacuum to afford INT 851K (150 mg, 0.19 mmol, 59%) as off-white solid. LCMS: m / z 696.31 [M-Boc+H] +.
[0502] Step 9: Synthesis of 4- ( (S) -5-chloro-6-fluoro-2-phenyl-2- ( (S) -pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -5-fluoro-6- (1- (hydroxymethyl) cyclopropoxy) -N- ( (R) -tetrahydrofuran-3-yl) nicotinamide (Example 851)
[0503] To a solution of INT 851K (140 mg, 175 μmol) in DCM (3 mL) was added TFA (0.2 mL) . The mixture was stirred at room temperature for 1 h and concentrated directly. The residue was purified by prep-HPLC (YMC-Triart C18, 30*250mm 10μm, Mobile phase: A: 0.05%TFA in H2O, B: acetonitrile, gradient: 10%to 30%B in 3 min, 30%to 45%B in 22 min, 25 ℃, Flow rate: 30 ml / min) to afford Example 851-iso1 (tR = 16.5 min) and Example 851-iso2 (tR = 18.5 min) .
[0504] Example 851-iso1 (20.7 mg, 33 μmol, 19%) : white solid. LCMS: m / z 612.15 [M+H] +. 1H NMR (400 MHz, CD3OD) δ 8.25 (s, 1H) , 7.57 -7.55 (m, 2H) , 7.51 -7.48 (m, 2H) , 7.44 -7.40 (m, 1H) , 7.09 (d, J = 8.8 Hz, 1H) , 4.30 -4.26 (m, 1H) , 4.14 -4.09 (m, 1H) , 4.05 -3.98 (m, 2H) , 3.81 -3.64 (m, 3H) , 3.58 -3.54 (m, 1H) , 3.39 -3.36 (m, 2H) , 3.31 -3.29 (m, 1H) , 3.25 -3.18 (m, 1H) , 2.31 -2.21 (m, 1H) , 2.14 -2.01 (m, 3H) , 1.92 -1.82 (m, 1H) , 1.73 -1.66 (m, 1H) , 1.07 -1.06 (m, 4H) .
[0505] Example 851-iso2 (36.8 mg, 60 μmol, 33%) : white solid. LCMS: m / z 612.16 [M+H] +. 1H NMR (400 MHz, CD3OD) δ 8.30 (s, 1H) , 7.59 -7.57 (m, 2H) , 7.52 -7.49 (m, 2H) , 7.45 -7.41 (m, 1H) , 7.08 (d, J = 8.8 Hz, 1H) , 4.43 -4.37 (m, 1H) , 4.28 -4.24 (m, 1H) , 4.04 -3.94 (m, 3H) , 3.85 -3.78 (m, 2H) , 3.62 -3.53 (m, 2H) , 3.40 -3.35 (m, 1H) , 3.26 -3.20 (m, 2H) , 2.31 -2.22 (m, 2H) , 2.14 -1.91 (m, 4H) , 1.07 -1.01 (m, 4H) .
[0506] Synthesis of Example 852:
[0507] Step 1: Synthesis of 4-Amino-5-fluoro-2-methylbenzonitrile (Int 852B)
[0508] To a solution of compound 4-bromo-2-fluoro-5-methylaniline (852A) (CAS: 418762-26-2, 5.0 g, 24.5 mmol) in DMF (50 mL) was added Zn (CN) 2 (8.6 g, 73.5 mmol) and Pd (PPh3) 4 (1.4 g, 1.2 mmol) . The resulting mixture was stirred at 110 ℃ for 18 h under N2 atmosphere. After cooling to room temperature, the reaction was diluted with EtOAc (500 mL) and washed with brine (250 mL×3) . The organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc =10: 1 to 5: 1) to afford compound 4-amino-5-fluoro-2-methylbenzonitrile (852B) (3.4 g, 20.7 mmol, 84%) as white solid. 1H NMR (600 MHz, DMSO-d6) δ 7.40 (d, J = 11.4 Hz, 1H) , 6.67 (d, J = 8.4 Hz, 1H) , 6.12 (s, 2H) , 2.29 (s, 3H) .
[0509] Step 2: Synthesis of 4-Amino-3-bromo-5-fluoro-2-methylbenzonitrile (Int 845C)
[0510] To a solution of compound 4-amino-5-fluoro-2-methylbenzonitrile (852B) (3.1 g, 20.7 mmol) in THF (50 mL) was added NBS (4.4 g, 24.8 mmol) . The resulting mixture was stirred at room temperature for 1 h and concentrated to dryness under vacuum. The residue was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 5: 1) to afford compound 4-amino-3-bromo-5-fluoro-2-methylbenzonitrile (852C) (4.2 g, 18.3 mmol, 88%) as yellow solid. 1H NMR (600 MHz, DMSO-d6) δ 7.58 (d, J = 10.8 Hz, 1H) , 6.37 (s, 2H) , 2.45 (s, 3H) .
[0511] Step 3: Synthesis of 3-Bromo-4-chloro-5-fluoro-2-methylbenzonitrile (Int 852D)
[0512] To a solution of compound 4-amino-3-bromo-5-fluoro-2-methylbenzonitrile (852C) (4.2 g, 18.3 mmol) in MeCN (50 mL) was added tert-butyl nitrite (2.8 g, 27.5 mmol) and CuCl (3.6 g, 36.7 mmol) . The resulting mixture was stirred at 60 ℃ for 1 h. After cooling to room temperature, the reaction was filtered over Celite and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 20: 1) to afford compound 3-bromo-4-chloro-5-fluoro-2-methylbenzonitrile (852D) (3.7 g, 14.9 mmol, 81.2%) as white solid. 1H NMR (600 MHz, DMSO-d6) δ 8.15 (d, J = 9.0 Hz, 1H) , 2.61 (d, J = 1.2 Hz, 3H) .
[0513] Step 4: Synthesis of 3-Bromo-4-chloro-5-fluoro-2-methyl-benzoic acid (Int 845E)
[0514] To a solution of compound 3-bromo-4-chloro-5-fluoro-2-methylbenzonitrile (852D) (14 g, 56.3 mmol) in 1, 4-Dioxane (1000 mL) was added 5 N NaOH (225 mL, 1.1 mol) . The mixture was stirred at 100 ℃ for 18 h. After cooling to room temperature, the reaction was concentrated to about 500 mL under reduced pressure, adjusted pH to 4-5 with 1 N HCl and extracted with EtOAc (300 mL×3) . The combined organic extracts were dried over Na2SO4, filtered and concentrated under reduced pressure to give compound 3-bromo-4-chloro-5-fluoro-2-methylbenzoic acid (852E) (15.0 g, 56.1 mmol, 99%yield) as light yellow oil, which was used in the next step without further purification. LCMS: m / z 265.04 [M-H] -.
[0515] Step 5: Synthesis of Methyl 3-bromo-4-chloro-5-fluoro-2-methyl-benzoate (852F)
[0516] To a solution of compound 3-bromo-4-chloro-5-fluoro-2-methylbenzoic acid (852E) (15.0 g, 56.1 mmol) in DMF (200 mL) was added iodomethane (15.9 g, 112.2 mmol) and K2CO3 (23.2 g, 168.2 mmol) . The reaction was stirred at room temperature for 1 h and diluted with EtOAc (500 mL) . The mixture was washed with brine (300 mL×3) , dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 100: 1 to 20: 1) to afford compound methyl 3-bromo-4-chloro-5-fluoro-2-methylbenzoate (12.3 g, 43.3 mmol, 77%) (852F) as white solid. 1H NMR (400 MHz, CDCl3) δ 7.60 (d, J =9.2 Hz, 1H) , 3.92 (s, 3H) , 2.68 (d, J = 1.2 Hz, 3H) .
[0517] Step 6: Synthesis of 3-Bromo-2- (bromomethyl) -4-chloro-5-fluoro-benzoate (845G)
[0518] To a solution of compound methyl 3-bromo-4-chloro-5-fluoro-2-methylbenzoate (852F) (12.3 g, 43.7 mmol) in MeCN (200 mL) was added AIBN (717 mg, 4.4 mmol) and NBS (8.5 g, 48.1 mmol) , then the mixture was stirred at 80 ℃ for 16 h under N2 atmosphere. After cooling to room temperature, the reaction was treated with H2O (500 mL) and extracted with EtOAc (300 mL×3) . The combined organic extracts were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 100: 1 to 20: 1) to afford compound methyl 3-bromo-2- (bromomethyl) -4-chloro-5-fluorobenzoate (852G) (15.0 g, 41.6 mmol, 95%) as white solid. 1H NMR (400 MHz, CDCl3) δ 7.78 (d, J = 8.8 Hz, 1H) , 5.20 (s, 2H) , 3.99 (s, 3H) .
[0519] Step 7: Synthesis of Diethyl 2- [ (2-bromo-3-chloro-4-fluoro-6-methoxycarbonyl-phenyl) methyl] propanedioate (852H)
[0520] To a solution of compound methyl 3-bromo-2- (bromomethyl) -4-chloro-5-fluorobenzoate (852G) (15.0 g, 41.6 mmol) in acetone (200 mL) was added K2CO3 (17.3 g, 124.9 mmol) and diethyl malonate (13.3 g, 83.2 mmol, 12.6 mL) , then the mixture was stirred at 60 ℃ for 16 h under N2 atmosphere. After cooling to room temperature, the reaction was treated with H2O (500 mL) and extracted with EtOAc (300 mL×3) . The combined organic extracts were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 50: 1 to 10: 1) to afford compound diethyl 2- (2-bromo-3-chloro-4-fluoro-6- (methoxycarbonyl) benzyl) malonate (852H) (15.0 g, 34.1 mmol, 82%) as white solid. 1H NMR (400 MHz, CDCl3) δ 7.64 (d, J = 8.8 Hz, 1H) , 4.18 -4.11 (m, 4H) , 3.91 (s, 3H) , 3.85 (d, J = 7.6 Hz, 2H) , 3.74 (d, J = 7.2 Hz, 1H) , 1.20 (t, J = 7.2 Hz, 6H) .
[0521] Step 8: Synthesis of Ethyl 4-bromo-5-chloro-6-fluoro-1-oxo-indane-2-carboxylate (852I-A) and ethyl 7-bromo-6-chloro-5-fluoro-3-hydroxy-1H-indene-2-carboxylate (852I-B)
[0522] To a solution of compound diethyl 2- (2-bromo-3-chloro-4-fluoro-6- (methoxycarbonyl) benzyl) malonate (852H) (15.0 g, 34.1 mmol) in EtOH (200 mL) was added sodium ethoxide (11.6 g, 34.1 mmol, 20%in EtOH) , then the mixture was stirred at room temperature for 2 h under N2 atmosphere. The reaction was adjusted pH to 4-5 with 1 N HCl, precipitate was formed, filtered and washed with H2O. The wet cake was dried under reduced pressure to give a mixture of compound ethyl 4-bromo-5-chloro-6-fluoro-1-oxo-2, 3-dihydro-1H-indene-2-carboxylate (852I-A) and compound ethyl 7-bromo-6-chloro-5-fluoro-3-hydroxy-1H-indene-2-carboxylate (852I-B) (8.1 g, 24.1 mmol) as off-white solid. 1H NMR (400 MHz, CDCl3) δ 10.30 (br. s, 0.5H) , 7.52 (d, J = 6.8 Hz, 0.5H) , 7.42 (d, J = 8.0 Hz, 0.5H) , 4.37 (q, J = 7.1 Hz, 1H) , 4.29 (q, J = 7.1 Hz, 1H) , 3.83 -3.80 (m, 0.5H) , 3.53 -3.48 (m, 1.5H) , 3.38 -3.31 (m, 0.5H) , 1.41 (t, J = 7.0 Hz, 1.5H) , 1.34 (t, J = 7.0 Hz, 1.5H) .
[0523] Step 9: Synthesis of Ethyl 4-bromo-5-chloro-6-fluoro-1-oxo-2-phenyl-indane-2-carboxylate (852J)
[0524] To a solution of compound 852I-A and 852I-B (4.0 g, 11.9 mmol) in DCM (100 mL) was added DIEA (2.3 g, 17.9 mmol, 3.1 mL) and diphenyliodonium trifluoromethanesulfonate (CAS: 66003-76-7, 6.1 g, 14.3 mmol) , the mixture was stirred at room temperature for 2 h. The reaction was treated with H2O (100 mL) and extracted with DCM (100 mL×3) . The combined organic extracts were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 100: 1 to 20: 1) to afford compound ethyl 4-bromo-5-chloro-6-fluoro-1-oxo-2-phenyl-2, 3-dihydro-1H-indene-2-carboxylate (852J) (3.8 g, 9.2 mmol, 77%) as yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.57 (d, J = 6.8 Hz, 1H) , 7.41 -7.31 (m, 5H) , 4.29 -4.20 (m, 2H) , 4.18 -4.13 (m, 1H) , 3.56 -3.51 (m, 1H) , 1.24 (t, J = 7.2 Hz, 3H) .
[0525] Step 10: Synthesis of Ethyl 4-bromo-5-chloro-6-fluoro-1-hydroxy-2-phenyl-indane-2-carboxylate (852K)
[0526] To a mixture of compound ethyl 4-bromo-5-chloro-6-fluoro-1-oxo-2-phenyl-2, 3-dihydro-1H-indene-2-carboxylate (852J) (3.6 g, 8.8 mmol) in EtOH (100 mL) was added NaBH4 (662 mg, 17.5 mmol) . The mixture was stirred at room temperature for 2 h, then treated with saturated aq. NH4Cl (100 mL) and extracted with EtOAc (100 mL×3) . The combined organic extracts were washed with brine (200 mL) , dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 50: 1 to 5: 1) to afford compound ethyl 4-bromo-5-chloro-6-fluoro-1-hydroxy-2-phenyl-2, 3-dihydro-1H-indene-2-carboxylate (852K) (2.8 g, 6.8 mmol, 77%) as colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.38 -7.30 (m, 4H) , 7.25 -7.24 (m, 1H) , 7.16 (d, J = 8.0 Hz, 1H) , 5.86 (d, J = 6.0 Hz, 1H) , 4.21 -4.14 (m, 2H) , 3.65 (s, 2H) , 1.19 (t, J = 7.0 Hz, 3H) .
[0527] Step 11: Synthesis of Ethyl 4-bromo-5-chloro-6-fluoro-2-phenyl-2, 3-dihydro-1H-indene-2-carboxylate (852L)
[0528] To a solution of compound ethyl 4-bromo-5-chloro-6-fluoro-1-hydroxy-2-phenyl-2, 3-dihydro-1H-indene-2-carboxylate (852K) (3.1 g, 7.5 mmol) in DCM (50 mL) was added triethylsilane (13.9 g, 119.9 mmol) , boron trifluoride etherate (3.2 g, 22.5 mmol) and trifluoroacetic acid (2.6 g, 22.5 mmol) at 0 ℃. The mixture was stirred at 50 ℃ for 12 h. After cooling to room temperature, the reaction was diluted with H2O (100 mL) and extracted with DCM (100 mL×3) . The organic layer was washed with saturated aq. NaHCO3 (100 mL) , dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 20: 1) to afford compound ethyl 4-bromo-5-chloro-6-fluoro-2-phenyl-2, 3-dihydro-1H-indene-2-carboxylate (852L) (1.6 g, 4.0 mmol, 54 %) as colorless oil. 1H NMR (400 MHz, DMSO-d6) δ 7.45 (d, J = 8.8 Hz, 1H) , 7.39 -7.27 (m, 5H) , 4.06 -3.87 (m, 4H) , 3.48 -3.43 (m, 1H) , 3.33 -3.28 (m, 1H) , 1.04 (t, J = 7.2 Hz, 3H) .
[0529] Step 12: Synthesis of (4-Bromo-5-chloro-6-fluoro-2-phenyl-2, 3-dihydro-1H-inden-2- yl) methanol (852M)
[0530] To a solution of ethyl 4-bromo-5-chloro-6-fluoro-2-phenyl-2, 3-dihydro-1H-indene-2-carboxylate (852L) (1.6 g, 4.0 mmol) in DCM (3.3 mL) was added DIBAL-H (20 mL, 20 mmol, 1 M in THF) dropwise at -78 ℃ under N2 atmosphere. The mixture was stirred at the same temperature for 1 h. Then the reaction was quenched with H2O (0.8 mL) , aq. 15%NaOH (0.8 mL) and H2O (2.0 mL) . The resulting mixture was dried over Na2SO4, filtered and concentrated under reduced pressure to afford the residue. The residue was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 10: 1) to afford compound (4-bromo-5-chloro-6-fluoro-2-phenyl-2, 3-dihydro-1H-inden-2-yl) methanol (852M) (1.2 g, 3.4 mmol, 84 %) as colorless oil.
[0531] Step 13: Synthesis of 4-Bromo-5-chloro-6-fluoro-2-phenyl-2, 3-dihydro-1H-indene-2-carbaldehyde (852N)
[0532] To a solution of compound (4-bromo-5-chloro-6-fluoro-2-phenyl-2, 3-dihydro-1H-inden-2-yl) methanol (852M) (500 mg, 1.4 mmol) in DCM (10 mL) was added Dess-martin periodinane (894 mg, 2.1mmol) . The mixture was stirred at room temperature for 0.5 h, then quenched with saturated aq. Na2SO3 (100 mL) and extracted with DCM (100 mL×3) . The organic layer was washed with saturated aq. NaHCO3 (100 mL) , dried over Na2SO4, filtered and concentrated under reduced pressure to afford compound 4-bromo-5-chloro-6-fluoro-2-phenyl-2, 3-dihydro-1H-indene-2-carbaldehyde (852N) (500 mg, 100%) as yellow solid.
[0533] Step 14: Synthesis of (1r, 4r) -4- ( ( (4-Bromo-5-chloro-6-fluoro-2-phenyl-2, 3-dihydro-1H-inden-2-yl) methyl) amino) cyclohexan-1-ol (852O)
[0534] To a solution of compound 4-bromo-5-chloro-6-fluoro-2-phenyl-2, 3-dihydro-1H- indene-2-carbaldehyde (852N) (500 mg, 1.4 mmol) in MeOH (5 mL) was added trans-4-aminocyclohexanol (814 mg, 7.1 mmol) . The mixture was stirred at room temperature for 12 h. Then NaBH4 (107 mg, 2.8 mmol) was added at 0 ℃, the mixture was stirred at room temperature for 2 h. The reaction was treated with saturated aq. NH4Cl (50 mL) and extracted with DCM (50 mL×3) . The organic layer was washed with brine (50 mL) , dried over Na2SO4, filtered and concentrated under reduced pressure to afford compound (1r, 4r) -4- ( ( (4-bromo-5-chloro-6-fluoro-2-phenyl-2, 3-dihydro-1H-inden-2-yl) methyl) amino) cyclohexan-1-ol (852O) (700 mg, crude) as brown oil. LCMS: m / z 451.90 [M+H] +.
[0535] Step 15: Synthesis of tert-Butyl ( (4-bromo-5-chloro-6-fluoro-2-phenyl-2, 3-dihydro-1H-inden-2-yl) methyl) ( (1r, 4r) -4-hydroxycyclohexyl) carbamate (852P)
[0536] To a solution of compound Synthesis of (1r, 4r) -4- ( ( (4-Bromo-5-chloro-6-fluoro-2-phenyl-2, 3-dihydro-1H-inden-2-yl) methyl) amino) cyclohexan-1-ol (852O) (700 mg, crude) in EtOH (7 mL) was added di-tert-butyl dicarbonate (3.5 mL) . The mixture was stirred at 80 ℃ for 12 h. After cooling to room temperature, the reaction was treated with H2O (50 mL) and extracted with DCM (50 mL×3) . The organic layer was washed with brine (50 mL) , dried over Na2SO4, filtered and concentrated under reduced pressure to afford the residue. The residue was purified by column chromatography (SiO2, eluent: DCM / MeOH = 20: 1) to afford compound tert-Butyl ( (4-bromo-5-chloro-6-fluoro-2-phenyl-2, 3-dihydro-1H-inden-2-yl) methyl) ( (1r, 4r) -4-hydroxycyclohexyl) carbamate (852P) (700 mg, 1.3 mmol, 89 %for two steps) as colorless oil. LCMS: m / z 451.93 [M+H-Boc] +. Racemic compound (852P) (700 mg) was separated by chiral preparative HPLC (Chiralcel AD-H, 50*250mm, 10 μm, hexane / IPA 80: 20, 25 ℃, flow rate: 80 mL / min) to afford the title compounds as pure enantiomers, respectively:
[0537] Compound 852P-A (260 mg, 0.47 mmol, 37%) : colorless oil, tR = 13.0 min.
[0538] Compound 852P-B (260 mg, 0.47 mmol, 37%) : colorless oil, tR = 17.0 min.
[0539] Step 16: Synthesis of 3-Fluoro-4- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) -2- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) benzonitrile
[0540] To a mixture compound 2-bromo-3-fluoro-4- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) benzonitrile (540 mg, 1.6 mmol) , bis (pinacolato) diboron (847 mg, 3.1 mmol) and KOAc (461 mg, 4.7 mmol, 3.0 equiv) in toluene (10 mL) and dioxane (1 mL) was added Pd (dppf) Cl2 (114 mg, 156.9 μmol) under N2 atmosphere. The mixture was stirred at 100 ℃ for 12 h. After cooling to room temperature, the mixture was concentrated under reduced pressure to afford the residue. The residue was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 5: 1) to afford compound 3-Fluoro-4- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) -2- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) benzonitrile (600 mg, 1.5 mmol, 97%) as yellow oil. 1H NMR (DMSO-d6) : δ 7.46 -7.44 (m, 1H) , 7.11 (t, J = 8.4 Hz, 1H) , 4.72 (t, J =3.2 Hz, 1H) , 4.31 -4.25 (m, 2H) , 4.13 -4.05 (m, 1H) , 3.91 -3.82 (m, 2H) , 3.59 -3.51 (m, 1H) , 1.83 -1.71 (m, 2H) , 1.63 -1.50 (m, 4H) , 1.29 (s, 12H) .
[0541] Step 17: Synthesis of tert-Butyl ( ( (2S) -5-chloro-4- (6-cyano-2-fluoro-3- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) phenyl) -6-fluoro-2-phenyl-2, 3-dihydro-1H-inden-2-yl) methyl) ( (1r, 4S) -4-hydroxycyclohexyl) carbamate (845Q-A)
[0542] To a mixture of compound 852P-A (130 mg, 234.3 μmol) , compound 3-Fluoro-4- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) -2- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) benzonitrile (92 mg, 234.3 μmol) and K3PO4 (149 mg, 702.9 μmol) in toluene (0.8 mL) and H2O (0.2 mL) was added SPhos Pd G2 (17 mg, 23.4 μmol) under N2 atmosphere. The mixture was stirred at 100 ℃ for 12 h. After cooling to room temperature, the mixture was concentrated under reduced pressure to afford the residue. The residue was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 1: 1) to afford compound tert-Butyl ( ( (2S) -5-chloro-4- (6-cyano-2-fluoro-3- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) phenyl) -6-fluoro-2-phenyl-2, 3-dihydro-1H-inden-2-yl) methyl) ( (1r, 4S) -4-hydroxycyclohexyl) carbamate (852Q-A) (40 mg, 54.1 μmol, 23 %) as yellow oil. LCMS: m / z 553.21 [M+H-Boc-THP] +.
[0543] Step 18: Synthesis of tert-Butyl ( ( (2S) -4- (6-carbamoyl-2-fluoro-3- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) phenyl) -5-chloro-6-fluoro-2-phenyl-2, 3-dihydro-1H-inden-2-yl) methyl) ( (1r, 4S) -4-hydroxycyclohexyl) carbamate (852R-A)
[0544] To a solution of tert-Butyl ( ( (2S) -5-chloro-4- (6-cyano-2-fluoro-3- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) phenyl) -6-fluoro-2-phenyl-2, 3-dihydro-1H-inden-2-yl) methyl) ( (1r, 4S) -4-hydroxycyclohexyl) carbamate (852Q-A) (40 mg, 54.1 μmol) in EtOH (2 mL) and H2O (0.4 mL) was added Parkin’s catalyst (CAS: 173416-05-2, 5 mg, 10.8 μmol) . The mixture was stirred at 80 ℃ for 1 h. After cooling to room temperature, the mixture was concentrated under reduced pressure to afford compound tert-Butyl ( ( (2S) -4- (6-carbamoyl-2-fluoro-3- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) phenyl) -5-chloro-6-fluoro-2-phenyl-2, 3-dihydro-1H-inden-2-yl) methyl) ( (1r, 4S) -4-hydroxycyclohexyl) carbamate (852R-A) (40 mg, 98%) as yellow oil. LCMS: m / z 655.24 [M+H-Boc] +.
[0545] Step 19: Synthesis of 2- ( (2S) -5-Chloro-6-fluoro-2- ( ( ( (1r, 4S) -4-hydroxycyclohexyl) amino) methyl) -2-phenyl-2, 3-dihydro-1H-inden-4-yl) -3-fluoro-4- (2-hydroxyethoxy) benzamide (852-ISO1&ISO2)
[0546] To a solution of compound tert-Butyl ( ( (2S) -4- (6-carbamoyl-2-fluoro-3- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) phenyl) -5-chloro-6-fluoro-2-phenyl-2, 3-dihydro-1H-inden-2-yl) methyl) ( (1r, 4S) -4-hydroxycyclohexyl) carbamate (852R-A) (40 mg, 52.8 μmol) in DCM (2 mL) was added 4 N HCl in dioxane (1 mL) . The mixture was stirred at room temperature for 2 h, adjusted pH to 8-9 with 0.5 N Na2CO3 and extracted with EtOAc (20 mL×3) . The organic layer was washed with brine (40 mL) , dried over Na2SO4, filtered and concentrated under reduced pressure to afford the residue. The residue was purified by preparative HPLC (Morphling AQ-C18, 5μm, 20*250mm, eluent A: 0.1%TFA in H2O, eluent B: MeCN, gradient: 10 to 98%B in 30 min, 25 ℃, flow rate: 20 mL / min) to afford 852-ISO1 (tR = 8.5 min) and 852-ISO2 (tR = 11.0 min) .
[0547] 852-ISO1 (7.4 mg, 12.91 μmol, 24%) : white solid, LCMS: m / z 571.23, 1H NMR (400 MHz, CD3OD) δ 7.63 -7.60 (m, 1H) , 7.43 (d, J = 4.4 Hz, 4H) , 7.44 -7.22 (m, 2H) , 7.23 (d, J = 8.8 Hz, 1H) , 4.31 -4.22 (m, 2H) , 3.98 (t, J = 4.6 Hz, 2H) , 3.49 -3.39 (m, 4H) , 3.36 -3.33 (m, 1H) , 3.32 -3.28 (m, 1H) , 3.01 (d, J = 16.4 Hz, 1H) , 2.85 -2.82 (m, 1H) , 2.03 -1.88 (m, 4H) , 1.37 -1.32 (m, 2H) , 1.28 -1.18 (m, 2H) .
[0548] 852-ISO2 (10.9 mg, 19.02 μmol, 36%) : white solid, LCMS: m / z 571.23, 1H NMR (400 MHz, CD3OD) δ 7.58-7.56 (m, 1H) , 7.46 -7.38 (m, 4H) , 7.36 -7.32 (m, 2H) , 7.27 (d, J = 8.8 Hz, 1H) , 4.26 (t, J = 4.6 Hz, 2H) , 3.98 -3.95 (m, 2H) , 3.54 -3.42 (m, 3H) , 3.36 -3.33 (m, 1H) , 3.26 -3.21 (m, 2H) , 3.14 (d, J = 16.0 Hz, 1H) , 2.97 -2.91 (m, 1H) , 2.05 -1.88 (m, 4H) , 1.52 -1.33 (m, 2H) , 1.27 -1.18 (m, 2H) .
[0549] Step 20: Synthesis of tert-Butyl ( ( (2R) -5-chloro-4- (6-cyano-2-fluoro-3- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) phenyl) -6-fluoro-2-phenyl-2, 3-dihydro-1H-inden-2-yl) methyl) ( (1r, 4R) -4-hydroxycyclohexyl) carbamate (852Q-B)
[0550] To a mixture of compound 852P-B (130 mg, 234.3 μmol) , compound 3-fluoro-4- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) -2- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) benzonitrile (92 mg, 234.3 μmol, 1.0 equiv) and K3PO4 (149 mg, 702.9 μmol) in toluene (0.8 mL) and H2O (0.2 mL) was added SPhos Pd G2 (17 mg, 23.4 μmol) under N2 atmosphere. The mixture was stirred at 100 ℃ for 12 h. After cooling to room temperature, the mixture was concentrated under reduced pressure to afford the residue. The residue was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 1: 1) to afford compound tert-Butyl ( ( (2R) -5-chloro-4- (6-cyano-2-fluoro-3- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) phenyl) -6-fluoro-2-phenyl-2, 3-dihydro-1H-inden-2-yl) methyl) ( (1r, 4R) -4-hydroxycyclohexyl) carbamate (852Q-B) (80 mg, 108.2 μmol, 46 %) as yellow oil. LCMS: m / z 553.21 [M+H-Boc-THP] +.
[0551] Step 21: Synthesis of tert-Butyl ( ( (2R) -4- (6-carbamoyl-2-fluoro-3- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) phenyl) -5-chloro-6-fluoro-2-phenyl-2, 3-dihydro-1H-inden-2-yl) methyl) ( (1r, 4R) -4-hydroxycyclohexyl) carbamate (852R-B)
[0552] To a solution of compound tert-Butyl ( ( (2R) -5-chloro-4- (6-cyano-2-fluoro-3- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) phenyl) -6-fluoro-2-phenyl-2, 3-dihydro-1H-inden-2-yl) methyl) ( (1r, 4R) -4-hydroxycyclohexyl) carbamate (852Q-B) (80 mg, 108.2 μmol) in EtOH (2 mL) and H2O (0.4 mL) was added Parkin’s catalyst (10 mg, 21.6 μmol) . The mixture was stirred at 80 ℃ for 1 h. After cooling to room temperature, the mixture was concentrated under reduced pressure to afford compound tert-Butyl ( ( (2R) -4- (6-carbamoyl-2-fluoro-3- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) phenyl) -5-chloro-6-fluoro-2-phenyl-2, 3-dihydro-1H-inden-2-yl) methyl) ( (1r, 4R) -4-hydroxycyclohexyl) carbamate (852R-B) (80 mg, 98%) as yellow oil. LCMS: m / z 655.24 [M+H-Boc] +.
[0553] Step 22: Synthesis of 2- (5-Chloro-6-fluoro-2- ( ( ( (1r, 4r) -4-hydroxycyclohexyl) amino) methyl) -2-phenyl-2, 3-dihydro-1H-inden-4-yl) -3-fluoro-4- (2-hydroxyethoxy) benzamide (852-ISO3&ISO4)
[0554] To a solution of compound tert-Butyl ( ( (2R) -4- (6-carbamoyl-2-fluoro-3- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) phenyl) -5-chloro-6-fluoro-2-phenyl-2, 3-dihydro-1H-inden-2-yl) methyl) ( (1r, 4R) -4-hydroxycyclohexyl) carbamate (852R-B) (80 mg, 105.6 μmol) in DCM (2 mL) was added 4 N HCl in dioxane (1 mL) . The mixture was stirred at room temperature for 2 h, then adjusted pH to 8-9 with 0.5 N Na2CO3 and extracted with EA (20 mL×3) . The organic layer was washed with brine (40 mL) , dried over Na2SO4, filtered and concentrated under reduced pressure to afford the residue. The residue was purified by preparative HPLC (Morphling AQ-C18, 5μm, 20*250mm, eluent A: 0.1%TFA in H2O, eluent B: MeCN, gradient: 10 to 98%B in 30 min, 25 ℃, flow rate: 20 mL / min) to afford 852-ISO3 (tR = 8.5 min) and 852-ISO4 (tR = 11.0 min) .
[0555] 852-ISO3 (4.4 mg, 7.7 μmol, 7 %) : white solid, LCMS: m / z 571.23, 1H NMR (400 MHz, CD3OD) δ 7.63 -7.60 (m, 1H) , 7.42 (d, J = 4.4 Hz, 4H) , 7.36 -7.30 (m, 2H) , 7.23 (d, J = 8.8 Hz, 1H) , 4.31 -4.22 (m, 2H) , 3.98 (t, J = 4.6 Hz, 2H) , 3.50 -3.39 (m, 4H) , 3.36 -3.32 (m, 1H) , 3.30 -3.28 (m, 1H) , 3.01 (d, J = 16.0 Hz, 1H) , 2.85 -2.79 (m, 1H) , 2.04 -1.87 (m, 4H) , 1.37 -1.32 (m, 2H) , 1.29 -1.17 (m, 2H) .
[0556] 852-ISO4 (8.3 mg, 14.5 μmol, 14 %) : white solid, LCMS: m / z 571.23, 1H NMR (400 MHz, CD3OD) δ 7.58 -7.56 (m, 1H) , 7.46 -7.37 (m, 4H) , 7.36 -7.32 (m, 2H) , 7.27 (d, J = 8.8 Hz, 1H) , 4.26 (t, J = 4.6, 2H) , 3.98 -3.95 (m, 2H) , 3.53 -3.42 (m, 3H) , 3.37-3.35 (m, 1H) , 3.26 -3.21 (m, 2H) , 3.14 (d, J = 16.0 Hz, 1H) , 2.97 -2.91 (m, 1H) , 2.05 -1.88 (m, 4H) , 1.46 -1.40 (m, 2H) , 1.27 -1.18 (m, 2H) .
[0557] Synthesis of Example 857:
[0558] Step 1: Synthesis of 2-Bromo-3-fluoro-4- ( ( (1S, 3R) -3-hydroxycyclopentyl) oxy) benzonitrile (INT 857B)
[0559] To a suspension of starting material INT 857A (cas: 1517611-20-9, 1.7 g, 7.8 mmol) and Cs2CO3 (3.81 g, 11.7 mmol) in DMF (40 mL) was added cis-cyclopentane-1, 3-diol (cas: 16326-97-9, 956 mg, 9.36 mmol) dropwise under nitrogen, then the mixture was stirred at room temperature for 2 h. The reaction was diluted with EtOAc (200 mL) and washed with brine (150 mL×3) . The organic phase was dried over Na2SO4, filtered and concentrated under reduced pressure to give the crude product, which was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 2: 1) to afford INT 857B (1.31 g, 4.36 mmol, 55%yield) as colorless oil. 1H NMR (400 MHz, CDCl3) δ7.45 (d, J = 12.0 Hz, 1H) , 6.97 (t, J = 8.0 Hz, 1H) , 4.94 -4.92 (m, 1H) , 4.44 -4.42 (m, 1H) , 2.23 -1.94 (m, 6H) .
[0560] Step 2: Synthesis of 2-Bromo-3-fluoro-4- ( ( (1S, 3R) -3-hydroxycyclopentyl) oxy) benzoic acid (compound 270-3)
[0561] To a solution of INT 857B (1.31 g, 4.36 mmol) in MeOH (10 mL) was added aqueous NaOH (6 M, 10 mL, 60 mmol) , then the solution was stirred at 90 ℃ for 3 h until the reaction was completed. The resulting solution was cooled to room temperature and adjusted to pH 5 by adding 3M HCl. Then the solution was extracted with DCM / MeOH (10 / 1, 50 mL×3) . The combined organics were dried over Na2SO4, filtered and concentrated under reduced pressure to give the crude INT 857C (1.1 g, 3.45 mmmol, 78%) as white solid. LCMS: m / z 319.0 [M+H] +.
[0562] Step 3: Synthesis of methyl 2-bromo-3-fluoro-4- ( ( (1S, 3R) -3-hydroxycyclopentyl) oxy) benzoate (INT 857D)
[0563] To a solution of INT 857C (1.1 g, 3.45 mmol) in DMF (15 mL) was added K2CO3 (715 mg, 5.17 mmol) and CH3I (734 mg, 5.17 mmol) , then the mixture was stirred at room temperature for 1 h until the starting material was consumed. The resulting solution was diluted with EtOAc (100 mL) and washed with brine (50 mL×3) . The organic phase was dried over Na2SO4, filtered and concentrated under reduced pressure to give the crude product, which was purified by column chromatography (SiO2, eluent: DCM / MeOH = 20: 1) to afford INT 857D (1.0 g, 3.00 mmol, 87%) . 1H NMR (400 MHz, CDCl3) δ 7.70 (d, J = 12.0 Hz, 1H) , 6.94 (t, J = 8.0 Hz, 1H) , 4.97 -4.95 (m, 1H) , 4.43 -4.42 (m, 1H) , 3.94 (s, 3H) , 2.21-1.93 (m, 6H) .
[0564] Step 4: Synthesis of methyl 2-bromo-3-fluoro-4- ( ( (1S, 3R) -3- ( (tetrahydro-2H-pyran-2-yl) oxy) cyclopentyl) oxy) benzoate (INT 857E)
[0565] To a solution of compound INT 857D (350 mg, 1.05 mmol) in DCM (5 mL) were added p-toluenesulfonic acid (18 mg, 0.11 mmol) and 3, 4-Dihydro-2H-pyran (177 mg, 2.1 mmol) , then the solution was stirred at room temperature for 2 h until the starting material was consumed. The resulting solution was treated with H2O (30 mL) and extracted with EtOAc (30 mL×2) . The combined organics were dried over Na2SO4, filtered and concentrated under reduced pressure to give the crude product, which was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 1: 1) to afford compound INT 857E (400 mg, 0.96 mmol, 91%) as yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.68 (d, J = 12.0 Hz, 1H) , 6.89 (d, J = 8.0 Hz, 1H) , 4.82 -4.80 (m, 1H) , 4.70 -4.58 (m, 1H) , 4.33 -4.26 (m, 1H) , 3.93 (s, 3H) , 3.56 -3.49 (m, 2H) , 2.49 -2.33 (m, 2H) , 1.98 -1.70 (m, 10H) .
[0566] Step 5: Synthesis of tert-butyl (2S) -2- ( (2S) -5-chloro-6-fluoro-4- (2-fluoro-6- (methoxycarbonyl) -3- ( ( (1S, 3R) -3- ( (tetrahydro-2H-pyran-2-yl) oxy) cyclopentyl) oxy) phenyl) -2-phenyl-2, 3-dihydrobenzofuran-2-yl) pyrrolidine-1-carboxylate (INT 857G)
[0567] To a pressure tube was added INT 857E (445 mg, 1.07 mmol) , INT 857F (870 mg, 1.6 mmol) , Pd2 (dba) 3 (98 mg, 0.11 mmol) , N-Xantphos (123 mg, 0.21 mmol) , K3PO4 (679 mg, 3.2 mmol) , toluene (8 mL) and water (0.5 mL) . The mixture was stirred at 100 ℃for 6 h under N2 atmosphere. After cooling to room temperature, the reaction was concentrated under reduced pressure to give the crude product, which was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 3: 1) to afford INT 857G (310 mg, 0.41 mmol, 38%) as yellow oil. LCMS: m / z 754.3 [M+H] +.
[0568] Step 6: Synthesis of 2- ( (S) -2- ( (S) -1- (tert-butoxycarbonyl) pyrrolidin-2-yl) -5-chloro-6-fluoro-2-phenyl-2, 3-dihydrobenzofuran-4-yl) -3-fluoro-4- ( ( (1S, 3R) -3- ( (tetrahydro-2H- pyran-2-yl) oxy) cyclopentyl) oxy) benzoic acid (INT 857H)
[0569] To a solution of INT 857G (310 mg, 0.41 mmol) in MeOH (6 mL) and H2O (2 mL) was added NaOH (66 mg, 1.64 mmol) , then the mixture was stirred at 50 ℃ for 2 h. The resulting solution was adjusted to pH 7 by addition of 2M HCl and extracted with DCM / MeOH (10 / 1, 50 mL) . The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to give INT 857H (280 mg, 0.38 mmol, 92%) as brown oil. LCMS: m / z 740.3 [M+H] +.
[0570] Step 7: Synthesis of tert-butyl (2S) -2- ( (2S) -5-chloro-6-fluoro-4- (2-fluoro-6- ( ( (3S, 4R) -4-hydroxytetrahydrofuran-3-yl) carbamoyl) -3- ( ( (1S, 3R) -3- ( (tetrahydro-2H-pyran-2-yl) oxy) cyclopentyl) oxy) phenyl) -2-phenyl-2, 3-dihydrobenzofuran-2-yl) pyrrolidine-1-carboxylate (INT 857I)
[0571] To a solution of INT 857H (280 mg, 0.38 mmol) and (3R, 4S) -4-aminotetrahydrofuran-3-ol (cas: 190792-70-2, 47 mg, 0.45 mmol) in DMF (5 mL) were added DIEA (196 mg, 1.91 mmol) and HATU (214 mg, 0.57 mmol) , then the solution was stirred at room temperature for 1 h. The reaction was diluted with EtOAc (40 mL) and washed with brine (30 mL×3) . The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to give the crude product, which was purified by column chromatograph (SiO2, eluent: DCM / MeOH = 20: 1) to afford INT 857I (300 mg, 0.36 mmol, 96%) as brown oil. LCMS: m / z 825.3 [M+H] +.
[0572] Step 8: Synthesis of 2- ( (S) -5-chloro-6-fluoro-2-phenyl-2- ( (S) -pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -3-fluoro-4- ( ( (1S, 3R) -3-hydroxycyclopentyl) oxy) -N- ( (3S, 4R) -4-hydroxytetrahydrofuran-3-yl) benzamide (Example 857) .
[0573] A solution of INT 857I (280 mg, 0.34 mmol) in 4M HCl in 1, 4-dioxane (5 mL) was stirred at room temperature for 2 h. The resulting solution was concentrated under reduced pressure to give the residue. The residue was purified by preparative HPLC (Morphling AQ-C18, 5μm, 20*250mm, eluent A: 0.1%TFA in H2O, eluent B: MeCN, gradient: 10%to 98%B in 30 min, 25 ℃, flow rate: 20 mL / min) to afford Example 857-iso1 (tR = 11.9 min) , Example 857-iso2 (tR = 13.2 min) , Example 857-iso3 (tR =14.8 min) and Example 857-iso4 (tR = 15.8 min) .
[0574] Example 857-iso4 (7.5 mg, 0.01 mmol, 3%) : white solid. LCMS: m / z 641.1 [M+H] +. 1H NMR (400 MHz, CD3OD) δ 7.59 -7.57 (m, 2H) , 7.52 -7.41 (m, 4H) , 7.21 (t, J =8.0 Hz, 1H) , 7.02 (d, J = 12.0 Hz, 1H) , 4.33 -4.14 (m, 4H) , 4.06 -3.98 (m, 2H) , 3.69 -3.66 (m, 1H) , 3.60 -3.55 (m, 2H) , 3.40 -3.37 (m, 1H) , 3.24 -3.20 (m, 2H) , 2.49 -2.42 (m, 1H) , 2.28 -2.20 (m, 1H) , 2.11 -1.64 (m, 9H) .
[0575] Synthesis of Example 858:
[0576] Step 1: Synthesis of (S) -4- ( (S) -2- ( (S) -1- (tert-butoxycarbonyl) pyrrolidin-2-yl) -5-chloro-6-fluoro-2-phenyl-2, 3-dihydrobenzofuran-4-yl) -6- (ethylthio) -5-fluoronicotinic acid (INT 858B)
[0577] To a solution of INT 858A (5.00 g, 6.49 mmol) and methan-d3-amine hydrochloride (0.69 g, 9.74 mmol) in DMF (50 mL) were added HATU (3.70 g, 9.74 mmol) and DIEA (2.90 g, 22.72 mmol) . The resulting mixture was stirred at room temperature overnight. After the reaction was completed, the mixture was diluted with H2O (100 mL) , and a lot of solid was generated. After filtration, the wet cake was washed with H2O (10 mL) and dried under vacuum to afford INT 858B (4.62 g, 7.29 mmol, 90%) as off-white solid. LCMS: m / z 533.21 [M-Boc+H] +.
[0578] Step 2: Synthesis of tert-butyl (S) -2- ( (S) -5-chloro-4- ( (S) -2- (ethylsulfonyl) -3-fluoro-5- ( (methyl-d3) carbamoyl) pyridin-4-yl) -6-fluoro-2-phenyl-2, 3-dihydrobenzofuran-2-yl) pyrrolidine-1-carboxylate (INT 858C)
[0579] To a solution of INT 858B (3.60 g, 5.69 mmol) in DCM (40 mL) was added mCPBA (85%, 2.95 g, 14.53 mmol) at 0 ℃. Then the mixture was stirred at room temperature for 2 h. After the reaction was completed, the mxiture was quenched with saturated aqueous Na2SO3 (20 mL) . After addition of saturated aqueous Na2CO3 (20 mL) , the mixture was extracted with DCM (100 mL×3) . The organic phase was dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, eluent: MeOH / DCM = 1: 100 to 1: 25) to give INT 858C (3.69 g, 5.55 mmol, 98%) as yellow solid. LCMS: m / z 565.20 [M-Boc+H] +.
[0580] Step 3: Synthesis of tert-butyl (S) -2- ( (S) -5-chloro-6-fluoro-4- ( (S) -3-fluoro-2- (1- (methoxycarbonyl) cyclopropoxy) -5- ( (methyl-d3) carbamoyl) pyridin-4-yl) -2-phenyl-2, 3-dihydrobenzofuran-2-yl) pyrrolidine-1-carboxylate (INT 858D)
[0581] To a solution of methyl 1-hydroxycyclopropane-1-carboxylate (367 mg, 3.15 mmol) in THF (5 mL) was added NaH (63 mg, 1.58 mmol) at 0 ℃ under N2 atmosphere. The mixture was stirred at that temperature for 20 min. Then a solution of INT 858C (0.70 g, 1.05 mmol) in THF (2 mL) was added dropwise. The resulting mixture was stirred at room temperature for another 1 h. After the reaction was completed, the mixture was quenched with H2O (40 mL) and extracted with EtOAc (50 mL×3) . The organic phase was dried over Na2SO4, filtrated and concentrated directly to give crude INT 858D (835 mg) as yellow oil. LCMS: m / z 587.24 [M-Boc+H] +.
[0582] Step 4: Synthesis of tert-butyl (S) -2- ( (S) -5-chloro-6-fluoro-4- ( (S) -3-fluoro-2- (1- (hydroxymethyl) cyclopropoxy) -5- ( (methyl-d3) carbamoyl) pyridin-4-yl) -2-phenyl-2, 3- dihydrobenzofuran-2-yl) pyrrolidine-1-carboxylate (INT 858E)
[0583] To a solution of INT 858D (0.83 g, 1.21 mmol) in THF (10 mL) was added LiBH4 (1.2 mL, 2.0 M, 2.40 mmol) at 0 ℃ under N2 atmosphere. The resulting mixture was stirred at room temperature overnight. After the reaction was completed, the mixture was quenched with saturated aqueous NH4Cl (40 mL) and extracted with EtOAc (50 mL×3) . The organic phase was dried over Na2SO4, filtrated and concentrated. The residue was purified by column chromatography (SiO2, eluent: MeOHOH / DCM =1: 100 to 1: 25) to give INT 858E (500 mg, 0.76 mmol, 72%for two steps) as white solid. LCMS: m / z 559.24 [M-Boc+H] +.
[0584] Step 5: Synthesis of (S) -4- ( (S) -5-chloro-6-fluoro-2-phenyl-2- ( (S) -pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -5-fluoro-6- (1- (hydroxymethyl) cyclopropoxy) -N- (methyl-d3) nicotinamide (Example 858)
[0585] To a solution of INT 858E (550 mg, 0.84 mmol) in DCM (11 mL) was added TMSI (836 mg, 4.18 mmol) at 0 ℃. The mixture was stirred at that temperature for 1 h. After the reaction was completed, the mixture was quenched with saturated aqueous NaHCO3 (20 mL) and extracted with DCM (20 mL×3) . The organic phase was dried over Na2SO4, filtrated and concentrated. The residue was purified by prep-HPLC (Morphling Triart-C18, 30*250mm 10μm, Mobile phase: A: 0.1%TFA in H2O, B: acetonitrile, gradient: 30%to 70%B in 15 min, 25 ℃, Flow rate: 30 mL / min) to give Example 858 (280 mg, 0.50 mmol, 60%) as white solid. LCMS: m / z 559.14 [M+H] +. 1H NMR (400 MHz, CD3OD) δ 8.30 (s, 1H) , 7.59 -7.57 (m, 2H) , 7.52 -7.49 (m, 2H) , 7.45 -7.41 (m, 1H) , 7.07 (d, J = 8.8 Hz, 1H) , 4.28 -4.24 (m, 1H) , 4.04 -3.93 (m, 2H) , 3.61 -3.57 (m, 1H) , 3.39 -3.34 (m, 1H) , 3.26 -3.20 (m, 2H) , 2.28 -2.19 (m, 1H) , 2.13 -1.94 (m, 3H) , 1.05 -1.01 (m, 4H) .
[0586] Synthesis of Example 872a:
[0587] Step 1: Synthesis of methyl (S) -4- ( (S) -2- ( (S) -1- (tert-butoxycarbonyl) pyrrolidin-2-yl) -5-chloro-6-fluoro-2-phenyl-2, 3-dihydrobenzofuran-4-yl) -6- ( (1S, 2R) -2- ( (tert-butyldiphenylsilyl) oxy) cyclobutoxy) -5-fluoronicotinate (INT 872aA)
[0588] To a solution of INT 872aA (1.59 g, 4.87 mmol) in THF (30 mL) was added 60%NaH (243 mg, 6.09 mmol) at 0 ℃, then the mixture was stirred at 0 ℃ for 1 h. After that, INT 872aB (2.69 g, 4.06 mmol) in THF (10 mL) was added, and the reaction was stirred at 0 ℃ for 1 h. The reaction was quenched with H2O (50 mL) and extrated with EtOAc (50 mL×2) . The combined organic extracts were dried over Na2SO4, filtered and concentrated under reduced pressure to give the crude product, which was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 5: 1) to afford INT 872aC (2.31 g, 2.58 mmol, 63%) as white solid. LCMS: m / z 795.0 [M+H-Boc] +.
[0589] Step 2: Synthesis of methyl (S) -4- ( (S) -2- ( (S) -1- (tert-butoxycarbonyl) pyrrolidin-2-yl) -5-chloro-6-fluoro-2-phenyl-2, 3-dihydrobenzofuran-4-yl) -5-fluoro-6- ( (1S, 2R) -2-hydroxycyclobutoxy) nicotinate (INT 872aD)
[0590] To a solution of INT 872aC (2.31 g, 2.58 mmol) in THF (25 mL) was added TBAF (1 M in THF, 10 mL, 10 mmol) at 0 ℃ under nitrogen, then the solution was stirred at room temperature for 3 h. The resulting solution was queched with H2O (50 mL) and extracted with EtOAc (50 mL) . The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to give the crude product, which was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 3: 1) to afford INT 872aD (1.47 g, 2.24 mmol, 86%) as white solid. LCMS: m / z 657.2 [M+H] +.
[0591] Step 3: Synthesis of (S) -4- ( (S) -2- ( (S) -1- (tert-butoxycarbonyl) pyrrolidin-2-yl) -5-chloro-6-fluoro-2-phenyl-2, 3-dihydrobenzofuran-4-yl) -5-fluoro-6- ( (1S, 2R) -2-hydroxycyclobutoxy) nicotinic acid (INT 872aE)
[0592] To a solution of INT 872aD (1.47 g, 2.24 mmol) in 1, 4-dioxane (10 mL) and H2O (5 mL) was added NaOH (1.79 g, 44.7 mmol) , then the solution was stirred at 70 ℃ for 2 h. After cooling to room temperature, the reaction was adjusted to pH 7 by adding 2M HCl and extracted with EtOAc (30 mL×2) . The combined organics were dried over Na2SO4, filtered and concentrated under reduced pressure to give INT 872aE (1.40 g, 2.18 mmol, 97%) as yellow oil. LCMS: m / z 643.2 [M+H] +.
[0593] Step 4: Synthesis of tert-butyl (S) -2- ( (S) -5-chloro-6-fluoro-4- ( (S) -3-fluoro-2- ( (1S, 2R) -2-hydroxycyclobutoxy) -5- ( ( (3R, 4S) -4-methyltetrahydrofuran-3-yl) carbamoyl) pyridin-4-yl) -2-phenyl-2, 3-dihydrobenzofuran-2-yl) pyrrolidine-1-carboxylate (INT 872aF)
[0594] To a solution of INT 872aE (1.4 g, 2.18 mmol) and (3R, 4S) -4-methyltetrahydrofuran-3-amine hydrochloride (CAS: 2703745-35-9, 358 mg, 2.61 mmol) in DMF (15 mL) were added HATU (1.23 g, 3.27 mmol) and DIEA (844 mg, 6.53 mmol) , then the solution was stirred at room temperature for 3 h. The reaction was diluted with EtOAc (60 mL) and washed with brine (30 mL×3) . The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to give the crude product, which was purified column chromatography (SiO2, eluent: DCM / MeOH = 20: 1) to afford INT 872aF (1.5 g, 2.07 mmol, 94%) as white solid. LCMS: m / z 726.3 [M+H] +.
[0595] Step 5: Synthesis of (S) -4- ( (S) -5-chloro-6-fluoro-2-phenyl-2- ( (S) -pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -5-fluoro-6- ( (1S, 2R) -2-hydroxycyclobutoxy) -N- ( (3R, 4S) -4-methyltetrahydrofuran-3-yl) nicotinamide (Example 872a)
[0596] To a solution of INT 872aF (1.5 g, 2.07 mmol) in DCM (5 mL) was added HCl in 1, 4-dioxane (10 mL) , then the solution was stirred at room temperature for 2 h. The resulting solution was concentrated under reduced pressure to give the crude product, which was purified by preparative HPLC (Morphling AQ-C18, 5μm, 20*250mm, eluent A: 0.1%TFA in H2O, eluent B: MeCN, gradient: 10%to 98%B in 30 min, 25 ℃, flow rate: 20 mL / min) to afford compound Example 872a-iso1 (tR = 15.5 min) and Example 872a-iso2 (tR = 20.6 min) .
[0597] Example 872a-iso1 (399.2 mg, 0.64 mmol, 31%) : white solid. LCMS: m / z 626.4 [M+H] +. 1H NMR (400 MHz, CD3OD) δ 8.26 (s, 1H) , 7.59 (d, J = 8.0 Hz, 2H) , 7.51 (t, J = 4.0 Hz, 2H) , 7.44 (t, J = 4.0 Hz, 1H) , 7.08 (d, J = 8.0 Hz, 1H) , 5.45 -5.41 (m, 1H) , 4.57 -4.52 (m, 1H) , 4.49 -4.46 (m, 1H) , 4.24 (t, J = 8.0 Hz, 1H) , 4.00 (t, J = 8.0 Hz, 2H) , 3.66 -3.59 (m, 2H) , 3.49 (t, J = 8.0 Hz, 1H) , 3.38 -3.37 (m, 1H) , 3.30 -3.20 (m, 2H) , 2.57 -2.48 (m, 1H) , 2.33 -2.12 (m, 4H) , 2.00 -1.91 (m, 4H) , 1.08 (d, J = 8.0 Hz, 3H) .
[0598] Example 872a-iso2 (198.5 mg, 0.32 mmol, 15%) : white solid. LCMS: m / z 626.4 [M+H] +. 1H NMR (400 MHz, CD3OD) δ 8.26 (s, 1H) , 7.59 (d, J = 8.0 Hz, 2H) , 7.52 (t, J = 4.0 Hz, 2H) , 7.44 (t, J = 4.0 Hz, 1H) , 7.08 (d, J = 8.0 Hz, 1H) , 5.48 -5.43 (m, 1H) , 4.57 -4.52 (m, 1H) , 4.49 -4.46 (m, 1H) , 4.24 (t, J = 8.0 Hz, 1H) , 4.00 (t, J = 8.0 Hz, 2H) , 3.66 -3.59 (m, 2H) , 3.49 (t, J = 8.0 Hz, 1H) , 3.38 -3.37 (m, 1H) , 3.30 -3.20 (m, 2H) , 2.57 -2.48 (m, 1H) , 2.33 -2.12 (m, 4H) , 2.00 -1.91 (m, 4H) , 1.08 (d, J = 8.0 Hz, 3H) .
[0599] Synthesis of 4- ( (2S, 4S) -5-chloro-6-fluoro-2-phenyl-2- (pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -5-fluoro-6- (2-hydroxyethoxy) -N- ( (3R) -5-methyltetrahydrofuran-3-yl) nicotinamide (Example 881)
[0600] Step 1: Synthesis of (S) -4- ( (tert-butyldiphenylsilyl) oxy) dihydrofuran-2 (3H) -one (INT 881B)
[0601] To a solution of starting material INT 881A (cas: 7331-52-4, 5.00 g, 48.98 mmol) and imidazole (6.67 g, 97.95 mmol) in DMF (50 mL) was added tert-butylchlorodiphenylsilane (20.19 g, 73.47 mmol) . The mixture was stirred at room temperature for 2 h under N2 atmosphere. The reaction was diluted with EtOAc (200 mL) and washed by brine (100 mL×3) . The organic phase was dried over Na2SO4, filtrated and concentrated. The residue was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 5: 1) to give compound INT 882B (13 g, 38.18 mmol, 77%) as yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.65 -7.63 (m, 4H) , 7.51 -7.41 (m, 6H) , 4.58 (s, 1H) , 4.24 -4.17 (m, 2H) , 2.54 -2.53 (m, 2H) , 1.09 (s, 9H) .
[0602] Step 2: Synthesis of (4S) -4- ( (tert-butyldiphenylsilyl) oxy) -2-methyltetrahydrofuran-2-ol (INT 882C)
[0603] To a solution of compound INT 882B (2 g, 5.87 mmol) in DCM (20 mL) was added methyllithium (1.6 M in THF, 4.4 mL, 7.04 mmol) at -78 ℃ under N2 atmosphere. The mixture was stirred at -78℃ for 3 h. The reaction was quenched by the addition of saturated aqueous NH4Cl (30 mL) . The aqueous layer was extracted with EtOAc (30 mL×2) . The combined organics were dried over Na2SO4, filtered and concentrated to give crude compound INT 882C (2.5 g) as yellow oil.
[0604] Step 3: Synthesis of tert-butyl ( ( (3S) -5-methyltetrahydrofuran-3-yl) oxy) diphenylsilane (INT 882D)
[0605] To a solution of compound INT 881C (2.50 g) in DCM (20 mL) was added boron trifluoride diethyl etherate (2.50 g, 17.62 mmol) and triethylsilane (1.37 g, 11.75 mmol) at -78 ℃. The mixture was stirred at -78℃ for 3 h. The reaction was quenched by the addition of saturated aqueous NH4Cl (30 mL) . The aqueous layer was extracted with DCM (20 mL×2) . The combined organics were dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 5: 1) to give compound INT 881D (630 mg, 1.85 mmol, 31%for two steps) as yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.69 -7.64 (m, 4H) , 7.47 -7.39 (m, 6H) , 4.49 -4.43 (m, 1H) , 4.35 -4.27 (m, 0.8H) , 3.96 -3.89 (m, 1H) , 3.85 -3.82 (m, 0.2H) , 3.72 -3.69 (m, 0.8H) , 3.64 -3.60 (m, 0.2H) , 2.16 -2.10 (m, 0.2H) , 2.01 -1.97 (m, 0.8H) , 1.37 -1.36 (m, 0.6H) , 1.25 -1.23 (m, 2.4H) , 1.09 (s, 9H) .
[0606] Step 4: Synthesis of (3S) -5-methyltetrahydrofuran-3-ol (compound INT 881E)
[0607] To a solution of compound INT 881D (620 mg, 1.82 mmol) in THF (6 mL) was added TBAF (1 M in THF, 2.7 mL, 2.7 mmol) . The mixture was stirred at room temperature for 2 h, then diluted with H2O (20 mL) and extracted with EtOAc (20 mL×3) . The combined organics were dried over Na2SO4, filtered and concentrated under reduced pressure to afford the residue. The residue was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 3: 1) to give compound INT 881E (130 mg, 1.27 mmol, 69%) as colorless oil.
[0608] Step 5: Synthesis of 2- [ (3S) -5-methyltetrahydrofuran-3-yl] isoindoline-1, 3-dione (INT 881F)
[0609] To a solution of compound INT 881E (130 mg, 1.27 mmol) , isoindoline-1, 3-dione (281 mg, 1.91 mmol) and PPh3 (500 mg, 1.91 mmol) in THF (3 mL) was added diethyl azodicarboxylate (246 mg, 1.41 mmol) at 0 ℃ under N2 atmosphere. The reaction mixture was stirred at room temperature overnight, then diluted with H2O (20 mL) and extracted with EtOAc (20 mL×2) . The combined organics were dried over Na2SO4, filtered and concentrated under reduced pressure to afford the residue. The residue was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 5: 1) to give compound INT 881F (100 mg, 0.43 mmol, 33%) as colorless oil. LCMS: m / z 232.16 [M+H] +.
[0610] Step 6: Synthesis of tert-butyl ( (3R) -5-methyltetrahydrofuran-3-yl) carbamate (compound INT 881G)
[0611] To a solution of compound INT 881F (100 mg, 0.43 mmol) in EtOH (2 mL) was added hydrazine hydrate (28 mg, 85%, 0.48 mmol) . The mixture was stirred at 70 ℃overnight. After cooling to room temperature, the reaction was diluted with DCM (20 mL) . After filtration, the filtrate was concentrated under reduced pressure. The residue was dissolve in DCM (2 mL) , then di-tert-butyldicarbonate (140 mg, 0.64 mmol) and DIEA (127 mg, 1 mmol) was added. The mixture was stirred at room temperature overnight. After concentration, the residue was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 10: 1 to 5: 1) to provide compound INT 881G (50 mg, 0.25 mmol, 57%) as colorless oil. LCMS: m / z 146.14 [M+H-tBu] +.
[0612] Step 7: Synthesis of (3R) -5-methyltetrahydrofuran-3-amine hydrochloride (compound INT 881H)
[0613] To a solution of compound INT 881G (50 mg, 0.25 mmol) in DCM (1 mL) was added HCl in 1, 4-dioxane (4 M, 0.5 mL, 2 mmol) . The mixture was stirred at room temperature for 2 h. Then the reaction was concentrated under reduced pressure to give compound INT 881H (30 mg, 0.22 mmol, 88%) as white solid.
[0614] Step 8: Synthesis of tert-butyl (2S) -2- ( (2S) -5-chloro-6-fluoro-4- ( (4S) -3-fluoro-5- ( ( (3R) -5-methyltetrahydrofuran-3-yl) carbamoyl) -2- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) pyridin-4-yl) -2-phenyl-2, 3-dihydrobenzofuran-2-yl) pyrrolidine-1-carboxylate (INT 881J)
[0615] To a solution of INT 881I (110 mg, 156 μmol) and INT 881H (30 mg, 297 μmol) in DMF (2 mL) were added HATU (88 mg, 235 μmol) and DIEA (60 mg, 470 μmol) . The mixture was stirred at room temperature overnight, then diluted with EtOAc (40 mL) and washed with brine (20 mL×3) . The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to afford the residue. The residue was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 5: 1 to 2: 1) to offer INT 881J (50 mg, 64 μmol, 41%) as colorless oil. LCMS: m / z 684.28 [M+H-Boc] +.
[0616] Step 9: Synthesis of (4S) -4- ( (S) -5-chloro-6-fluoro-2-phenyl-2- ( (S) -pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -5-fluoro-6- (2-hydroxyethoxy) -N- ( (3R) -5-methyltetrahydrofuran-3-yl) nicotinamide (Example 881)
[0617] To a solution of INT 881J (50 mg, 64 μmol) in DCM (2 mL) was added 4 N HCl in 1, 4-dioxane (1 mL) . The mixture was stirred at room temperature for 2 h, then concentrated under reduced pressure to afford the residue. The residue was purified by preparative HPLC (Morphling AQ-C18, 10μm, 20*250mm, eluent A: 0.1%TFA in H2O, eluent B: MeCN, gradient: 20%to 98%B in 20 min, 25 ℃, flow rate: 20 mL / min) to afford Example 881 (20 mg, 33 μmol, 51%) as white solid. LCMS: m / z 600.10. 1H NMR (400 MHz, CD3OD) 1H NMR (400 MHz, CD3OD) δ 8.26 (s, 1H) , 7.51 -7.49 (m, 2H) , 7.41 -7.38 (m, 2H) , 7.34 -7.29 (m, 1H) , 6.95 (d, J = 9.4 Hz, 1H) , 4.61 -4.52 (m, 2H) , 4.45 -4.38 (m, 1H) , 4.19 -4.07 (m, 1H) , 3.98 -3.91 (m, 2.5H) , 3.84 -3.80 (m, 0.5H) , 3.67 -3.64 (m, 1.5H) , 3.51 -3.45 (m, 1.5H) , 3.16 -3.08 (m, 1H) , 2.99 -2.91 (m, 1H) , 2.81 -2.74 (m, 1H) , 2.49 -2.41 (m, 0.5H) , 2.09 -2.02 (m, 0.5H) , 1.88 -1.63 (m, 4.5H) , 1.514 -1.44 (m, 0.5H) , 1.33 (d, J = 6.2 Hz, 2H) , 1.26 (d, J = 6.2 Hz, 1H) .
[0618] Synthesis of Example 882:
[0619] Step 1: Synthesis of rel-2-bromo-4- ( (1S, 2R) -2- ( (tert-butyldiphenylsilyl) oxy) cyclobutoxy) -3-fluorobenzonitrile (INT 882C)
[0620] To a solution of starting material INT 882A (cas: 1517611-20-9, 1.0 g, 4.6 mmol) and INT 882B (3.0 g, 9.2 mmol) in THF (10 mL) was added 60%NaH (239 mg, 6.0 mmol) , the resulting mixture was stirred at room temperature for 2 h. The reaction was treated with saturated aqueous NH4Cl (30 mL) and extracted with EtOAc (50 mL) . The organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 10: 1) to afford INT 882C (2.4 g, 4.6 mmol, 99%) as yellow oil.
[0621] Step 2: Synthesis of rel -2-bromo-3-fluoro-4- ( (1S, 2R) -2-hydroxycyclobutoxy) benzoic acid (INT 882D)
[0622] To a solution of INT 882C (2.4 g, 4.6 mmol) in MeOH (48 mL) was added 6M NaOH (23 mL, 138.0 mmol) , the resulting mixture was stirred at 75 ℃ overnight. The reaction was cooled to room temperature, treated with saturated aqueous NaH2PO4 (100 mL) and extracted with EtOAc (200 mL) . The organic layer was washed with brine (100 mL) , dried over Na2SO4, filtered and concentrated to afford INT 882D (1.4 g, 4.6 mmol, 100%) as yellow oil.
[0623] LCMS: m / z 302.96 [M-H ] +.
[0624] Step 3: Synthesis of rel-methyl 2-bromo-3-fluoro-4- ( (1S, 2R) -2-hydroxycyclobutoxy) benzoate (INT 882E)
[0625] To a solution of INT 882D (1.4 g, 4.6 mmol) and CH3I (782 mg, 5.5 mmol) in DMF (10 mL) was potassium carbonate (951 mg, 6.9 mmol) . The resulting mixture was stirred at room temperature for 2 h. The reaction was treated with water (100 mL) and extracted with EtOAc (200 mL) . The organic layer was washed with brine (100 mL) , dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 5: 1) to afford INT 882E (830 mg, 2.6 mmol, 57%) as colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.70 -7.67 (m, 1H) , 6.88 -6.84 (m, 1H) , 4.89 -482 (m, 1H) , 4.58 -4.51 (m, 1H) , 3.94 (s, 3H) , 2.25 -2.14 (m, 4H) .
[0626] Step 4: Synthesis of rel-tert-butyl (S) -2- ( (S) -5-chloro-6-fluoro-4- ( (S) -2-fluoro-3- ( (1S, 2R) -2-hydroxycyclobutoxy) -6- (methoxycarbonyl) phenyl) -2-phenyl-2, 3-dihydrobenzofuran-2-yl) pyrrolidine-1-carboxylate (INT 882G) and rel-tert-butyl (S) -2- ( (S) -5-chloro-6-fluoro-4- ( (R) -2-fluoro-3- ( (1S, 2R) -2-hydroxycyclobutoxy) -6- (methoxycarbonyl) phenyl) -2-phenyl-2, 3-dihydrobenzofuran-2-yl) pyrrolidine-1-carboxylate (INT 882H)
[0627] To a solution of INT 882E (250 mg, 783 μmol) , INT 882F (513 mg, 940 μmol) , K3PO4 (499 mg, 2.4 mmol) and N-XantPhos (86 mg, 156.68 μmol) in toluene (10 mL) and H2O (2 mL) was added Pd2 (dba) 3 (72 mg, 78.34 μmol) under N2 atmosphere, the resulting mixture was stirred at 100 ℃ overnight and concentrated under vacuum. The residue was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 3: 1 to 1: 1) to afford INT 882G and INT 882H.
[0628] INT 882G (80 mg, 121 μmol, 16%) : yellow oil. LCMS: m / z 556.38 [M+H-Boc] + . INT 882H (60 mg, 91 μmol, 12%) : yellow oil. LCMS: m / z 556.13 [M+H-Boc] +.
[0629] Step 5: Synthesis of rel- (S) -2- ( (S) -2- ( (S) -1- (tert-butoxycarbonyl) pyrrolidin-2-yl) -5-chloro-6-fluoro-2-phenyl-2, 3-dihydrobenzofuran-4-yl) -3-fluoro-4- ( (1S, 2R) -2-hydroxycyclobutoxy) benzoic acid (INT 882I)
[0630] To a solution of INT 882G (80 mg, 121.75 μmol) in MeOH (11 mL) and H2O (2.8 mL) was added sodium hydroxide (49 mg, 1.2 mmol) , the resulting mixture was stirred at 50 ℃ overnight. After cooling to room temperature, the reaction was treated with saturated aqueous NaH2PO4 (30 mL) and EtOAc (40 mL) . The organic layer was washed with brine (30 mL) and dried over Na2SO4. After filtration, the filtrate was concentrated to afford INT 882I (78 mg, 121.75 μmol, 100%) as yellow oil. LCMS: m / z 542.15 [M+H-Boc] +.
[0631] Step 6: Synthesis of rel-tert-butyl (S) -2- ( (S) -5-chloro-6-fluoro-4- ( (S) -2-fluoro-3- ( (1S, 2R) -2-hydroxycyclobutoxy) -6- ( ( (R) -tetrahydrofuran-3-yl) carbamoyl) phenyl) -2-phenyl-2, 3-dihydrobenzofuran-2-yl) pyrrolidine-1-carboxylate (INT 882J)
[0632] To a solution INT 882I (78.3 mg, 121.75 μmol) , (R) -tetrahydrofuran-3-amine (21 mg, 243.52 μmol) and TEA (25 mg, 243.52 μmol) in DMF (2 mL) was added HATU (83 mg, 219.17 μmol) , the resulting mixture was stirred at room temperature overnight. The reaction was treated with brine (30 mL) and extracted with EtOAc (40 mL) . The organic layer was washed with brine (30 mL) , dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, eluent: DCM / MeOH =20: 1) to afford INT 882J (73 mg, 102.50 μmol, 84%) as colorless oil. LCMS: m / z 711.13 [M+H] +.
[0633] Step 7: Synthesis of (S) -2- ( (S) -5-chloro-6-fluoro-2-phenyl-2- ( (S) -pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -3-fluoro-4- ( (1S, 2R) -2-hydroxycyclobutoxy) -N- ( (R) -tetrahydrofuran-3-yl) benzamide (Example 882-iso1) and (S) -2- ( (S) -5-chloro-6-fluoro-2-phenyl-2- ( (S) -pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -3-fluoro-4- ( (1R, 2S) -2-hydroxycyclobutoxy) -N- ( (R) -tetrahydrofuran-3-yl) benzamide (Example 882-iso2)
[0634] To a solution of INT 882J (73 mg, 102.50 μmol) in DCM (1 mL) was added 4 N HCl in dioxane (1 mL, 4 mmol) . The mixture was stirred at room temperature for 2 h. The reaction was concentrated to dryness under vacuum. The residue was purified by preparative HPLC (Morphling AQ-C18, 5μm, 20*250mm, eluent A: 0.1%TFA in H2O, eluent B: MeCN, gradient: 10%to 98%B in 30 min, 25 ℃, flow rate: 20 mL / min) to afford Example 882-iso1 (tR = 10.5 min) and Example 882-iso2 (tR = 12.0 min) . Example 882-iso1 (9.0 mg, 14.70 μmol, 14%) : white solid. LCMS: m / z 611.14. 1H NMR (400 MHz, CD3OD) δ 7.57 -7.55 (m, 2H) , 7.51 -7.47 (m, 2H) , 7.43 -7.37 (m, 2H) , 7.19 -7.15 (m, 1H) , 7.04 (d, J = 8.4 Hz, 1H) , 4.61 -4.56 (m, 1H) , 4.28 -4.23 (m, 1H) , 4.12 -4.05 (m, 1H) , 3.73 -3.62 (m, 3H) , 3.55 -3.51 (m, 1H) , 3.36 -3.34 (m, 2H) , 3.31 -3.29 (m, 2H) , 3.24 -3.17 (m, 1H) , 2.34 -2.22 (m, 4H) , 2.15 -2.00 (m, 4H) , 1.95 -1.87 (m, 1H) , 1.66 -1.56 (m 1H) .
[0635] Example 882-iso2 (3.6 mg, 5.88 μmol, 5.7%) : white solid. LCMS: m / z 611.20. 1H NMR (400 MHz, CD3OD) δ 7.59 -7.57 (m, 2H) , 7.52 -7.49 (m, 2H) , 7.45 -7.41 (m, 2H) , 7.18 -7.14 (m, 1H) , 7.03 (d, J = 9.2 Hz, 1H) , 4.55 -4.51 (m, 1H) , 4.39 -4.35 (m, 1H) , 4.25 -4.21 (m, 1H) , 3.97 -3.91 (m, 1H) , 3.84 -3.77 (m, 2H) , 3.59 -3.55 (m, 1H) , 3.51 -3.48 (m, 1H) , 3.39 -3.35 (m, 2H) , 3.25 -3.19 (m, 2H) , 2.30 -2.19 (m, 5H) , 2.15 -1.99 (m, 4H) , 1.97 -1.87 (m, 1H) .
[0636] Step 8: Synthesis of rel- (R) -2- ( (S) -2- ( (S) -1- (tert-butoxycarbonyl) pyrrolidin-2-yl) -5-chloro-6-fluoro-2-phenyl-2, 3-dihydrobenzofuran-4-yl) -3-fluoro-4- ( (1S, 2R) -2-hydroxycyclobutoxy) benzoic acid (INT 882K)
[0637] To a solution of INT 882H (60 mg, 91 μmol) in MeOH (11 mL) and H2O (1.9 mL) was added sodium hydroxide (33 mg, 821 μmol) , the resulting mixture was stirred at 50 ℃ overnight. After cooling to room temperature, the reaction was treated with saturated aqueous NaH2PO4 (30 mL) and extracted with EtOAc (30 mL) . The organic layer was washed with brine (30 mL) and dried over Na2SO4. After filtration, the filtrate was concentrated to afford INT 882K (59 mg, 91 μmol, 100%) as yellow oil. LCMS: m / z 542.30 [M+H-Boc] +.
[0638] Step 9: Synthesis of rel-tert-butyl (S) -2- ( (S) -5-chloro-6-fluoro-4- ( (R) -2-fluoro-3- ( (1S, 2R) -2-hydroxycyclobutoxy) -6- ( ( (R) -tetrahydrofuran-3-yl) carbamoyl) phenyl) -2-phenyl-2, 3-dihydrobenzofuran-2-yl) pyrrolidine-1-carboxylate (INT 882L)
[0639] To a solution INT 882K (59 mg, 91 μmol) , (R) -tetrahydrofuran-3-amine (16 mg, 182 μmol) and TEA (19 mg, 182 μmol) in DMF (2 mL) was added HATU (62 mg, 164 μmol) , the resulting mixture was stirred at room temperature overnight. The reaction was treated with brine (20 mL) and extracted with EtOAc (40 mL) . The organic layer was washed with brine (30 mL) , dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, eluent: DCM / MeOH=20: 1) to afford INT 882L (44 mg, 61 μmol, 68%) as colorless oil. LCMS: m / z 711.21 [M+H] +. Step 10: Synthesis of (R) -2- ( (S) -5-chloro-6-fluoro-2-phenyl-2- ( (S) -pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -3-fluoro-4- ( (1S, 2R) -2-hydroxycyclobutoxy) -N- ( (R) -tetrahydrofuran-3-yl) benzamide (Example 882-iso3) and (R) -2- ( (S) -5-chloro-6-fluoro-2-phenyl-2- ( (S) -pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -3-fluoro-4- ( (1R, 2S) -2-hydroxycyclobutoxy) -N- ( (R) -tetrahydrofuran-3-yl) benzamide (Example 882-iso4)
[0640] To a solution of INT 882L (44 mg, 61 μmol) in DCM (1 mL) was added 4 N HCl in dioxane (1 mL, 4 mmol) . The mixture was stirred at room temperature for 2 h. The reaction was concentrated under vacuum. The residue was purified by preparative HPLC (Morphling AQ-C18, 5μm, 20*250mm, eluent A: 0.1%TFA in H2O, eluent B: MeCN, gradient: 10%to 98%B in 30 min, 25 ℃, flow rate: 20 mL / min) to afford Example 882-iso3 (tR = 16.5 min) and Example 882-iso4 (tR = 19.0 min) . Example 882-iso3 (6.7 mg, 10 μmol, 17%) : white solid. LCMS: m / z 611.16 [M+H] +. 1H NMR (400 MHz, CD3OD) δ 7.57 -7.55 (m, 2H) , 7.51 -7.48 (m, 2H) , 7.43 -7.37 (m, 2H) , 7.19 -7.15 (m, 1H) , 7.04 (d, J = 8.8 Hz, 1H) , 4.62 -4.58 (m, 1H) , 4.28 -4.24 (m 1H) , 4.12 -4.05 (m, 1H) , 3.74 -3.69 (m, 3H) , 3.56 -3.52 (m, 1H) , 3.37 -3.34 (m, 2H) , 3.31 -3.29 (m, 2H) , 3.25 -3.19 (m, 1H) , 2.33 -2.21 (m, 4H) , 2.16 -2.00 (m, 4H) , 1.95 -1.86 (m, 1H) , 1.65 -1.58 (m, 1H) .
[0641] Example 882-iso4 (4.4 mg, 7 μmol, 11.6%) : white solid. LCMS: m / z 611.15 [M+H] +. 1H NMR (400 MHz, CD3OD) δ 7.59 –7.57 (m, 2H) , 7.52 –7.49 (m, 2H) , 7.45 –7.41 (m, 2H) , 7.18 –7.14 (m, 1H) , 7.03 (d, J = 9.2 Hz, 1H) , 4.57 –4.52 (m, 1H) , 4.40 –4.35 (m, 1H) , 4.27 –4.22 (m, 1H) , 3.97 –3.91 (m, 1H) , 3.84 –3.77 (m, 2H) , 3.59 –3.54 (m, 1H) , 3.52 –3.48 (m, 1H) , 3.39 –3.34 (m, 2H) , 3.27 –3.21 (m, 2H) , 2.30 –2.19 (m, 5H) , 2.14 –2.04 (m, 3H) , 2.00 –1.90 (m, 2H) .
[0642] Synthesis of Example 883:
[0643] Step 1: Synthesis of tert-butyl (2S) -2- ( (2S) -4- (5-carbamoyl-3-fluoro-2- ( ( (1S, 3R) -3-hydroxycyclopentyl) oxy) pyridin-4-yl) -5-chloro-6-fluoro-2-phenyl-2, 3-dihydrobenzofuran-2-yl) pyrrolidine-1-carboxylate (INT 883A)
[0644] To a solution of INT 883A (120 mg, 0.18 mmol) in DMF (2.5 mL) was added NH4Cl (19 mg, 0.36 mmol) , HATU (103 mg, 0.27 mmol) and DIEA (81 mg, 0.63 mmol) . The mixture was stirred at room temperature for 2 h. Then the reaction was quenched with H2O (3 mL) , and a lot of solid was generated. After filtration, the solid was purified by column chromatography (SiO2, eluent: MeOH / DCM = 1: 100 to 1: 20) to give INT 883B (107 mg, 0.16 mmol, 91%) as white solid. LCMS: m / z 556.23 [M-Boc+H] +.
[0645] Step 2: Synthesis of 4- ( (S) -5-chloro-6-fluoro-2-phenyl-2- ( (S) -pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -5-fluoro-6- ( ( (1S, 3R) -3-hydroxycyclopentyl) oxy) nicotinamide (Example 883)
[0646] To a solution of INT 883B (107 mg, 0.16 mmol) in DCM (2 mL) was added TFA (0.2 mL) . The mixture was stirred at room temperature for 1 h. Then the reaction was concentrated. The residue was dissolved in THF (2 mL) and a solution of LiOH (30 mg, 0.71 mmol) in H2O (0.4 mL) was added dropwise. The mixture was stirred at room temperature for another 0.5 h and extracted with EtOAc (5 mL×3) . The combined organics were dried over Na2SO4, filtrated and concentrated. The residue was purified by preparative HPLC (Morphling AQ C18, 20*250mm 5μm, Mobile phase: A: 0.1%TFA in water, B: acetonitrile, gradient: 10%to 25%B in 2 min, 25%to 98%B in 48 min, 25 ℃, Flow rate: 20 mL / min) to afford Example 883-iso1 (tR = 11.7 min) and Example 883-iso2 (tR = 12.9 min) .
[0647] Example 883-iso1 (21.2 mg, 38 μmol, 24%) : white solid. LCMS: m / z 556.13 [M+H] +. 1H NMR (400 MHz, CD3OD) δ 8.38 (s, 1H) , 7.59 -7.57 (m, 2H) , 7.52 -7.48 (m, 2H) , 7.45 -7.41 (m, 1H) , 7.05 (d, J = 8.8 Hz, 1H) , 5.54 -5.48 (m, 1H) , 4.33 -4.21 (m, 2H) , 3.61 -3.57 (m, 1H) , 3.38 -3.35 (m, 1H) , 3.25 -3.19 (m, 2H) , 2.53 -2.46 (m, 1H) , 2.28 -1.79 (m, 9H) .
[0648] Example 883-iso2 (25.2 mg, 45 μmol, 28%, ) : white solid. LCMS: m / z 556.15 [M+H] +. 1H NMR (400 MHz, CD3OD) δ 8.38 (s, 1H) , 7.58 -7.56 (m, 2H) , 7.52 -7.48 (m, 2H) , 7.44 -7.40 (m, 1H) , 7.05 (d, J = 8.8 Hz, 1H) , 5.54 -5.49 (m, 1H) , 4.34 -4.23 (m, 2H) , 3.61 -3.57 (m, 1H) , 3.38 -3.35 (m, 1H) , 3.25 -3.18 (m, 2H) , 2.52 -2.45 (m, 1H) , 2.28 -2.21 (m, 1H) , 2.15 -1.78 (m, 8H) .
[0649] Synthesis of Example 884
[0650] Step 1: Synthesis of tert-Butyl 2-bromo-2- ( (tert-butoxycarbonyl) amino) acetate (INT 884B)
[0651] To a solution of starting material INT 884A (cas: 111652-20-1, 2 g, 8.65 mmol) in CCl4 (70 mL) was added NBS (1.69 g, 9.51 mmol) under nitrogen, then the solution was refluxed for 2 h until the starting materail has been consumed. The resulting solution was cooled to 0 ℃ and filtered. The filtrate was concentrated under reduced pressure to give INT 884B (2.6 g, 8.38 mmol, 96%) as yellow oil. 1H NMR (400 MHz, CDCl3) δ 2.18 (s, 1H) , 1.83 (s, 1H) , 1.54 (s, 9H) , 1.48 (s, 9H) .
[0652] Step 2: Synthesis of 4- (tert-Butyl) 1-methyl 3- ( (tert-butoxycarbonyl) amino) -2, 2-dimethylsuccinate (INT 884C)
[0653] To a solution of INT 884B (2.6 g, 8.38 mmol) in DCM (90 mL) was added (1-methoxy-2-methyl-prop-1-enoxy) -trimethyl-silane (2.9 g, 16.8 mmol) , TiCl4 (1.75 g, 9.2 mmol) and Et3N (93 mg, 9.2 mmol) under nitrogen at -78 ℃, then the solution was stirred at room temperature for 2 h. The reaction was quenched with H2O (50 mL) . The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to give the crude product, which was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 3: 1) to afford INT 884C (1.52 g, 4.59 mmol, 54%) as colorless oil. 1H NMR (400 MHz, CDCl3) δ 5.27 (d, J = 8.0 Hz, 1H) , 4.62 (d, J = 12.0 Hz, 1H) , 3.72 (s, 3H) , 1.47 (s, 9H) , 1.45 (s, 9H) , 1.28 -1.26 (m, 3H) , 1.12 (s, 3H) .
[0654] Step 3: Synthesis of tert-Butyl (1, 4-dihydroxy-3, 3-dimethylbutan-2-yl) carbamate (INT 884D)
[0655] To a solution of INT 884C (500 mg, 1.51 mmol) in DCM (5 mL) was added DIBAL-H (1M in THF, 6.8 mL, 6.8 mmol) at 0 ℃ under nitrogen, then the solution was stirred at 0 ℃ for 1 h, and then at room temperature for 1 h. The reaction was queched by addition of Na2SO4 (2 g) and 10 drops of H2O at 0 ℃. Then the suspension was filtered and washed with EtOAc (20 mL) , the filtrate was concentrated under reduced pressure to give the residue. The residue was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 2: 1) to afford INT 884D (50 mg, 0.21 mmol, 14%) as white solid. 1H NMR (400 MHz, CDCl3) δ 5.32 (s, 1H) , 5.18 -5.16 (m, 1H) , 3.81 -3.74 (m, 2H) , 3.67 -3.61 (m, 1H) , 3.45 -3.43 (m, 1H) , 3.42 -3.39 (m, 1H) , 1.47 (s, 9H) , 1.03 (s, 3H) , 0.86 (s, 3H) .
[0656] Step 4: Synthesis of tert-Butyl (4, 4-dimethyltetrahydrofuran-3-yl) carbamate (INT 884E)
[0657] To a solution of INT 884D (60 mg, 0.26 mmol) and PPh3 (135 mg, 0.51 mmol) in DCM (5 mL) was added DEAD (179 mg, 1.03 mmol) under N2 atmosphere, then the solution was stirred at room temperature for 1 h until the starting material was consumed. The resulting solution was concentrated under reduced pressure to give the crude product, which was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 3: 1) to afford INT 884E (48 mg, 0.22 mmol, 86%) as white solid. 1H NMR (400 MHz, CDCl3) δ 4.56 (br s, 1H) , 4.20 -4.13 (m, 1H) , 4.01 -3.93 (m, 1H) , 3.58 -3.55 (m, 2H) , 3.53 -3.50 (m, 1H) , 1.47 (s, 9H) , 1.13 (s, 3H) , 1.03 (s, 3H) .
[0658] Step 5: Synthesis of 4, 4-Dmethyltetrahydrofuran-3-amine hydrochloride (INT 884F)
[0659] A solution of INT 884E (170 mg, 0.79 mmol) in 4 M HCl in 1, 4-dioxane (5 mL) was stirred at room temperature for 2 h. The reaction was concentrated to give INT 884F (90 mg, 0.59 mmol, 75%) as white solid. LCMS: m / z 116.0 [M+H] +.
[0660] Step 6: Synthesis of tert-butyl (2S) -2- ( (2S) -5-chloro-4- ( (4S) -5- ( (4, 4-dimethyltetrahydrofuran-3-yl) carbamoyl) -3-fluoro-2- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethoxy) pyridin-4-yl) -6-fluoro-2-phenyl-2, 3-dihydrobenzofuran-2-yl) pyrrolidine-1-carboxylate (INT 884H)
[0661] To a solution of INT 884F (150 mg, 0.96 mmol) in DMF (5 mL) were added DIEA (412 mg, 3.18 mmol) , INT 884G (589 mg, 0.80 mmol) and HATU (450 mg, 1.19 mmol) , then the solution was stirred at room temperature for 2 h. The reaction was diluted with EtOAc (50 mL) and washed with brine (30 mL×3) . The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to give the crude product, which was purified by column chromatography (SiO2, eluent: petroleum ether / EtOAc = 2: 1) to afford INT 884H (477 mg, 0.60 mmol, 77%) as white solid. LCMS: m / z 798.3 [M+H] +.
[0662] Step 7: Synthesis of (4S) -4- ( (S) -5-chloro-6-fluoro-2-phenyl-2- ( (S) -pyrrolidin-2-yl) -2, 3-dihydrobenzofuran-4-yl) -N- (4, 4-dimethyltetrahydrofuran-3-yl) -5-fluoro-6- (2-hydroxyethoxy) nicotinamide (Example 884) .
[0663] A solution of INT 884H (477 mg, 0.60 mmol) in 4M HCl in dioxane (10 mL) was stirred at room temperature for 2 h. The resulting solution was concentrated under reduced pressure to give the crude product, which was purified by preparative HPLC (Morphling AQ-C18, 5μm, 20*250mm, eluent A: 0.1%TFA in H2O, eluent B: MeCN, gradient: 10%to 98%B in 30 min, 25 ℃, flow rate: 20 mL / min) to afford Example 884-iso1 (tR = 9.8 min) and Example 884-iso2 (tR = 14.3 min)
[0664] Example 884-iso1 (74.7 mg, 0.12 mmol, 20%) : white solid. LCMS: m / z 614.2 [M+H] +. 1H NMR (400 MHz, CD3OD) δ 8.30 (s, 1H) , 7.59 (d, J = 8.0 Hz, 2H) , 7.51 (t, J = 8.0 Hz, 2H) , 7.44 (t, J = 8.0 Hz, 1H) , 7.08 (d, J = 8.0 Hz, 1H) , 4.59 -4.58 (m, 2H) , 4.24 -4.23 (m, 2H) , 4.15 -4.13 (m, 1H) , 3.95 -3.92 (m, 2H) , 3.65 -3.58 (m, 4H) , 3.34 -3.25 (m, 2H) , 2.32 -1.96 (m, 5H) , 1.15 (s, 3H) , 1.12 (s, 3H) .
[0665] Example 884-iso2 (75.3 mg, 0.12 mmol, 20%) : white solid. LCMS: m / z 614.2 [M+H] +. 1H NMR (400 MHz, CD3OD) δ 8.24 (s, 1H) , 7.57 (d, J = 8.0 Hz, 2H) , 7.50 (t, J = 8.0 Hz, 2H) , 7.44 (t, J = 8.0 Hz, 1H) , 7.09 (d, J = 8.0 Hz, 1H) , 4.58 -4.56 (m, 2H) , 4.28 -4.20 (m, 2H) , 4.18 -4.16 (m, 1H) , 3.94 -3.92 (m, 2H) , 3.73 -3.71 (m, 2H) , 3.69 -3.68 (m, 2H) , 3.57 -3.55 (m, 1H) , 3.26 -3.22 (m, 2H) , 2.37 -2.11 (m, 1H) , 2.09 -1.97 (m, 3H) , 1.01 (s, 3H) , 0.90 (s, 3H) .
[0666] The example (s) in the table below are synthesized using a route like the one described above.
[0667] The example (s) in the table below are synthesized using a route like the one described above.
[0668] Biological Assay
[0669] Example 1. TEAD-YAP binding disruption assay by TR-FRET
[0670] Material and Reagents
[0671] 1. Recombinant human TEAD3216-435-FLAG: His-YAP50-100 co-expressed complex; Recombinant human TEAD4217-434-FLAG: His-YAP50-100 co-expressed complex
[0672] 2. 5X Kinase Buffer A (Thermo Fisher, CAT#PV6135)
[0673] 3. LANCE Eu-W1024 Anti-6xHis Antibody (PerkinElmer, CAT#AD0110)
[0674] 4. Anti-FLAG IgG conjugated to SureLight-Allophycocyanin (PerkinElmer, CAT#AD0059F)
[0675] 5. DMSO (Thermo Fisher Scientific)
[0676] 6. Compounds -10 mM stock in DMSO
[0677] 7. Victor Nivo multimode plate reader (PerkinElmer)
[0678] 8. OptiPlate-384, white opaque 384-well microplate (PerkinElmer, CAT#6007290)
[0679] Experimental procedure
[0680] Disruption of TEAD-YAP complex of each compound tested was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) techonology. 4 nM recombinant his-tagged YAP50-100 in complex with FLAG-tagged TEAD3 or TEAD4, varying concentrations of inhibitors, 2 nM LANCE Eu-W1024 anti-6xHis antibody and 100 nM APC conjugated anti-FLAG antibody was incubated in 1X Kinase Buffer A for 1 h. Measurement was performed in a reaction volume of 15 μL by adding 5 μL of the test compound, 5 μL of TEAD-YAP complex and 5 μL of Ab detection mixture into white opaque 384-well assay plates. The TR-FRET signal was read on a plate reader with an excitation wavelength of 340 nm and detection wavelengths of 615 and 665 nm. Binding affinity was determined for each compound by measuring TR-FRET signal at various concentrations of compound and plotting the relative fluorescence Emission Ratio (665 nm / 615 nm) against the inhibitor concentration to estimate the IC50 from [Compound] vs Emission Ratio using the four parameters dose-response inhibition curve with a variable slope model in GraphPad Prism. IC50 values (nM) are shown in the following Table 1.
[0681] Table 1. IC50 values (nM) of the compounds in the present invention in TEAD-YAP disruption TR-FRET. IC50: A≤20 nM; 20 nM<B≤100 nM; 100 nM<C≤1 μM; 1 μM<D≤10 μM; E>10 μM
[0682] Example 2. YAP-TEAD reporter gene activity assay
[0683] To monitor YAP / TAZ-TEAD activity, NCI-H2052 mesothelioma cells (ATCC, CRL-5915) were stably transduced with lentiviruses expressing firefly luciferase under the control of a YAP / TAZ-TEAD-binding promoter sequence (BPS Bioscience, 79833) . The resulting cell line NCI-H2052 YAP / TAZ-TEAD-reporter-Luc was selected and culture in RPMI1640 medium containing 10%FBS, 1%Penicillin / Streptomycin and 1ug / mL Puromycin at 37℃ in a humidified 5%CO2 incubator.
[0684] To test the ability of compounds to inhibit YAP / TAZ-TEAD-dependent transcription, NCI-H2052 YAP / TAZ-TEAD-reporter-Luc cells were seeded at 3000 cells / 40uL / well in to white 384-well plates. Test compounds dissolved in DMSO were prepared in 3-fold serial dilution manner and added to the cell culture to give the correct dose range for 12-point concentration. The final DMSO concentration was controlled at 0.1%. After adding the compounds, the cells were culture for 24 hours at 37℃. Subsequentially, 40uL of Bio-Glo luciferase substrate (Promega, G7941) was added to each well and incubate at room temperature for 15 minutes. Compound-mediated modulation of YAP-TEAD reporter gene activity was determined by measuring the luminescence intensity on VICTOR Nivo multimode plate reader (PerkinElmer) . For data analysis, the background luminescence intensity value determined in wells containing growth medium only was subtracted from all data points and IC50s was calculated using a four-parametric fit model with Prism GraphPad.
[0685] Table 2. IC50 values (nM) of the compounds in the present invention in YAP-TEAD reporter gene activity assay.
[0686] Example 3. Cell viability assay
[0687] The effect of compounds on cell viability was assessed using NCI-H2052 (ATCC, CRL-5915) and NCI-H226 (ATCC, CRL-5826) mesothelioma cells cultured in RPMI1640 medium containing 10%FBS and 1%Penicillin / Streptomycin at 37℃ in a humidified 5%CO2 incubator. Briefly, both cell lines were seeded at 1000 cells / 40uL / well into white 384-well plates with addition of serial diluted compounds described above. After incubation for 72 hours in the incubator, 40uL of CellTiter-Glo solution (Promega, G9241) was added to each well and incubate at room temperature for 10 minutes. Compound-induced cell viability change was determined by measuring the luminescence intensity on VICTOR Nivo multimode plate reader (PerkinElmer) . For data analysis, the background luminescence intensity value determined in wells containing growth medium only was subtracted from all data points. Dose-dependent compound efficacy was expressed as percentage of DMSO-treated control and IC50s was calculated using a four-parametric fit model with Prism GraphPad.
[0688] Table 3. IC50 values (nM) of the compounds in cell viability assay
[0689] Example 4. Pharmacokinetic Studies in Mice
[0690] Balb / c Mouse, SPF grade were administered with the Example compound via IV and oral gavage as a clear and colorless solution. Plasma was collected from mice per time point at 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, 24 h after administration. The concentrations of the test article were measured in plasma by HPLC–MS / MS at each time point. Chromatographic separation was carried out on Waters BEH C18 Column (2.1×50 mm, 1.7 μm) column (MAC-MOD Analytical, Chadds Ford, PA) , using a gradient elution method with water and acetonitrile, both containing 0.1 %formic acid. Mass spectrometric measurements in positive electrospray ionization were directed at quantifying the mass transition with [M + H] + as the precursor ion on API6500, triple quadruple mass spectrometer (Sciex, Framingham, MA) . The relevant pharmacokinetic parameters were estimated using noncompartmental methods using WinNonlin (Enterprise, version 8.2) .
[0691] Table 4: The results of the PK studies are in mice.
[0692] Conclusion: Example compounds of the invention show good mouse PK, and also translate to good PK results on other species.
[0693] Example 5. hERG Patch Clamp
[0694] Manual patch clamp method was adopted to detect the inhibitory effect of compounds on hERG potassium ion channels
[0695] Concentration-effect relation curve of the tested compounds to the hERG channel current is recorded from the HEK293-hERG stable cell strain using a manual patch clamp technology. According to a Hill equation, the ratio of the hERG current peak value under each concentration to its blank control current peak value and the corresponding concentration were curve-fitted. The result showed that the compounds had no obvious inhibitory effect on the hERG potassium channel current stably expressed in HEK293 cells within the detection concentration range. Conclusion: Example compounds of the invention show hERG inhibition with IC50 ranging from 1 to 50 uM. As a result, example compounds of the invention lead to a wider therapeutic window and a lower potential for cardiotoxicity.
Claims
1.A compound of formula (I-a) , or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein,X is CH2 or N;Q is selected from the group consisting of C6-10 aryl, C3-10 cycloalkyl, C6-10 hereroaryl containing one or more heteroatoms selected from N, O or S, and C6-10 heterocyclyl containing one or more heteroatoms selected from N, O or S, optionally substituted with one or more substituents selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkylamino, NH3-C1-6 alkyl, and -S (O) 2Re;W is - (CRaRb) n-NRcRd, or W is a C3-6 mono-cycloalkyl, C3-6 mono-, C7-10 fused-or C6-10 bridged heterocyclyl containing 1, 2 or 3 heteroatoms selected from N, O, or S, optionally substituted with one or more substituents selected from hydrogen, deuterium, halogen, amino, C1-3 alkylamino, cyano, hydroxyl, C1-3 alkyl, with the proviso that the carbon atom adjacent to the N atom is the attachment point to the parent moiety;Ra and Rb are each independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, and C3-10 cycloalkyl;Rc and Rd are each independently selected from (i) hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, and C1-6 hydroxyalkyl, (ii) C3-10 cycloalkyl, C3-10 heterocyclyl containing one or more heteroatoms selected from N, O or S, C6-10 aryl and C6-10 heteroaryl containing one or more heteroatoms selected from N, O or S, optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-6 aminoalkyl, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, and C1-6 hydroxyalkyl;or, Rc and Rd together with the N atom to which they are attached form a 3-10 membered heterocyclyl optionally containing another 1, 2 or 3 heteroatoms selected from N, O or S and a 5-10 membered heteroaryl optionally containing another 1, 2 or 3 heteroatoms selected from N, O or S, wherein the heterocyclyl and the heteroaryl are optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-6 aminoalkyl, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, and C1-6 hydroxyalkyl;or, Ra and Rd together with the C and N atoms to which they are attached form a 3-10 membered heterocyclyl optionally containing another 1, 2 or 3 heteroatoms selected from N, O or S and a 5-10 membered heteroaryl optionally containing another 1, 2 or 3 heteroatoms selected from N, O or S, wherein the heterocyclyl and the heteroaryl are optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-6 aminoalkyl, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, and C1-6 hydroxyalkyl;R1, R2, R3 and R4 are selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-6 aminoalkyl, cyano, -CONH-, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, and 3-6 membered cycloalkyl, optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, and C1-6 alkyl;R5 is selected from the group consisting of hydrogen, deuterium, halogen, amino, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 aminoalkyl, C1-6 hydroxyalkoxy, -O- (CH2) m5- (CRa8Rb8) m7- (CH2) m6-OH, - (CRaRb) n-C (O) Re, -OS (O) 2Re, -S (O) 2Re, and C3-6 cycloalkyl, optionally substituted with one or more substituents selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, and C1-6 hydroxyalkyl;R6 is selected from (i) hydrogen, deuterium, halogen, amino, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 aminoalkyl, C1-6 hydroxyalkoxy, C2-6 aminoalkenyl, C2-6 aminoalkynyl, C2-6 hydroxyalkynyl, - (CRaRb) n-C (O) Re, -OS (O) 2Re, - (CRaRb) n-C (O) NHRe, -S (O) 2Re, -NReC (O) Rf; (ii) C3-10 cycloalkyl, C2-10 spiro heterocyclyl-C1-6 alkylene-, C3-10 heterocyclyl-C1-6 alkylene-, C3-10 heterocyclyl, C6-10 aryl and C5-10 heteroaryl, wherein the spiro heterocyclyl, heterocyclyl, and heteroaryl comprise 1, 2 or 3 heteroatoms selected from N, O or S, wherein the cycloalkyl, heterocyclyl, spiro heterocyclyl, aryl and heteroaryl are each optionally substituted with one or more substituents selected from hydrogen, halogen, amino, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, oxo, C3-10 heterocyclyl, C1-6 acyl, C3-10 heterocyclyl-NH-, and C3-10 haloheterocyclyl; (iii) (C1-6 alkyl) 2P (O) -, -C1-6 alkyleneNHCH2CHmF3-m, -C1-6 alkylene-NH-Rg;Re is selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-6 alkyl, deuterated C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, C5-10 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O or S;Rf is selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl;Rg is C3-10 cycloalkyl, C3-10 heterocyclyl, C2-10 spiro heterocyclyl, wherein the cycloalkyl, heterocyclyl and spiro heterocyclyl are each optionally substituted with one or more substituents selected from hydrogen, halogen, amino, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, oxo, and CF3;Ra8 and Rb8 are each independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl;optionally, one Ra8 and one Rb8 together with different C atoms they are attached to form a C3-6 cycloalkyl, C6-10 aryl, C5-10 heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O or S, 5-10 membered heterocyclyl containing 1, 2 or 3 heteroatoms selected from N, O or S, optionally substituted with one or more substituents seleted from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl;each n is independently selected from 0, 1, 2 or 3; andeach m is independently selected from 0, 1, 2;m5 and m6 are independently selected from 0, 1, 2 or 3,and m7 is 2, 3 or 4.2.The compound of claim 1, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, Q is selected from the group consisting of phenyl, pyridyl, pyrrolyl, thiazolyl, cyclopropyl, cyclobutyl, cyclopentyl, optionally substituted with 1 or 2 substituents selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, cyano, C1-3 alkyl, -NHCH3, -NHCH2CH3, -S (O) 2F, and -S (O) 2Cl.3.The compound of claim 1, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof,wherein,Ra and Rb are each independently selected from the group consisting of hydrogen;Rc and Rd are each independently hydrogen, deuterium, halogen, amino, cyano, C1-3 alkyl;each n is independently selected from 0, 1, 2 or 3.4.The compound of claim 1, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein,Ra and Rb are hydrogen;Rc is selected from hydrogen, deuterium, halogen, amino, cyano, C1-3 alkyl;Rd is C3-6 cycloalkyl optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-6 aminoalkyl, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl;each n is independently selected from 0, 1, 2 or 3.5.The compound of claim 1, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein,Ra is hydrogen;Rb is C3-6 cycloalkyl optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-6 aminoalkyl, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl;Rc and Rd are each independently hydrogen, deuterium, halogen, amino, cyano, and C1-3 alkyl;each n is independently selected from 0, 1, 2, 3.6.The compound of claim 1, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, W is a C3-6 mono-cycloalkyl, C3-6 mono-, C7-10 fused-or C6-10 bridged heterocyclyl containing 1, 2 or 3 heteroatoms selected from N, O, or S, optionally substituted with one or more substituents selected from hydrogen, deuterium, halogen, amino, C1-3 alkylamino, cyano, hydroxyl, C1-3 alkyl, with the proviso that the carbon atom adjacent to the N atom is the attachment point to the parent moiety.7.The compound of claim 1, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, W is selected from the group consisting of optionally substituted with one or more substituents selected from hydrogen, deuterium, halogen, amino, -NHCH3, cyano, hydroxyl, and C1-3 alkyl.8.The compound of claim 1, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, R1, R2, R3 and R4 are each independently selected from the group consisting of (i) hydrogen, deuterium, F, Cl, Br, amino, C1-3 aminoalkyl, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl, (ii) cyclopropyl, cylcobutyl, optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, C1-3 alkyl.9.The compound of claim 1, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, R5 is selected from the group consisting of (i) hydrogen, deuterium, halogen, amino, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl, C1-3 aminoalkyl, C1-3 hydroxyalkoxy, -COH, -CH2COH, -CH2COOH, -COOH, -OS (O) 2F, -S (O) 2F, -CONH2, and -CH2CONH2; (ii) cyclobutyl, cyclopropyl or cyclopentyl optionally substituted with one or more substituents selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, and C1-3 hydroxyalkyl.10.The compound of claim 1, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, R6 is selected from the group consisting of hydrogen, deuterium, halogen, amino, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl, C1-3 aminoalkyl, -, C2-3 aminoalkynyl, C2-3 hydroxyalkynyl, C1-3 hydroxyalkoxy, -C (O) H, -CH2C (O) H, -CH2COOH, -COOH, -OS (O) 2F, -S (O) 2F, -CONH2, -CH2CONH2, -NHC (O) CH3, -NCH3C (O) CH3, and -S (O) 2NH2.11.The compound of claim 1, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, R6 is selected from the group consisting of 12.The compound of claim 1-11, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, the compound is of formula (I-b) wherein,X is CH2 or N;ring B is a 5-10 membered hereroaryl comprising 1, 2 or 3 heteroatoms selected from N, O or S and a 3-8 membered cycloalkyl, optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, aminoalkyl, cyano, hydroxyl, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, hydroxyalkyl, oxo and nitro;Q, W, R1, R2, R3, R4, R5 and R6 are as defined in any one of claims 1 to 11.13.The compound of claim 12, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein,ring B is selected from the group consisting ofoptionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, aminoalkyl, cyano, hydroxyl, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, hydroxyalkyl, oxo and nitro.14.The compound of claim 1-11, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, the compound is of formula (I-c) , wherein,X1, X2, X3, X4 and X5 are each independently selected from CH2, NH, O, S or bond;X6 is CH or N;R7 is hydrogen;or, two of R7 together with two adjacent atoms to which they are attached form a 3-6 membered cycloalkyl group;or, two of R7 together with two non-adjacent atoms to which they are attached form a 3-6 membered cycloalkyl group;or, two of R7 together with the same atom to which they are attached form a 3-6 membered cycloalkyl group;m is 0, 1, 2 or 3;X, Q, R1, R2, R3, R4, R5 and R6 are as defined in any one of claims 1 to 11;provided that, whenisR5 is –O (CH2) 2OH, then R1 is not selected from H or methoxy;provided that, whenisR5 is methoxy, then R1 is not selected from methoxy, hydroxyl;provided that, whenisR2, R3, R4 and R5 are not hydrogen; provided that, whenisR2, R3, R4 and R5 are not hydrogen;rovided that, whenisR5 is not methoxy;provided that, when R5 is-OCHF2, thenis notprovided that, when R5 is –O (CH2) 2OH, thenis not15.The compound of claim 14, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, is selected from the group consisting of 16.The compound of claim 1-11, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, the compound is of formula (I-d) wherein,Y is CH2, N, O or S;z1, z2, z3 and z4 are each independently selected from CH2, NH, O, S or bond;R8 is selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-6 aminoalkyl, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, and C1-6 hydroxyalkyl;k is 1, 2 or 3;X, Q, R1, R2, R3, R4, R5 and R6 are as defined in any one of claims 1 to 11.17.The compound of claim 16, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, is selected from the group consisting of 18.The compound of claim 1-11, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, the compound is of formula (I-e) wherein,Y is CH2, N, O or S;Ring C is a 5-, 6-, 7-membered hereroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S;R9 is selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-6 aminoalkyl, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl;j is 1, 2 or 3;X, Q, W, R1, R2, R3, R4, R5 and R6 are as defined in any one of claims 1 to 11.19.The compound of claim 18, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, is 20.The compound of claim 1-11, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, the compound is of formula (I-f) wherein,Y is CH2, N, O or S;y1, y2, y3 y4 and y5 are each independently selected from CH, N, S, with the proviso that (i) at least two of y1, y2, y3 y4 and y5 are N atom, or (ii) at least one of y1, y2, y3 y4 and y5 is S atom;Q, W, R1, R2, R3, R4, R5 and R6 are as defined in any one of claims 1 to 11.21.The compound of claim 20, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein is selected from 22.The compound of claim 1-11, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, the compound is of formula (I-g) wherein,Y is CH2, N, O or S;Ring D is a 5-, 6-, 7-membered hereroaryl comprising 1, 2 or 3 heteroatoms selected from N, O, S and B,Q, W, R1, R2, R3, R4, R5 and R6 are as defined in any one of claims 1 to 11.23.The compound of claim 22, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein is selected from 24.The compound of claim 1-11, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, the compound is of formula (I-h) wherein,Y is CH2, NH, O or S;M1 is CH, N;M2 is CH, CH2, N, NH, O or S;M3 is CH, CH2, N, NH, O or S;M4 is CH, CH2, N, NH, O, S or bond;M5 is CH, CH2, N, NH, O or S;M6 is CH, N, O, S;L1 is NH, CH2, CHRh, O or S;L2 is CH2, O or S;L3 is NH, CH2, O or S;Rh is hydrogen, deuterium, halogen, amino, aminoalkyl, cyano, hydroxyl, C1-3 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl, oxo and nitro;p is 0, 1, 2 or 3;Q, W, R1, R2, R3, R4, R5 and R6 are as defined in any one of claims 1 to 11.25.The compound of claim 24, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, is selected from phenyl, thienyl, 26.The compound of claim 1-11, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, the compound is of formula (I-i) wherein,Y is CH2, N, O or S;ring E is a 5-, 6-, 7-membered hereroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S;preferably, ring E isX, Q, W, R1, R2, R3, R4, R5 and R6 are as defined in any one of claims 1 to 11.27.The compound of claim 1-11, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, the compound is of formula (I-j) wherein,Y is CH2, N, O or S;R10 is selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-6 aminoalkyl, cyano, hydroxy, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl;z is 1, 2 or 3;X, Q, R1, R2, R3, R4, R5 and R6 are as defined in any one of claims 1 to 11;provided that R6 is not -CONH2 or -CONH-CH3.28.The compound of claim 1-11, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, the compound is of formula (I-k) wherein,k1 is 0 , 1, 2 or 3;X, Q, W, R1, R2, R3, R4, R5 and R6 are as defined in any one of claims 1 to 11.29.The compound of claim 1-11, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, the compound is of formula (I-l) wherein,Y is CH2, NH, O or S;E is selected from the group selected from fused C4-12 heterocyclic containing one or more heteroatoms from N, O or S, fused C4-12 cycloalkyl;preferably, E is selected from the group selected from fused C6-10 heterocyclic containing one or more heteroatoms from N, fused C6-10 cycloalkyl;preferably, E is selected from the group selected fromL4 is selected from bond, alkyl-NH-;preferably, L4 is selected from bond, C1-4 alkyl-NH-;each Re is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-6 aminoalkyl, cyano, hydroxy, C1-6 alkyl, deuterated C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl;X, Q, R1, R2, R3, R4, R5 and R6 are as defined in any one of claims 1 to 11;k1 is 0 , 1, 2 or 3;k2 is 1, 2 or 3.30.The compound of claim 1-11, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, the compound is of formula (I-m) wherein,Y is CH2, NH, O or S;x11, x12, x13, x14, x15 and x16 are each independently selected from CH, CH2, N, NH, O, S or bond;preferably, is selected from the group consisted of phenyl, pyridyl, pyrazolyl, pyrrolyl, thiazolyl, cyclopropyl, cyclobutyl and cyclopentyl;preferably, is selected from phenyl and pyrazol-4-yl;R11 and R12 are each independently selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-6 aminoalkyl, cyano, hydroxy, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl;X, Q, R1, R2, R3, R4, R5 and R6 are as defined in any one of claims 1 to 11;k1 is 0 , 1, 2 or 3;g is 0 , 1, 2 or 3; andg1 is 0 , 1, 2 or 3.31.The compound of claim 1-11, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, the compound is of formula (I-n) and (I-n1) and (I-n2) , wherein,R1 is selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, and C1-6 alkyl;R2 is selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, C1-3 alkyl, amino, C1-3 aminoalkyl, and cyano;R3 is selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-3 aminoalkyl, cyano, -CONH-, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl;R4 is selected from the group consisting of deuterium, halogen, amino, C1-3 aminoalkyl, cyano, -CONH-, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl, C1-3 hydroxyalkenyl;R5 is selected from the group consisting of deuterium, halogen, amino, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl, C1-3 aminoalkyl, C1-3 hydroxyalkoxy, - (CRaRb) n-C (O) Re, -OS (O) 2Re, -S (O) 2Re, -O- (CH2) m5--CRa5Rb5- (CH2) m6-OH, C3-6 cycloalkyl, optionally substituted with one or more substituents selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, and C1-3 hydroxyalkyl;R6 is selected from -C (O) OCH3, -CONH2, -NHC (O) OC1-6 alkyl, -NHCH2C (O) NH2, -NHC (O) NHC1-6 alkyl, -C≡CCH2Re1, -C≡CRe1, -CH3, -NHC (O) Re1, -C≡CCH2NH2, S (O) 2Re, -CONHC1-6 alkyl, -C1-6 alkylene-NHC1-6 alkyl, -C1-6 alkyleneNH2, -C1-6 alkylene-N (C1-6 alkyl) 2, -CH (OH) C1-6 alkyl, -CH2 (OCH2) C1-6 alkyl, -CH2OMe, -C (O) H, C1-6 hydroxyalkyl, -NHC1-6 alkyl, - (CH2) n1NH (CH2) m1Rf, - (CH2) n1O (CH2) m1Rf, -CH (Rg) NH (CH2) m1Rf, -C1-6 alkyleneNHC (O) C1-6 alkyl, R6A, -C1-6 alkylene-R6A, -C1-6 alkylene-R6B, -C1-6 alkylene-NHCH2CHm2F3-m2, -C1-6 alkylene-NHC1-6 alkylene-OH, -C1-6 alkylene-NHC1-6 alkylene-OC1-6 alkyl, -C1-6 alkylene-NHm3 (C1-6 alkyl) 1-m3C (O) NHm4 (C1-6 alkyl) 2-m4, -C1-6 alkylene-NHC (O) OR6C, (C1-6 alkyl) 2P (O) -, (C1-6 alkyl) 2N- (C1-6 alkyl) P (O) -, MeNH-C3-10 cycloalkylene-, OH-C3-10 cycloalkylene-, NHm4 (C1-6 alkyl) 2-m4 (COOH) CH-, -C (O) NH-R6B, and -C (O) -R6B;R6A is C5-10 heteroaryl which is optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-3 aminoalkyl, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C2-3 haloalkyl, C1-3hydroxyalkyl, -CH2OC1-6 alkyl;R6B is C5-10 heterocyclyl, C5-10 heterocyclyl, C5-10 spiro heterocyclyl, wherein the heterocyclyl and spiro heterocyclyl are optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-3 aminoalkyl, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C2-3 haloalkyl, C1-3hydroxyalkyl, -CH2OC1-6 alkyl, oxo, C5-10 heterocyclyl, C1-6 acyl, C5-10 heterocyclyl, C5-10 heterocyclyl-NH-, and halo-C5-10 heterocyclyl;R6C is C1-6 alkyl, C3-10 cycloalkyl, wherein said cycloalkyl is optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-3 aminoalkyl, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C2-3 haloalkyl, C1-3hydroxyalkyl, -CH2OC1-6 alkyl, oxo;Re1 is selected from the group consisting of deuterium, halogen, amino, cyano, hydroxyl, -C (O) NH2, deuterated C1-3 alkyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl, C5-10 heteroaryl comprising 1 2 or 3 heteroatoms selected from N, O or S;Rf is selected from the group consisting of C3-10 cycloalkyl, 5-10 membered hereroaryl, C5-10 spiro heterocyclyl, C5-10 heterocyclyl, wherein the hereroaryl, spiro heterocyclyl, and heterocyclyl comprise 1, 2 or 3 heteroatoms selected from N, O and S, wherein the the cycloalkyl, hereroaryl, spiro heterocyclyl and heterocyclyl are each optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-3 aminoalkyl, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C2-3 haloalkyl, C1-3 hydroxyalkyl, oxo, nitro and CF3; preferably, Rf is seleced fromRg is selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl;Ra and Rb are each independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, and C3-10 cycloalkyl;Re is selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, C5-10 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O or S;n, n1 and m1 are each indepently 0, 1, 2 or 3;m3 is 0, 1;m2 and m4 are each indepently 0, 1, 2; and,m5 and m6 are 0, 1, 2 or 3, and the sum of m5 plus m6 is 3;provided that, the compound is not32.The compound of claim 31, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein,R1 is selected from the group consisting of hydrogen, deuterium, F, Cl, Br, hydroxyl, C1-3 alkyl;R2 is selected from the group consisting of hydrogen, deuterium, F, Cl, Br, hydroxyl, C1-3 alkyl, amino, C1-3 aminoalkyl, cyano;R3 is selected from the group consisting of hydrogen, deuterium, F, Cl, Br, amino, C1-3 aminoalkyl, cyano, -CONH-, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl;R4 is selected from the group consisting of deuterium, F, Cl, Br, amino, C1-3 aminoalkyl, cyano, -CONH-, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl, C1-3 hydroxyalkenyl;R5 is selected from the group consisting of deuterium, halogen, amino, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, -OMe, -OEt, -OC3H7, C1-3 haloalkyl, C1-3 hydroxyalkyl, C1-3 aminoalkyl, C1-3 hydroxyalkoxy, - (CRaRb) n-C (O) Re, -OS (O) 2Re, -S (O) 2Re, C3-6 cycloalkyl, optionally substituted with one or more substituents selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl.33.The compound of claim 31, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein,R6 is selected from the group consisting of -C (O) OCH3, -CONH2, -NHC (O) OC1-3 alkyl, -NHCH2C (O) NH2, -NHC (O) NHC1-3 alkyl, -C≡CCH2Re1, -C≡CRe1, -CH3, -NHC (O) Re1, -C≡CCH2NH2, S (O) 2Re, -CONHC1-3 alkyl, -C1-3 alkylene NHC1-3 alkyl, -C1-3 alkylene NH2, -C1-3 alkylene N (C1-3 alkyl) 2, -CH (OH) C1-3 alkyl, -CH2 (OCH2) C1-3 alkyl, -CH2OMe, -C (O) H, C1-3 hydroxyalkyl, -NHC1-3 alkyl, - (CH2) n1NH (CH2) m1Rf, - (CH2) n1O (CH2) m1Rf, -CH (Rg) NH (CH2) m1Rf, , -C1-3 alkyleneNHC (O) C1-3 alkyl, R6A, -C1-3 alkylene-R6A, -C1-3 alkylene-R6B, -C1-3 alkylene-NHCH2CHm2F3-m2 , -C1-3 alkylene –NH-C1-3 alkylene-OH, -C1-3 alkylene-NH-C1-3 alkylene-OC1-3 alkyl, -C1-3 alkylene-NH m3 (C1-3 alkyl) 1-m3C (O) NHm4 (C1-3 alkyl) 2-m4, -C1-3 alkylene-NHC (O) OR6C, (C1-3 alkyl) 2P (O) -, (C1-3 alkyl) 2N- (C1-3 alkyl) P (O) -.34.The compound of claim 31, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, R6 is selected from the group consisting of -CH2NHMe, -CH2NHEt, -CH2NHC3H7, - (CH2) 2NHMe, - (CH2) 2NHEt, - (CH2) 2NH C3H7, - (CH2) 3NHMe, - (CH2) 3NHEt, (CH2) 3NHC3H7, -CH2N (Me) 2, -CH2N (Et) 2, -CH2N (C3H7) 2, - (CH2) 2N (Me) 2, - (CH2) 2N (Et) 2, - (CH2) 2N (C3H7) 2, - (CH2) 3N (Me) 2, - (CH2) 3N (Et) 2, - (CH2) 3N (C3H7) 2, -CH2OH, - (CH2) 2OH, - (CH2) 3OH; -CH2OMe, -CH2(OCH2) Me, -CH2 (OCH2) Et, -CH2 (OCH2) C3H7, -CH2NHCH2CF3, - (CH2) 2NHCH2CF3, - (CH2) 3NHCH2CF3, -CH2NHCH2CHF2, - (CH2) 2NHCH2CHF2, - (CH2) 3NHCH2CHF2, -CH2NHC (O) OMe, -CH2NHC (O) OEt, -CH2NHC (O) OC3H7, - (CH2) 2NHC (O) OMe, - (CH2) 2NHC (O) OEt, - (CH2) 2NHC (O) OC3H7, - (CH2) 3NHC (O) OMe, - (CH2) 3NHC (O) OEt, and - (CH2) 3NHC (O) OC3H7.35.The compound of claim 1-11, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, the compound is of formula (I-o) wherein,ring B is a 5-10 membered hereroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S, optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, aminoalkyl, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, oxo and nitro;preferably, ring B is selected from the group consisting ofoptionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, aminoalkyl, cyano, hydroxyl, C1-3 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl, oxo and nitro.36.The compound of claim 1-32, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, the compound is of formula (I-p) and (I-p1) , wherein,X is CH2 or N;Rp is selected from the group consisting of (i) hydrogen, deuterium, halogen, amino, cyano, hydroxy, C1-6 aminoalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, (ii) 3-6 membered cycloalkyl, optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, aminoalkyl, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, oxo and nitro;preferably, 3-6 membered cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl and cyclohexane, optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, aminoalkyl, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, oxo and nitro;k1 is 0, 1, 2 or 3.37.The compound of claim 1-11, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, the compound is of formula (I-q) , (I-q1) , (I-q2) , (I-q3) , (I-q4) , (I-q5) , (I-q6) , (I-q7) and (I-q8) ; wherein,R1 is selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, C1-6 alkyl;R2 is selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, C1-3 alkyl, amino, C1-3 aminoalkyl, cyano;R3 is selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-3 aminoalkyl, cyano, -CONH-, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl;R4 is selected from the group consisting of deuterium, halogen, amino, C1-3 aminoalkyl, cyano, -CONH-, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl, C1-3 hydroxyalkenyl;R5 is selected from the group consisting of deuterium, halogen, amino, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl, C1-3 aminoalkyl, C1-3 hydroxyalkoxy, - (CRaRb) n-C (O) Re, -OS (O) 2Re, -S (O) 2Re, -O- (CH2) m5 -CRa5Rb5- (CH2) m6-OH, -O- (CH2) m5- (CRa8Rb8) m7- (CH2) m6-OH , C3-6 cycloalkyl, -O-C3-6 cycloalkyl, -NRa6Rb6, wherein, the C3-6 cycloalkyl is optionally substituted with one or more substituents selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl;R6 is selected from -C (O) OCH3, -CONH2, -NHC (O) OC1-6 alkyl, -NHCH2C (O) NH2, -NHC (O) NHC1-6 alkyl, -C≡CCH2Re1, -C≡CRe1, -CH3, -NHC (O) Re1, -C≡CCH2NH2, S (O) 2Re, -CONHC1-6 alkyl, -CONHC1-6 deuterated alkyl, -C1-6 alkylene NHC1-6 alkyl, -C1-6 alkyleneNH2, -C1-6 alkylene-N (C1-6 alkyl) 2, -CH (OH) C1-6 alkyl, -CH2 (OCH2) C1-6 alkyl, -CH2OMe, -C (O) H, C1-6 hydroxyalkyl, -NHC1-6 alkyl, - (CH2) n1NH (CH2) m1Rf, - (CH2) n1O (CH2) m1Rf, -CH (Rg) NH (CH2) m1Rf, -C1-6 alkylene NHC (O) C1-6 alkyl, R6A, -C1-6 alkylene-R6A, -C1-6 alkylene-R6B, -C1-6 alkylene-NHCH2CHm2F3-m2, -C1-6 alkylene-NHC1-6 alkylene-OH, -C1-6 alkylene-NH-C1-6 alkylene-OC1-6 alkyl, -C1-6 alkylene-NHm3 (C1-6 alkyl) 1-m3C (O) NHm4 (C1-6 alkyl) 2-m4, -C1-6 alkylene-NHC (O) OR6C, (C1-6 alkyl) 2P (O) -, (C1-6 alkyl) 2N- (C1-6 alkyl) P (O) -, MeNH-C3-10 cycloalkylene-, OH-C3-10 cycloalkylene-, NHm4 (C1-6 alkyl) 2-m4 (COOH) CH-, -C (O) NH-R6B, -C (O) -R6B;R6A is -C2-10 heteroaryl which is optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-3 aminoalkyl, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C2-3 haloalkyl, C1-3hydroxyalkyl, -CH2OC1-6 alkyl;R6B is C5-10 cylcoalkyl, C5-10 spiro cylcoalkyl, C5-10 fused cylcoalkyl, C5-10 bridged cylcoalkyl, C5-10 heterocyclyl, C5-10 spiro heterocyclyl, C5-10 fused heterocyclyl and C5-10 bridged heterocyclyl, wherein said heterocyclyl, spiro heterocyclyl, fused heterocyclyl and bridged heterocyclyl contain one or more heteroatoms slected from N, O or S, optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-3 aminoalkyl, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C2-3 haloalkyl, C1-3hydroxyalkyl, -CH2OC1-6 alkyl, oxo, C5-10 heterocyclyl, C1-6 acyl, C5-10 heterocyclyl -NH-, halo C5-10 heterocyclyl;preferably, R6B is selected from the group ofoptionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, fluoro, chloro, amino, C1-3 aminoalkyl, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C2-3 haloalkyl, C1-3hydroxyalkyl; R6C is C1-6 alkyl, C3-10 cycloalkyl, the cycloalkyl is optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-3 aminoalkyl, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C2-3 haloalkyl, C1-3hydroxyalkyl, -CH2OC1-6 alkyl, oxo;Re1 is selected from the group consisting of deuterium, halogen, amino, cyano, hydroxyl, C (O) NH2, deuterated C1-3 alkyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl, C5-10 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O or S;Rf is selected from the group consisting of C3-10 cycloalkyl, 5-10 membered hereroaryl, C2-10 spiro heterocyclyl, C5-10 heterocyclyl, wherein the hereroaryl, spiro heterocyclyl, heterocyclyl comprising 1, 2 or 3 heteroatoms selected from N, O and S, the cycloalkyl, hereroaryl, spiro heterocyclyl and heterocyclyl are each optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, amino, C1-3 aminoalkyl, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C2-3 haloalkyl, C1-3hydroxyalkyl, oxo, nitro, and CF3; preferably, Rf is seleced fromRg is selected from the group consisting of deuterium, halogen, amino, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl;Ra and Rb are each independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, C3-10 cycloalkyl;Ra5, Rb5, Ra8 and Rb8 are each independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl;or, Ra5 and Rb5 together with atom which they are attached to form a C3-6 cycloalkyl, C6-10 aryl, C5-10 heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O or S, 5-10 membered heterocyclyl containing 1, 2 or 3 heteroatoms selected from N, O or S, optionally substituted with one or more substituents seleted from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl;optionally, one Ra8 and one Rb8 together with different C atoms they are attached to form a C3-6 cycloalkyl, C6-10 aryl, C5-10 heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O or S, 5-10 membered heterocyclyl containing 1, 2 or 3 heteroatoms selected from N, O or S, optionally substituted with one or more substituents seleted from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl;Ra6 and Rb7 are each independently selected from the group consisting of deuterium, halogen, amino, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 hydroxyalkyl;Re is selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, C5-10 heteroaryl comprising 1 2 or 3 heteroatoms selected from N, O or S;Rq21 is selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, C3-10 cycloalkyl;preferably, Rq21 is selected from the hydrogen;Rq22 is selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, C3-10 cycloalkyl;preferably, Rq22 is selected from the group consisting of C1-6 haloalkyl, C3-6 cycloalkyl;or, Rq21 and Rq21 together with the carbon atom to which they are attached form a C3-6 cycloalkyl;preferably, Rq21 and Rq21 are together with the carbon atom to which they are attached form cyclobutyl, cyclopropyl;Rq23 and Rq24 are selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 hydroxyalkyl, C3-10 cycloalkyl;or, Rq23 and Rq24 together with the carbon atom to which they are attached form a C3-6 cycloalkyl;ring E is selected from the group C3-10 cycloalkyl, C6-10 aryl, 5-10 membered hereroaryl, 5-10 membered heterocyclyl, wherein containing 1, 2 or 3 heteroatoms selected from N, O or S;n, n1 and m1 are each indepently 0, 1, 2 or 3;m3 is 0, 1;m2 and m4 are each indepently 0, 1 or 2;m5 and m6 are each indepently 0, 1, 2 or 3,and m7 is 2, 3 or 4.38.The compound of claim 1-37, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, R5 is selected from the group consisting of optionally substituted with one or more substituents seleted from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, and C1-3 hydroxyalkyl.39.The compound of claim 1-37, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, R6B is selected from the group consisting of optionally substituted with one or more substituents seleted from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkoxy, C1-3 haloalkyl, and C1-3 hydroxyalkyl.40.The compound of claim 1-37, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein, one Ra8 and one Rb8 together with different C atoms they are attached to form 41.The compound of any one of claims 1-37, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the compound is: 42.A pharmaceutical composition comprising a therapeutically effective amount of the compound of claims 1 to 41, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt solvate, or prodrug thereof, and a pharmaceutically acceptable carrier.43.A method for treating disease mediated by YAP / TAZ-TEAD activation, comprising administering to a subject in need thereof an effective amount of a compound of any one of claims 1-41, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt solvate, or prodrug thereof, or the pharmaceutical composition of claim 42.44.A method for treating cancer comprising administering to a subject in need thereof an effective amount of a compound of any one of claims 1-41, or a tautomer, cis-or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt solvate, or prodrug thereof, or the pharmaceutical composition of claim 42.45.According to the method of claim 43 or 44, the disease or cancer is selected from mesothelioma (including pleural mesothelioma, malignant pleural mesothelioma, peritoneal mesothelioma, pericardial mesothelioma and mesothelioma of the tunica vaginalis) , carcinoma (including cervical squamous cell carcinoma, endometrial carcinoma, esophageal squamous cell carcinoma, esophageal adenocarcinoma, urothelial carcinoma of the bladder and squamous cell carcinoma of the skin) , poroma (benign poroma) , porocarcinoma (including malignant porocarcinoma) , supratentorial ependymoma (including childhood supratentorial ependymoma) , epithelioid hemangioendothelioma (EHE) , ependymal tumor, a solid tumor, breast cancer (including triple negative breast cancer) , lung cancer (including non-small cell lung cancer) , ovarian cancer, colorectal cancer (including colorectal carcinoma) , melanoma, pancreatic cancer (including pancreatic adenocarcinoma) , prostate cancer, gastric cancer, esophageal cancer, liver cancer (including hepatocellular carcinoma, cholangiocarcinoma and hepatoblastoma) , neuroblastoma, Schwannoma, kidney cancer, sarcoma (including rhabdomyosarcoma, embryonic rhabdomyosarcoma (ERMS) , osteosarcoma, undifferentiated pleomorphic sarcomas (UPS) , Kaposi’s sarcoma, soft-tissue sarcoma and rare soft-tissue sarcoma) , bone cancer, brain cancer, medulloblastoma, glioma, meningioma, and head and neck cancer (including head and neck squamous cell carcinoma) .
Citation Information
Patent Citations
Biaryl derivatives as inhibitors of YAP / TAZ-TEAD protein-protein interaction
CN115298170A
Aromatic compound as well as pharmaceutical composition and application thereof
CN116217554A
New compounds inhibitors of the YAP / TAZ-TEAD interaction and their use in the treatment of malignant mesothelioma
WO2017064277A1
Therapeutic compounds and methods of use
WO2021097110A1
Inhibitor of interaction between YAP / TAZ and TEAD, preparation thereof, pharmaceutical composition thereof and use thereof
WO2023155927A1
Cited By
Oxy-amide derivatives, preparation method and medical use thereof
WO2025232876A1
Covalent p300 inhibitor compounds
WO2026128761A1
